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Summary 
Breast cancer is the most common female cancer in Scotland, in common with many 
Western countries. This thesis aimed to analyse changes in the incidence and 
molecular epidemiology of breast cancer in Scotland. Part 1 concentrated on 
epidemiological research, with data derived from various agencies, and Part 2 on a 
laboratory project aimed at looking at changes in the molecular profile of breast 
cancers in two cohorts of patients in Glasgow. 
              The period between 1987 and 1994 in which coverage of the country by the 
breast screening programme gradually increased was expected to raise incidence 
rates as seen in studies in Scandinavia and elsewhere; after 1994, incidence rates 
should have returned to normal in women aged 55-64, with incidence in women 
aged 50-54 remaining slightly above pre-existing rates. An observed/expected 
analysis of breast cancer incidence rates after 1994 was performed; this showed a 
58% increase in rates in women aged 50-54 above that which would have been 
expected had the trends continued as expected in the absence of screening. In 55-59 
year olds and 60-64 year olds there were 42% and 40% increases, respectively, 
above expected rates. 
          Reproductive risk factors such as low parity and late age at first pregnancy are 
important risk factors in breast cancer.  Reproductive risk factors are likely to affect 
the ‘birth-cohort’ incidence of breast cancer but the temporal effects of breast 
screening make this difficult to interpret. Breast cancer incidence in Scotland by year 
of birth was examined using a Lexis diagram. In women aged 50-54, 55-59 and 60-
64, breast cancer incidence rates increased by birth cohort during the presence of the 
prevalent round of screening, a finding which is likely to have been due to detection 
of large numbers of asymptomatic tumours. However, in women who were offered 
screening after the prevalent round, incidence continued to rise with successive birth 
year, suggesting a contribution from risk factors. This is the first study of birth 
cohort incidence of breast cancer and its relation to screening (published in Breast 
Cancer Research and Treatment).  
      The contribution of screening and risk factors to breast cancer incidence in 
Scotland was also assessed. A small rise in screening uptake between 1990 and 2001 
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and an increase in standardised detection ratio may indicate that screening 
improvements could be contributing to increasing incidence.  The number of first 
pregnancies to women in Scotland aged 35-59 has risen from several hundred in 
1976 to 2000 in 2001. A plot of completed family size in Scotland against maternal 
birth year shows that a steadily declining trend has been developing since the 1935 
birth cohort. Based on data from the Scottish Health Surveys, the percentage of 
women with a BMI of over 25 has increased from 47.2% to 57.3% between 1995 
and 2003. Mean BMI in women has increased from 25.7 to 26.9 over the same 
period. It is likely that the observed changes have contributed to changes in breast 
cancer incidence in Scotland.  Using prescription and population data, the prevalence 
of HRT use in women aged 40-64 in Scotland was estimated; this estimated 
prevalence has increased from 13.8% in 1993 to 17% in 2001. It is difficult to know 
if this small increase in prevalence of HRT could have influenced breast cancer 
epidemiology.  
          A study of breast cancer incidence by deprivation quintile showed that breast 
cancer incidence between 1991 and 2000 rose in all quintiles. Interaction analysis 
suggested that breast cancer incidence is rising to the same extent in deprived and 
affluent women. The risk factor analyses above were also applied to women of 
different socioeconomic standing (the results were published in Breast Cancer 
Research and Treatment). 
       A laboratory project was carried out to assess whether increasing survival from 
breast cancer could be a result of changing molecular epidemiology. This project 
was an comparison of the prevalence of breast cancers which were ER, PR and Her2 
positive and of different grades in two cohorts of Glasgow patients, from  1984-86 
and 1996-1997.  The application of current molecular techniques to stored tissue 
aimed to improve the quality of data compared to previous studies based on clinical 
databases using heterogeneous techniques. There were significant differences in 
grade distribution of tumours in the two cohorts (p=0.009) with fewer grade  1 and 
more grade 3 tumours in the second cohort. Further study showed the grade 
difference to be exerted by the tumours in screened women in the second cohort with 
there being no difference in grade between symptomatic patients in the two groups.    
64.2% of the tumours in cohort 1 and 71.5% of the tumours in cohort 2 were ER 
 15 
positive (p=0.042); this is also likely to be a clinically significant difference.  The 
difference between the cohorts appeared to be exerted by high percentage of screen-
detected tumours in cohort 2 being ER positive; however this finding still supports a 
theory of changing biology. 44.9% of the tumours in cohort 1 and 49.9% of tumours 
in cohort 2 were PR positive (p=0.181). 21.5% of tumours in cohort 1 and 20.6% of 
tumours in cohort 2 were Her-2 positive; this was not a significant difference.  An 
increase in ER positivity was seen in all age groups in the study, though multivariate 
analysis did suggest a contribution from a higher number of women over 60 in the 
more recent cohort.  Kaplan-Meier analysis showed survival to be higher in the 
second cohort than the first. There was a significant difference in survival between 
ER positive and negative patients. Cox’s regression was performed; as expected this 
showed a multifactorial contribution to increases in survival in these cohorts rather 
than it being  entirely due to changes in ER status. However the changes in ER status 
shown in a population of Glasgow patients over time may mean that the results of 
clinical trials carried out in many years ago need to be interpreted with caution when 
applying them to the women of today.  The results of this project were published in 
the British Journal of Cancer. 
                  Overall, the epidemiological studies within this thesis shed an important 
new light on the factors contributing to breast cancer incidence in Scotland, with a 
major finding being a significant association between birth cohort and breast cancer 
incidence suggesting a significant impact being made by reproductive risk factors.  
This hypothesis is supported by the analysis of risk factor trends in Scotland 
undertaken within the thesis. The laboratory study has shown a significant lowering 
in grade and increase in ER positive status of tumours in a cohort of Glasgow 
women over time; while the changes are statistically explainable by known effects of 
a breast screening programme on tumour detection they could still represent a true 
change in biology.  The results of all the studies contained in the thesis could have 
significant implications for future health service planning.  
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Chapter 1: Introduction 
 
1.1. Breast cancer incidence trends  
Changes in breast cancer incidence in the UK and relation to breast screening 
 
Breast cancer is the most commonly diagnosed cancer in women in the UK, with 
over 40,000 cases diagnosed annually (Cancer Research UK 2007). The 
epidemiology of breast cancer has been dynamic over the last 30 years, undergoing 
increases in incidence and reductions in mortality.  
      In 1995 Quinn and Allen described the changes in incidence of breast cancer in 
England and Wales up to 1992. From 1979 to 1987 the overall incidence had 
increased by about 2% every year, from 74 to 86 per 100,000 per year. A sharp 
increase, however, was seen from 1988 to 1991, with the annual rate of increase 
more than doubling, to 4.5% per year. In 1988, the NHS national mammographic 
screening programme began, and the impact of a screening programme on disease 
incidence makes interpretation of trends from 1988 onwards more complex. The 
NHS breast screening programme invites women over the age of 50 for screening 
mammograms 3-yearly, stopping at age 64 (although certain areas have also piloted 
screening for women aged 64-70 and 40-49). The first ever ‘round’ of screening - the 
time taken for all eligible women in the country to be invited for screening – would  
have contributed to an markedly increased incidence of breast cancer by picking up 
pre-existing  asymptomatic tumours, a well recognised phenomenon in breast cancer 
epidemiology  (M!ller et al. 2005; Olsen et al. 2003; Schouten et al. 2002; Zahl, 
Strand, & Maehlen 2004). In England the prevalent round of screening was 
completed by 1995 (Blanks et al. 2000) and in Scotland by 1994 (Scottish Health 
Statistics 2000).  In 1992 the prevalent round had not yet been completed, but  
incidence rates in women aged 50-64 were still 25% higher than in 1987 (Quinn & 
Allen 1995). Incidence rates had risen slightly from 1987 in 65-69 year olds, but in 
women older and younger than screening age there had been only slight fluctuations 
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in  incidence over this period.    Published data for Scotland up to 1992 demonstrate 
that trends were similar to those in England and Wales (Brewster et al. 1996).  
           Breast cancer incidence data for the UK for 1975-2005 (Cancer Research UK 
2009) showed a large rise in incidence in the screened age group following the start 
of the breast screening programme, and then a slight fall towards the end of the 
prevalent round, as predicted above (see figure 1.1 below). Incidence rates remained 
stable thereafter until 1997, at which point they began to rise again. There has been a 
levelling off of incidence rates in women of screening age since 2003. In women 
younger than screening age, rates have remained relatively stable over this whole 
period.  A rise can be seen in incidence in women aged 65-69 that has developed 
steadily since 1979 and especially since 2001 which cannot be explained by the 
screening programme.  Incidence in women aged 70 and over increased up to 1997 
at which point it levelled off.  
 
Figure 1.1: age-specific female breast cancer incidence rates, UK, 1975-2005 
(Cancer Research UK 2009) 
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               After the completion of the prevalent round of a screening programme, it 
has been postulated that the overall incidence rate of breast cancer should fall to a 
point higher than before screening was introduced but not markedly higher 
(Schouten et al. 2002). Women aged 50-53 will always be undergoing ‘prevalence’ 
screening – although screening begins at age 50, women in different primary care 
catchment areas are invited sequentially which takes 3 years, so that some women 
are 53 by the time they are invited. Screens in these women will raise the incidence 
rate but other women, having had a negative screen, will only develop tumours at a 
rate that reflects what the incidence rate would have been in the absence of 
screening, even if they are detected at an early stage on a subsequent screen rather 
than symptomatically, and should not contribute to incidence rate rises. If the 
background incidence rate is stable then the overall incidence rate should 
theoretically remain stable. In fact, Feuer and Wun in their model of breast cancer 
incidence in the screening era (Feuer & Wun 1992) suggest that once screening has 
reached steady state, the overall breast cancer incidence rate will fall back to exactly 
the rate before screening began because the tumours that are screen-detected each 
year will effectively be removed from the potential ‘pool’ of tumours that would 
have been detected the following year and this balances out any extra tumours 
detected by screening.  
         As can be seen in the data above, the incidence rate of breast cancer in women 
aged 50-64 is continuing to rise rather than level off as expected. In this thesis I will 
demonstrate that a similar pattern is developing in Scotland.  In establishing reasons 
for this increased incidence rate, consideration must be made as to the possible 
contribution of changes in screening and the possible contribution of a continued rise 
in background incidence rate; incidence rates in England & Wales were rising 2% 
per year before screening began (Quinn & Allen 1995). 
Impact of screening on incidence figures: worldwide experience. 
 
In 2007 Michael Waller and others (2007) studied the effect of screening on breast 
cancer incidence in England and Wales between 1971 and 2000. They constructed a 
Poisson age-period-cohort model, based on breast cancer incidence and population 
data and the proportion of women attending each screening opportunity, with the 
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model then generating incidence rate ratios corrected for age, period and cohort. The 
authors found that the incidence of breast cancer was higher in women attending 
screening for the first time, as expected (the rate ratio was 1.73). Incidence was also 
18-35% higher in screening attenders at subsequent screening rounds. However, the 
authors felt that continued rises in breast cancer incidence during the periods of 
‘subsequent’ screening were evidence that the background incidence of breast cancer 
would have been increasing in the absence of the screening programme.  
       In Limburg in the Netherlands, the expected changes in incidence with the 
prevalent round were seen; however, a second peak of incidence was seen after this, 
with rates up to 45% higher than pre-screening levels. The authors postulated that a 
combination of improvements in screening and increasing background incidence 
explained these findings (Schouten et al. 2002).  In Norway and Sweden, the 
introduction of screening raised incidence rates by over 50% (Zahl, Strand, & 
Maehlen 2004); a slightly increasing background incidence may have contributed 
but the authors concluded that the majority of the increase is due to screening and 
represents overdiagnosis of cancers which would have otherwise not presented in the 
patient’s lifetime.  
        Studies of breast cancer incidence in the Nordic countries (Sweden, Denmark, 
Finland, Iceland, Sweden, Norway) confirmed the initial increase in rates following 
the initial round of screening,  slightly  higher incidence rates while women remain 
in the screening programme, and  a decrease in rates as women leave the programme 
(Moller et al. 2005). The authors performed an age-period-cohort analysis which 
suggested that the increase in risk for women born in 1920 to 1940 was largely 
explainable by screening.  Jonsson et al (2005) studied breast cancer rates in Sweden 
following the introduction of screening. They adjusted rates in each age group for 
the effect of advanced time of diagnosis and found that this accounted for all the 
excess incidence since the screening programme began. Another study of rates in 
Denmark (Olsen et al. 2003) confirmed the expected prevalence peak and found that 
incidence rates after the prevalence round  were only very slightly higher than before 
screening had been introduced.  
       There have been several studies of incidence and screening in the United States. 
Studies of incidence patterns within the nine SEER (Surveillance, Epidemiology and 
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End Results) programme registry states (Feuer & Wun 1992; White, Lee et al 1990; 
Wun, Feuer, & Miller 1995) suggest that the use of screening mammography rather 
than risk factor changes are largely responsible for increases in breast cancer 
incidence in middle-aged women, although the relative contributions varied 
depending on the age range of the women. Feuer & Wun (1992) assessed how much 
of the breast cancer incidence rises in the United States up to that point could be 
explained by increases in the uptake of screening mammography. The authors felt 
that that the studies that had gone before failed to take into account the lead time 
(preclinical screen-detectable time) of breast cancer and how this varies between age 
groups, and also failed to extrapolate pre-existing secular incidence trends. The 
authors started by studying breast cancer incidence rates in different age ranges in 
women in the nine SEER registry states between 1940 and 1987. They found that 
there had been a rise in breast cancer incidence rates from 1982 onwards which was 
greater than the extrapolated pre-existing secular trend. Screening had been available 
from 1970 onwards, but there was evidence to suggest that uptake before 1982 had 
been minimal and that the effects of screening were likely to be seen from 1982 
onwards. They went on to study incidence between 1981 and 1987 more closely. For 
each different age range they calculated the percentage of tumour diagnoses which 
were attributable to symptom-detected diagnoses, screen-detected tumours in women 
having a first screen after 1982 and screen-detected tumours in women having had a 
subsequent screen after 1982, based on data available on uptake of screening, 
screening detection ratios and time for breast cancers. Their calculations revealed 
that in all age groups those tumours that were screen-detected after 1982 accounted 
for all of the incidence of breast cancer above the extrapolated pre-existing secular 
trends. 
‘Overdiagnosis’ in breast screening 
 
       One other prediction is that once a screening programme is developed there will 
be a decrease in incidence rates in the age range above the screening age – i.e., 
women who have had a last negative screen and stop being screened. If they develop 
cancers these will take time to develop into symptomatic tumours (the ‘lead time’) 
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and thus women aged just above the screening age group should present in smaller 
numbers than before.  
         Zahl et al. (2004) found that introduction of screening to Norway increased 
incidence rates in the 50-69 age group by 50%. They showed that there was no 
corresponding decline in incidence rates in women 70-74, concluding that one third 
of invasive cancers in the 50-69 age group would not have been detected in the 
patient’s lifetime. They suggest that ‘overdiagnosis’ i.e. diagnosis of slow-growing 
cancers that would not become evident in the patient’s lifetime, is a bigger factor in 
breast cancer epidemiology that first thought. Overdiagnosis has long been 
recognised as a factor in the epidemiology of prostate cancer, but its contribution in 
breast cancer remains controversial. Duffy et al. suggest that overdiagnosis is likely 
to be as little as 5% (Duffy et al. 2005);  in a recent study comparing cumulative 
lifetime rates of breast cancer in screened women and controls Zackrisson et al. 
(2006) argue that overdiagnosis is at least 10% , with several correspondents arguing 
it may be even higher, up to 25% (Gotzsche 2006; Welch, Schwartz, & Woloshin 
2006;  Zahl & Maehlen 2006).  
        It could be argued that if overdiagnosis was a major problem, screening 
programmes would not have had the effects on reducing mortality described in the 
Swedish and UK trials (Rayter & Kutt 2004). One alternative explanation for the 
failure of incidence rates to ‘fall away’ in the first group after screening ended is that 
these women may have elected to continue being screened; the NHS breast screening 
programme allows women to self-refer for mammograms over screening age. 
However it is doubtful whether rates of self-referral would be high enough to explain 
the lack of drop-off in incidence rates. 
Changes in screening in the UK 
 
     Since 1988 there have been major changes in the screening programme that have 
considerably advanced its performance. One mark of the performance of a screening 
programme is the standardised detection ratio: the ratio of incidence of screen 
detected tumours to background incidence rates – the standardised detection ratio or 
SDR. The European Community guidelines on mammography state that this should 
be over 3 for a first screen and 1.5 for a subsequent screen although the NHS breast 
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screening programme targets are 1.1 for both. The SDR of the breast screening 
programme overall has only been above 1 since 1996/97, and increased 36% from 
0.83 to 1.13 between 1994 and 1999, suggesting major improvements (Blanks, 
Moss, & Patnick 2000).  Important steps have been a change from one  to two view 
mammography for prevalent screens,  film density has been standardised at 1.4-
1.8D, implementation of quality assurance procedures and the establishment of a  
skill base of radiographers and radiologists (Blanks, Moss, & Patnick 2000).    
Improvements in screening since the prevalent round of screening was completed 
may be contributing to a continued rise in incidence rates, particularly in those 
women undergoing a first or ‘prevalent’ mammogram, as more small asymptomatic 
tumours will be revealed. For women undergoing subsequent screens, improvements 
in detection rate will result in fewer interval cancers but may not have such a great 
effect on incidence rates.   
         Rates of uptake of screening invitations will also contribute to the effects of a 
screening programme on incidence. Percentage of uptake of invitations in the NHS 
breast screening programme in the UK has remained more or less constant at 75% 
over time. (Blanks, Moss, & Patnick 2000) 
       
1.2. Potential reasons for an increasing ‘background’ incidence of 
breast cancer 
 
It is important to exclude an artefactual increase in incidence rates caused by 
changes in data registration. Peto (Peto et al. 2000) has suggested that current 
recorded incidence rates are dominated by large artefactual increases but Coleman 
(Coleman 2000) argues that  cancer registration practices (as opposed to death 
certification practices) have remained more or less unchanged and that recorded 
incidence rates should be accurate. Figures here have been age standardised, usually 
to the European population, thus compensating for any change in the age structure of 
the population. 
       Reproductive and hormonal factors are particularly important in the 
development of breast cancer. There have been major changes in fertility patterns in 
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Western societies and it is possible that such changes could be contributing to rising 
breast cancer rates.  
Reproductive, hormonal and other risk factors 
 
Reproductive risk factors for breast cancer 
Established risk factors for breast cancer include early menarche and late 
menopause, late age at first pregnancy, the oral contraceptive pill and hormone 
replacement therapy and postmenopausal obesity. In 1980 Korenman published his 
‘oestrogen window’ hypothesis (Korenman 1980). He hypothesised an endocrine 
contribution to breast cancer based on previous studies showing the protective effect 
of early age at first pregnancy and negative effect of early menarche, late menopause 
and nulliparity. He postulated that breast cancer was induced by carcinogens in a 
susceptible breast and that duration of oestrogen exposure determined risk. 
        Indeed, it has been shown that oestrogen exposure stimulates breast tissue 
epithelial proliferation and hence DNA synthesis, increasing the chance of a 
potentially cancer-causing mutation being amplified. That initial mutation may itself 
be caused by certain carcinogenic metabolites of oestrogen (Mitrunen & Hirvonen 
2003; Russo & Russo 1998). Numerous retrospective and prospective studies of 
serum oestradiol level and breast cancer risk have shown higher rates of 
postmenopausal breast cancer in women with the highest serum oestradiol levels, 
with relative risks in the prospective trials up to double in the highest quintile of 
oestradiol levels compared to the lowest (Dorgan et al. 1997; Key et al. 1996; Key et 
al. 2003; Thomas et al. 1997; Thomas, Reeves, & Key 1997; Toniolo et al. 1995).  
For women of the same age and with the same childbearing pattern, relative risk of 
breast cancer is higher in those who are postmenopausal than those who are 
premenopausal (RR 0.81 for menopause at age 50-54) or perimenopausal (RR 0.77) 
(Collaborative Group on Hormonal Factors in Breast Cancer 1997). Risk of breast 
cancer increases with increasing age at menopause – relative risk increases overall 
by about 2.8% for each year older at menopause (Collaborative Group on Hormonal 
Factors in Breast Cancer  1997). However, Korenman’s theory of prolonged 
oestrogen exposure does not explain certain features such as the strong protective 
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effect of early age at first pregnancy, and it is clear that there are more complex 
mechanisms involved.  
      Pike et al. (1983) proposed that breast tissue ‘ages’ at different rates  - i.e. 
exhibits different proliferation rates - in different stages of life. He proposed that the 
rate of breast tissue ageing decreases after first pregnancy; so women who have first 
pregnancy at a late age have had a prolonged period with a high breast tissue 
proliferation rate and hence greater risk of developing breast cancer in the future. 
Late age at first pregnancy has been shown to confer higher lifetime risk of breast 
cancer than nulliparity (Colditz 2005; Kampert, Whittemore, & Paffenbarger, Jr. 
1988; Pathak, Osuch, & He 2000; Pathak & Whittemore 1992; Rosner, Colditz, & 
Willett 1994). Pike (1983) explained this by a brief large rise in breast tissue ageing 
rate around the time of first pregnancy; with early age at first pregnancy this is offset 
by the longer period of reduced proliferation rate but with late age at first pregnancy 
no such offset occurs, causing risk to be higher than in nulliparous women. His 
model appeared to fit the epidemiological data.  
       Many studies have also confirmed an increased relative lifetime risk of breast 
cancer with decreasing total parity and nulliparity (Colditz 2005; Kampert, 
Whittemore, & Paffenbarger, Jr. 1988; Pathak, Osuch, & He 2000; Pathak & 
Whittemore 1992; Rosner, Colditz, & Willett 1994). Several authors have modified 
the Pike model to produce a model that explains various epidemiological phenomena 
including the effects of total parity on breast cancer risk. (Colditz 2005; Kampert, 
Whittemore, & Paffenbarger, Jr. 1988; Pathak & Whittemore 1992) Within these 
models, risks in older and younger women can be shown to be very different; there is 
a demonstrable ‘crossover age’ before which the effects of nulliparity, parity and late 
age at first pregnancy on breast cancer risk are in fact opposite.  The crossover age is 
influenced by age at first pregnancy and parity and can be shown to be anywhere 
between 40 and 65 years of age. Cumulative (lifetime) incidence is affected by the 
same factors as incidence after the crossover time, with data from the large Nurses 
Health Study (Rosner, Colditz, & Willett 1994) which involved 1,212,855 person-
years of follow-up  showing cumulative  incidence of breast cancer  at age 70 20% 
lower, 10% lower and 5% higher for parous versus nulliparous women for first birth 
at age 20, 25 and 35 respectively. A woman with multiple births at young age could 
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have up to a 50% lifetime relative risk reduction compared to a woman with late age 
at first pregnancy. 
 Henderson et al hypothesised that an increased number of regular ovulatory cycles 
increased the risk of developing breast cancer, and that women with early menarche 
developed ovulatory cycles much sooner after menarche (Rosner, Colditz, & Willett 
1994). Both theories are supported by the work of others (Apter & Vihko 1983;  
Butler et al. 2000; MacMahon et al. 1982; Olsson, Landin-Olsson, & Gullberg 1983; 
Wu et al. 1996). One possible explanation for the detrimental effect of regular cycles 
is that most of the mitotic activity in the breast occurs in the luteal phase (Ferguson 
& Anderson 1981; Nazario et al. 1995), and that as the duration of luteum is constant 
in most women from month to month,  a woman with regular short cycles will spend 
more time in luteum (i.e. with ‘susceptible’ breast tissue) than  women with irregular  
longer cycles.  
Oral contraceptives 
The Collaborative Group on Hormonal Factors in Breast Cancer analysed data from 
epidemiological studies in 53 297 women with breast cancer and 100 239 women 
without breast cancer to assess the effects of combined oral contraceptives on breast 
cancer risk.  Women currently using combined oral contraceptives or who had 
stopped using them less than 10 years before, had an increased risk of breast cancer 
(The Collaborative Group on Hormonal Factors in Breast Cancer 1996). Women 
who had stopped using them 10 or more years previously had no significantly 
increased risk of breast cancer. Increasing duration of use and age at first use had 
little effect on relative risks, although first use under 20 did increase the relative risk 
of breast cancer being diagnosed at a young age. 
Hormone replacement therapy  
The effects of hormone replacement therapy on breast cancer risk are likely to be 
related to their effect of artificially delaying menopause and contributing to 
cumulative oestrogen exposure. The Collaborative Group on Hormonal Factors 
analysed 54 epidemiological studies involving 52,705 women with breast cancer and 
108,411 women without breast cancer to assess the effects of hormone replacement 
therapy use on breast cancer risk (The Collaborative Group on Hormonal Factors in 
Breast Cancer 1997).  They estimated that in North America and Europe, the 
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cumulative excess number of breast cancers diagnosed per 1000 women for women 
starting HRT at 50 and using for 5,10,15 years is 2 (C.I. 1-3) , 6 (3-9) and 12 (5-20)  
respectively. In current-users of HRT or women who had recently stopped using 
HRT, who had used it for less than 5 years, the relative risk of breast cancer 
increased by a factor of 1.023 with each year of use;  relative risk of breast cancer 
was 1.35 for HRT use for duration of use of 5 years or longer. Women who had 
stopped using HRT more than 5 years previously did not have a significantly 
increased risk of breast cancer. Cancers diagnosed in users of HRT were less 
advanced clinically than those in non-users. There appeared to be little difference 
between the different types of hormonal therapy in their effects on breast cancer risk. 
However the results of the Million Women Study (Beral 2003) suggested that risk of 
breast cancer was higher for combined HRT than oestrogen-only HRT. 
  The Million Women Study was a non-randomised cohort study, following one 
million women aged 50-64 and relating the use of HRT in the 828923 
postmenopausal women in the study  to  outcomes including breast cancer incidence 
and death. Current users of HRT had greater risk of breast cancer than never-users; 
risk for current users was 1.21 for those who had used HRT for under 5 years and 
1.34 for those who had used HRT for over 5 years. In contrast to the findings of the 
Collaborative Group (The Collaborative Group on Hormonal Factors 1997), women 
who had stopped using HRT as recently as under a year previously were not shown 
to be at increased risk of breast cancer.   
Obesity        
Extensive study has been made of obesity and its importance in breast cancer. 
Conventionally, a body mass index of  18.5-24.9 is classed as ‘normal’, 25-29.9 as 
‘overweight’ and a BMI of  30 or over as ‘obese’. Pooled analysis of seven major 
prospective cohort studies in 2000 (van den Brandt et al. 2000) concluded that  high 
BMI had a significant positive association with postmenopausal breast cancer  risk – 
with the opposite being true for premenopausal breast cancer risk. To quantify this 
further, for each 4 kg/m
2
 increase above ‘low’ BMI  in postmenopausal women the 
relative risk of breast cancer increased by a factor of 1.02. The RR for a 
postmenopausal woman with a BMI of 33 kg/m
2 
or more compared with women 
with a BMI of less than 21 kg/m
2 
 was 1.27 (95 percent CI: 1.03-1.55). In 
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postmenopausal women, circulating oestrogens are mainly produced from adipose 
tissue via the enzyme aromatase. Excess adipose tissue in postmenopausal women 
increases serum oestradiol levels (Kaye et al. 1991),  and this is one mechanism by 
which obesity may lead to breast cancer. Indeed in a meta-analysis of seven 
prospective studies of BMI and breast cancer risk, adjusting for serum oestradiol 
markedly reduced the effect of rise in BMI on relative risk of breast cancer (from 
1.19 to 1.02 for a 5 kg/m2 increase in BMI) (Key et al. 2003).  The breast adipose 
tissue is especially rich in aromatase, and therefore local oestrogen production by the 
breast may be carcinogenic (Miller 1991). There has been recent interest into other 
mechanisms by which obesity may promote breast cancer; this includes interest in 
the adipocytokines (cytokines produced by adipose tissue) such as leptin. Leptin 
levels are increased in obesity; leptin has been shown to induce aromatase activity in 
breast cell lines and to stimulate growth of ER positive breast cancer cell lines (Rose, 
Gilhooly, & Nixon 2002 ; Rose, Komninou, & Stephenson 2004). 
Alcohol 
Large cohort studies have shed light on the influence of alcohol consumption on risk 
of breast cancer. Data from the Million Women cohort study in the UK suggests that 
for every additional alcoholic drink regularly consumed per day, the increase in 
breast cancer incidence up to age 75 is 11 cases per 1000 women (Allen et al. 2009).  
In the Women’s Health study, the relative risk of breast cancer with alcohol 
consumption of 30g or over of alcohol consumed per day was 1.43 in comparison to 
no alcohol at all (Zhang et al. 2007).  Various animal studies have shown that 
alcohol can induce breast tumours in mice; postulated mechanisms include effects on 
oestrogen metabolism, effects on folate metabolism, direct mutagenesis and 
oxidative stress (Dumitrescu & Shields 2005). Alcohol consumption is associated 
with more frequent, shorter menstrual cycles and increased serum oestrogen 
metabolites (Cooper et al. 1996). In addition alcohol can contribute to obesity, which 
as discussed above is an independent risk factor for breast cancer. 
Dietary Factors 
In 2007 the World Cancer Research Fund assessed the available evidence on dietary 
factors in the aetiology of breast cancer (World Cancer Research Fund 2007). They 
found that meta-analysis of case-control data suggested a significantly increased risk 
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of postmenopausal breast cancer with high dietary fat intake, probably as a result of 
its contribution to increased aromatase activity (see the section on obesity above). 
Analysis of the data on all other aspects of dietary intake showed that the studies 
were of insufficient rigour to allow a comparison to be made.    
Smoking 
The association of smoking with risk of other cancers has  long been documented but  
many years of study of breast cancer and smoking have resulted in studies with 
conflicting outcomes and methodological flaws , as reviewed by Terry et al. in 2002. 
More recent studies have attempted to try to clarify the association.  A large cohort 
study into smoking and breast cancer risk was carried out in California between 1995 
and 2000 (Reynolds et al. 2005) While an isolated study, it  was hailed as being a 
thorough, detailed prospective cohort study with large numbers. The hazard ratio of 
breast cancer in those women who smoked compared to never-smokers was 1.32.  
Exercise 
There is increasing evidence that increasing physical activity in the postmenopausal 
period could substantially reduce the risk of breast cancer (Monninkhof et al. 2007; 
Neilson et al. 2009). It is difficult to elucidate, however, whether this is simply as a 
result of  the parallel decrease in BMI that results from exercise, because all of the 
proposed mediators (e.g oestradiol activity, insulin resistance) of physical activity on 
breast cancer risk mediate obesity and breast cancer risk in the same way (Neilson et 
al. 2009). Several ongoing randomized controlled trials are attempting to determine 
whether physical activity is an independent risk factor. 
Trends in reproductive / hormonal factors 
As in many Western societies, fertility patterns in the UK are changing. This is 
probably a result of social changes, such as couples actively delaying starting a 
family until later, changing attitudes towards women and work, the availability of 
the  oral  contraceptive pill and possibly the rise in the number of  stepfamilies. 
Mean age at first pregnancy is  increasing in the UK; there was a 110% increase in 
rates of pregnancies in women aged 35-39 between 1978-80 and 1997/98 
(Population Trends  2000). Parity (as measured by completed family size) has been 
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decreasing with increasing birth cohort from the 1930s onwards (Office of National 
Statistics 2004); parity had been rising before this, reflecting the 1960s ‘baby boom’.  
Prescriptions of the oral contraceptive pill in the UK rose immediately from the 
introduction of the pill in 1961 (Population Trends 2000). The numbers of 
prescriptions reached a peak in the late 1970s to early 80s, and then fell slightly, 
levels of use thereafter remaining fairly stable, with distribution of age of use 
remaining fairly consistent.  
       Hormone replacement therapy has been used for relief of menopausal symptoms 
since the 1930s.  Numbers of prescriptions more than doubled between 1973 and 
1976 but fell again, until the late 1980s when they began to rise again (Townsend 
1998). Numbers of prescriptions remained fairly stable between 1998 and 2001 
(Townsend & Nanchahal 2005) but there is evidence that usage has fallen since 
2002, probably due women’s increased awareness of its risks (Parkin 2009). 
Estimates of population prevalence calculated from prescription data suggested that 
prevalence in England in 45-64 year-olds rose from 2.2% in 1987 to 21.7% in 1994 
(Townsend 1998).  The same study estimated that prevalence in Scotland in the same 
age group increased from 1% in 1987 to 20.4% in 1994.   Another study of HRT use 
among a database of several million patients in England showed that the prevalence 
of current HRT use in women aged 45-64 rose from 18.6% to 27.7% between 1992 
and 1998 (Bromley, de Vries, & Farmer 2004). In all studies, use of HRT was 
maximal among 50-54 year olds. Most women take HRT for at least 6 months and 
many much longer. In one study 77% of women who started HRT in 1995 took it for 
a year, 52% of women took it for at least 3 years, and 46% for at least 4 years 
(Bromley, de Vries, & Farmer 2004). The same study suggested a trend towards 
increasing duration of use; 89% of women starting HRT in 1998 took it for at least a 
year, compared to 77% of those starting in 1995.  
In this thesis I will investigate the magnitude of such changes in Scotland and how 
they may have affected breast cancer risk.  
Birth Cohort Incidence of Breast Cancer and Risk Factor Trends 
It is interesting to look at birth cohort incidence and how it relates to trends in 
reproductive factors. Birth cohort incidence is the incidence of breast cancer over 
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time in women born in a particular 5-year range. Birth cohort incidence ratios are 
useful as women of each birth cohort will overall have had a similar risk experience 
to the rest of their cohort; the individual influences on each cohort as they age 
theoretically gives the women within it a unique risk factor profile. Risk factor 
influences on each cohort include exposure to the oral contraceptive, population 
fertility patterns and exposure to hormone replacement therapy.   
     Swerdlow and Dos Santos Silva (dos Santos Silva & Swerdlow 1995) looked at 
the relationship between incidence and mortality in the UK of breast cancer and 
population reproductive factors, up until 1985. Birth cohort incidence trends become 
more difficult to analyse after this point, as screening will raise incidence rates in 
several birth cohorts once the women reach screening age, making the contribution 
of risk factors difficult to assess. Trends in average completed family size did appear 
to reflect the cohort risk of breast cancer. Average completed family size fell from 
3.3 per woman born in 1875 to 2.0 in women born in the early 1930s, coinciding 
with a marked increase in breast cancer relative risk for successive birth cohorts over 
this time. Family size then rose with successive birth cohorts to 2.4 for 1935 birth 
cohorts, coinciding with a reduction in risk.  However between the 1935 and 1950 
cohorts completed family size fell with successive cohorts but cohort incidence also 
fell.  
         Elsewhere, Swerdlow showed that birth cohort incidence in Scotland gradually 
increased until the birth date in the late 1930s, and risk decreased with more recent 
year of birth up to 1987 (Swerdlow et al. 1998).  Robertson and Boyle also found a 
reduction in incidence of breast cancer in more recent birth cohorts in their 1997 
study, and they speculated that these women could have been healthier than cohorts 
that had gone before as a result of dietary changes.   
      Studies carried out elsewhere, such of that by Chia et al in Singapore and 
Sweden (Chia et al. 2005), showed that birth cohort incidence continued to rise after 
the 1935 birth cohort, and it is possible that the relatively young age of the later birth 
cohorts in these earlier studies confounded the incidence figures, despite the age-
standardisation used in the study. An age-period-cohort analysis carried out using 
breast cancer incidence data for Hong Kong revealed that the increase in incidence 
was principally a cohort effect, with relative risk increasing in a linear fashion with 
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successive birth cohorts; there was an up to 3-fold increase in risk in women born in 
the 1960s compared to 1900 (Leung et al. 2002).  
A relationship between age at first pregnancy and incidence rates was not evident in 
Swerdlow and dos Santos Silva’s study (dos Santos Silva & Swerdlow 1995). The 
percentage of women having a first child at ages under 25 increased from 40% of 
women born in 1920 to 60% of women born in 1945 but cohort cancer incidence 
increased rather than decreased. 45% of those born in 1955 had a first child at ages 
under 25; however breast cancer cohort incidence declined rather than increased as 
would be expected with this trend towards later age of first pregnancy. Trends in 
nulliparity bore little relation to trends in incidence. The study by Chia et al. (2005) 
demonstrated a relationship between cohort incidence of breast cancer and temporal 
trends in age at first pregnancy in Singapore but not in Sweden.  
    
Temporal Incidence of Breast Cancer and Risk Factor Trends 
A study by Coombs et al. calculated the potential contribution of  HRT use to breast 
cancer incidence in Australia (Coombs et al. 2005).They based the study on the 
epidemiological theory  that a small individual risk (such as that provided by HRT 
use in terms of breast cancer risk) can become magnified into a significant 
population risk if the prevalence of the risk factor is high enough. They calculated 
the proportion of breast cancers in Australia every year that were attributable to HRT 
use; this proportion was estimated to be 9%. Their analyses revealed that reduction 
in HRT prescribing in terms of restricting use to women under 65 and limiting length 
of prescription could reduce breast cancer incidence by up to 5.7%.  They concluded 
that when HRT prevalence is high the effect of the increased breast cancer risk is 
relatively high.  
1.3. Breast cancer mortality and survival 
 
In the Eurocare study of cancer registries published in 1995 (Quinn & Allen 1995), 
England and Scotland were ranked 8
th
 and 10
th
 respectively out of 12 countries in 
Europe in terms of survival from breast cancer.  However, survival now appears to 
be increasing and mortality to be decreasing in both countries, despite increasing 
incidence. Coleman (2000) showed 5 year survival in England and Wales to have 
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steadily improved across all age groups since 1970. The greatest increase was in 
women aged 50-69 at diagnosis, in whom 5-year survival increased from by 7% 
from 1989 to 1993. Figures from the Office of National Statistics (Quinn & Allen 
1995) showed overall 5 year survival to have improved by 6% between 1986-90 and 
1991-93. Survival in women aged 50-69 increased by 7-10%, compared to survival 
increases of 1-4% in younger and older women. 
        Peto (2000) had reported the fall in mortality from breast cancer in UK women  
between 1987 and 1997 aged 20-49, 50-69 and 70-79 to be 22%, 22% and 12% 
respectively. Coleman (2000) showed standardised mortality figures adjusted for 
changes in coding,  and showed a better estimate to be a drop of   21%, 21% and 7% 
respectively. Quinn (Quinn & Allen 1995) showed that in women aged 55-69 
mortality changed little throughout the 1980s but fell sharply after 1990; in 1994 the 
rate for these women was 12% lower than in 1987. The standardised mortality rate 
for all ages from breast cancer in Scotland decreased by 23% between 1975 and 
2000 (figures from Scottish Executive Information & Statistics Division).  
       For mortality statistics, changes in death registration practice and revisions of 
ICD coding could potentially interfere with trends in mortality. For example, 
between 1984 and 1993 the Office of Population Censuses and Surveys in England 
and Wales used a different interpretation of the WHO rules on determining 
underlying cause of death, reverting to the old method in 1993. It is important to 
determine whether mortality rates are calculated from data on all-cause mortality or 
mortality due to breast cancer. 
Explanations for increases in survival and mortality 
Postulated reasons for decreasing mortality include screening, better treatment, shift 
to lower stage and grade tumours at time of diagnosis, and changes in receptor status 
of tumours. Several studies in the UK have attempted to assess the relative 
contribution of factors to the decreasing mortality rates and increasing survival rates; 
all acknowledge the complex interaction between different factors. 
        Since the advent of both screening and increased ‘breast awareness’ in women, 
lead-time bias (longer time between diagnosis and death because of early detection 
but no true increase in survival) and length bias (slower growing tumours 
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preferentially detected by screening) have become confounding factors when 
considering increasing survival figures for breast cancer. Improved survival over 
time may not reflect improved cancer treatment, instead simply representing the 
lead-time bias of tumours detected early. Mortality rates, however, should definitely 
decrease with improvements in cancer treatment and detection (Welch, Schwartz, & 
Woloshin 2000).  
              Breast cancer is a progressive disease; the aim of service mammography 
screening is to detect breast cancers at an early stage, when there is less chance that 
micrometastases have occurred and there is more chance of definitive treatment 
effecting a cure. Several reviews of randomised controlled trials have suggested 
screening mammography could reduce breast cancer mortality by about 20% for 
screened women over a period of 10 years (Hackshaw 2003; Nystrom et al. 2002) 
Duffy et al. (2002) suggested the reduction could be 40%. 16 year mortality figures 
from the UK Trial of Early Detection of Breast Cancer revealed a 27% lower 
mortality from breast cancer in screened women (1999). One Cochrane Review of 
studies, however, suggests that the available evidence does  not support a  breast-
cancer specific mortality  reduction (Olsen & Gotzsche 2001) as a result of 
inconsistencies in aspects such as  recording of cause of death., although the authors 
of the studies reviewed have disputed these findings.  Nevertheless, as the prevalent 
round of screening was not complete until 1995, many of the deaths in the 1990s will 
have been in women already diagnosed with breast cancer before attending 
screening, and so the impact of screening on mortality statistics so far is likely to be 
much less than 20%. As time goes on however, fewer patients will have been 
diagnosed before the screening era and the effect on mortality may become clearer. 
              The changing management of breast cancer has undoubtedly contributed to 
improvements in survival, particularly in terms of pharmacological management.  
The use of adjuvant therapies such as hormone therapy in the form of tamoxifen, 
which markedly reduced recurrence rates in women with ER positive tumours 
(EBCTCG 2005) has  become widespread in its availability and clinical application  
over the past two decades, having been introduced in the early 1980s. Similarly the 
availability and application of various forms of chemotherapy has increased 
markedly over this time; with chemotherapy clearly improving survival when used in 
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appropriate clinical situations, especially younger women and women with ER 
negative disease this will have undoubtedly have contributed to improvements in 
survival and mortality. In recent years the use of aromatase inhibitors in specific 
clinical instances has increased, although there will have been little contribution to 
population survival figures over the time periods in question here.   
   Another important factor has been the reorganisation of breast cancer services, 
with women being managed by multidisciplinary teams of surgeons and oncologists, 
surgery being carried out by surgeons specialising in breast cancer surgery, and the 
availability of consensus guidelines. There is evidence that these trends have 
positively influenced survival; Gillis and Hole showed a 17% reduction in risk of 
death for patients treated by specialist breast surgeons as opposed to non-specialists 
(Gillis & Hole 1996). 
           Attempts have been made to quantify the contributions made of each of these 
factors to increasing survival. Blanks et al (Blanks et al. 2000) designed a model 
based on expected mortality rates without screening, to determine the contribution of 
screening to falling mortality. They estimated 30% of the reduction in mortality in 
1998 was due to screening, with 70% due to other factors. Thomson et al. (2004) 
assessed reasons for an 11% increase in 8-year survival in Scotland between 1987 
and 1993. They suggested that 47% of the improvement was directly explicable by 
screening, with a further 33% due to clinicopathologic factors (change in stage, 
grade, ER status). Treatment factors did not appear to contribute to survival in their 
model. Bradburn et al. (1998) showed improved survival for postmenopausal 
women. Their analysis suggested that treatment factors explained much of the 
improvement; changes in prognostic factors did not contribute. Stockton et al. (1997) 
found an odds ratio of 1.5 of being diagnosed stage I/II in 1986-89 compared with 
1982-85. They estimated 44% and 60% of the improvement in survival to be due to 
stage shift in patients under 50 and 50-64 respectively. They felt this stage shift was 
unlikely to be due to screening, as screening was still in its infancy in 1989, and 
more likely to be due to breast awareness.  Elkin et al. (2005),  in a  study of changes 
in tumour size distribution, estimated that within-stage size migration explained 61% 
of the improvement in survival of the patients in the study. Pisani  & Forman (2004) 
found that almost all the improvement in survival from their patients from 1982-90 
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to 1991-99 was accounted for by adjusting for stage. They did note a small 
improvement in stage specific survival for all stages except IV. 
 
1.4 Is the biology of breast cancer changing? 
 
The most striking feature of the epidemiology of breast cancer in the UK described 
above is the improvement in mortality and survival despite increasing incidence, 
especially in middle-aged women.  Screening has undoubtedly contributed to 
incidence changes, with its impact so far on survival and mortality less clear; 
improvements in  treatment may have contributed to reduced mortality even in the 
face of the increased incidence. There is also growing evidence that the excess of 
incidence of breast cancer noted in recent years may be countered by an increasing 
incidence of tumours which are less ‘aggressive’ and have intrinsically better 
prognosis.  This would help to explain reductions in mortality and improvements in 
survival. 
       Detecting a general shift in tumour biology of breast cancers could have 
profound implications for the treatment of breast cancer, as treatment decisions are 
often made on the basis of longstanding clinical trial evidence. If we know that 
tumour characteristics have changed since the publication of these trials, it may be 
that we must interpret results of previous trials with caution before applying them to 
our patients. 
Evidence for changing biology 
 
Changes in receptor status 
 
Studies in Marin County in San Francisco, an area with a homogenous population of 
a relatively high socio-economic status,  suggest that incidence rate increases in 
breast cancer in women seen there appears to consist of an increasing rate of 
development of oestrogen receptor positive tumours, with the rate of receptor-
negative tumours staying fairly constant (Benz, Clarke, & Moore 2003) 
Few studies of changing oestrogen receptor status have been carried out in the UK. 
Bradburn and others 1998) looked retrospectively at ER and PR status of tumours in 
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Guy’s Hospital Breast Unit. They showed an increase in percentage of ER positive 
tumours from 46% to 66% between 1975-79 and 1985-89, and an increase in 
percentage of PR positive tumours from 24% to 48% between 1975-79 and 1985-89. 
In this study, the number of tumours who did not undergo testing for hormone 
receptors decreased markedly between the two time periods; therefore it is possible 
that increased receptor positivity simply represented increased detection.   Henley et 
al ( 2005) detailed a comparison of selected patients treated in  Glasgow from 1980-
88 and from 1996-2001; 49% of patients in 1980-88 and 78% of patients in 1996-
2001 were ER positive.  
        A recent major study by Glass (2007) calculated incidence rates of breast 
cancer within women in a health-plan and plotted the incidence of ER positive and 
ER negative disease; they found dramatic differences in incidence rate trends by ER 
status. Rates of ER positive disease followed the overall incidence pattern for breast 
cancer, with a 5% annual increase from 1980 to 1983, an 18.9% annual increase 
from 1983 to 1986 and a 2.1 % increase from 1986 to 2001; ER negative disease 
showed a different pattern, with an annual decrease of 2.1% between 1980 and 1995, 
3.7% form 1995 to 1999 and 9.8% from 1999 to 2006. 
            Li et al (2003) studied  receptor status of tumours in the SEER registry 
(USA) between 1992 and 1998. While they too noted a decrease in the number of 
tumours of unknown status, they then looked specifically at those tumours of known 
status. The percentage of those with known status that were ER+ increased from 75.4 
to 77, and PR+ from 65 to 67.7. Their data also suggested that the increase in ER 
positive tumours was limited to early stage disease. They felt that a possible 
explanation was that ER status may be affected by use of HRT and that using HRT 
may result in increased contact with health services and thus early detection of 
disease. 
         In a study of  ER status in 11195 tumours in the US between 1973 and 1992, 
the percentage of ER + tumours increased  significantly across the period (Pujol et 
al. 1994). They did find ER positive status was commoner in older women, in 
smaller tumours and was unrelated to nodal status but the rise persisted after 
adjusting for age, tumour size and type of assay, showing that there was a true rise in 
ER positive tumours.  A study by Celentano  et al. (1998) of trends in ER status by 
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birth cohort found a decreasing odds ratio of ER positivity with successive birth 
cohorts although there appeared a small increase and decrease in odds ratio before 
and after  1941-45 birth cohort.  
            The main confounding factor in many of these studies is that most have 
combined data from ligand binding assays and immunohistochemistry, with the more 
recent patients in their studies having had oestrogen receptor status determined by 
IHC (although Glass (2007) noted that there had been no changes in laboratory 
procedures in their study period). Detection of oestrogen receptors was formerly 
carried out using ligand binding assays such as the dextran-charcoal method which 
measured absolute levels of oestrogen receptor in the ‘cytosol’- the supernatant 
following ultracentrifugation of tissue - but now immunohistochemistry has been 
almost universally adopted. Immunohistochemistry has been accepted as the more 
sensitive and specific method of analysis (Allred et al. 1990), as there is no 
interference with receptors by endogenous or exogenous circulating oestrogen. In 
addition IHC is easier to perform, less expensive, safer, applicable to a wide variety 
of samples , and microscopy of the specimen allows identification of ER positive 
cells in a low cellularity specimen and identification of ER positive benign 
epithelium (Allred et al. 1990; Allred et al. 1998; Harvey et al. 1999; Pertschuk & 
Axiotis 1999). But most importantly, given the use of oestrogen receptor in clinical 
breast cancer management, oestrogen receptor status established by 
immunhistochemistry has also been shown to predict response to endocrine therapy 
better than ligand binding assays (Allred et al. 1990; Allred et al. 1998; Harvey et al. 
1999). Several studies found no straightforward relationship between tumour ER 
content by LBA and the ratio of ER positive to ER negative cells at IHC, and it is 
likely to be this ratio which is most important for predicting endocrine 
responsiveness and survival.  The direct concordance between the two methods in 
various trials was reviewed by Allred (Allred et al. 1990); in permanent sections the 
concordance of the methods ranged between 82% and 96%, with the discordance 
most likely due to ligand binding being ‘false positive’.  
         Another potential source of artefact (Pujol et al. 1994)  in studies could be an 
improvement in  transit time and transit methods to laboratories from theatre (for 
example specimens being placed directly in formalin), with faster transit times 
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reducing protein breakdown and resulting in better detection of hormone receptors.  
It should be noted that there still remains a great deal of heterogeneity within 
different laboratories as to the antibodies used for ER determination, scoring system 
and cutoffs used to determine positivity and type of sample (frozen or paraffin) 
(Layfield et al. 2003; Pertschuk & Axiotis 1999) 
 
Changes in grade 
No studies have been made of population changes in tumour grade. However several 
studies have suggested  a trend  toward lower grade in tumours detected at screening 
(Anderson et al. 2004; Crisp et al. 1993; Duffy et al. 1991; Tabar et al. 1999) 
  
Changes in size 
One recent large study within the SEER registry showed that within each stage 
category, the proportion of small tumours had increased significantly over time 
(Elkin et al. 2005).   
 
Screening and changing biology 
The epidemiology of breast cancers could be different in the screening era, with a 
higher percentage of slow growing, better prognosis, cancers in women of screening 
age, thus affecting survival and mortality figures. However, as noted above, the 
effects of screening on survival are potentially subject to lead-time bias. Length bias 
- detection by prevalence screening of slower growing tumours which spend a longer 
time in the preclinical ‘sojourn period’- is another potential confounding factor when 
assessing the biology of breast cancers in the screening era. Any studies of the 
effects of screening on the biology of breast cancer have to take account of potential 
bias.  
        As noted in the section ‘Explanation for improvements in mortality & survival’, 
phenotypic drift has been postulated to occur (Tabar et al 1999), with differentiation 
being lost as tumours progress. Due to the intrinsic intratumour heterogeneity of 
breast cancers, areas of the tumour that are higher grade may grow more rapidly than 
the rest of the tumour and so a tumour that starts out as mostly low grade with a tiny 
area of high grade tumour may eventually become a tumour that is mostly high 
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grade. Screening may therefore interrupt this process and detect tumours when they 
are of low grade. The results of several studies (Anderson et al. 2004; Crisp et al. 
1993; Duffy et al. 1991; Nordèn et al. 1997) showing lower grade in screening 
detected cancers, even when women undergoing prevalence screening are excluded 
due to the high potential for  length bias (ie preferential detection of slow-growing 
tumours) in this group, have been used to support the theory of phenotypic drift 
(Tabar et al. 1999). 
         The large study by Elkin et al (Elkin et al. 2005) of changes in tumour size 
over time did not collect data on the screening status of the tumours in the study. 
However it is very likely that the advent of screening resulted in the changes 
demonstrated. Studies of the characteristics of tumours detected by screening have 
shown them to be of smaller size than non-screen-detected tumours (Cortesi et al. 
2006; Duffy et al. 1991; Ernst et al. 2002; Klemi et al. 1992) the resulting increase in 
survival being the basis for the introduction of mammographic screening 
programmes.  
        Several comparative studies have shown that screen-detected tumours are more 
likely to be oestrogen receptor positive than negative.  A comparative cohort study 
by Klemi et al. (Klemi et al. 1992) showed a relative risk of ER negativity of 0.29 
after controlling for tumour size.  Another, population registry-based, study showed 
screen-detected tumours were significantly more likely to be ER positive. (Ernst et 
al. 2002) However other studies have shown no difference in hormone receptor 
status between screen-detected and symptomatic tumours (Nordèn et al. 1997).   
   A comprehensive review of the literature on stability of ER expression throughout 
progression of breast cancer concluded that ER remained a stable phenotype 
(Robertson 1996); therefore there is no evidence to suggest phenotypic drift of 
oestrogen receptor status.  It appears, then, that a trend towards increasing incidence 
of tumours with intrinsically better prognosis may be contributed to by screening in 
the case of grade and size but not receptor status.  
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1.5. How do biological differences in breast cancer influence 
prognosis? 
 
Oestrogen receptor (ER) 
ER is a nuclear transcription factor which regulates the expression of several genes 
involved in control apoptosis and cell proliferation, both in normal breast epithelium 
and in breast cancers. It is activated by the binding of oestrogen to the hormone 
binding domain. After this binding the receptor dimerises to another ER receptor, 
and this dimmer in turn binds to oestrogen responsive elements in the promoter 
regions of the target genes. These include ps2, progesterone receptor (as discussed 
below) and the bcl2 apoptosis inhibitor. There also appears to be some interaction 
with genes that do not contain oestrogen responsive elements such as the AP1 
transcription factor family (Osborne 1998). 
             Detection of the presence of oestrogen receptor was formerly carried out by 
ligand binding assays, in which case cytosolic oestrogen was measured in fmol per 
mg of protein. Cut-offs for positivity were generally based on the limits of detection 
of the various assays, ranging from 3 fmol/mg (Harvey et al. 1990) to 5 fmol/mg 
(Allred et al. 1990) to  10 fmol/mg (Aamdal et al. 1984). In several of the original 
studies into the endocrine responsiveness and outcome of tumours whose ER status 
was determined by IHC (Allred et al. 1990; Allred et al. 1998; Pertschuk et al. 1990) 
10% of cells staining positive was used as a cut-off for ER positivity. This cut-off  
was shown to give adequate separation between positive and negative groups in 
terms of prognosis (Ogawa et al. 2004) and has been adopted by many laboratories 
worldwide (Allred et al. 1998; Layfield et al. 2003). However, in a study of 1900 
patients where ER positivity was taken as 1% or more positively staining cells, 
Allred (Allred et al. 1998) found that this still correlated with endocrine 
responsiveness and hence improved disease-free survival;  nevertheless few 
clinicians would use 1% as a cut-off for positivity. 
         Oestrogen receptor positive tumours are generally of lower grade than receptor 
negative tumours (Fisher et al. 1981; Maynard et al. 1978; Millis 1980; Stierer et al. 
1993) and have been shown to have a lower proliferation rate than receptor negative 
 41 
tumours, as shown in a study of  S-phase fractions in 127,000 tumours (Wenger et al. 
1993).  While ER positive tumours can be shown to have less ‘aggressive’ 
histopathological features, and the presence of the ER allows treatment with 
endocrine therapy, the issue of whether ER positive tumours have an intrinsically 
better prognosis is less clear. The most useful studies in this regard are studies with 
long term follow up and survival analysis in women who received surgical treatment 
with no adjuvant therapy, and there are few such studies.  
      Gelbfish et al. (1988) studied 204 patients with primary operable breast cancer 
whose receptor status was determined by dextran-charcoal and who received no 
adjuvant therapy. There was found to be no significant difference in disease-free 
interval between ER positive and negative patients. Butler et al (1985) followed 556 
node-negative patients who received only surgery. They found no significant 
difference in both overall and disease-free survival between the ER negative and ER 
positive patients. Coradini et al. (2000) analysed 1793 patients who had node 
negative tumours and no systemic therapy, and who had at least 10 years of follow-
up. They concluded that ER positivity was not correlated with survival in the first 
few years of follow-up but thereafter gave a higher risk of relapse. Similarly, 
multivariate analysis by Hilsenbeck (1998) showed a pattern of initial lack of 
prognostic ability changing later on to poorer prognosis with ER positivity; while 
their patients were a heterogeneous group who had different adjuvant treatments, 
they stated that the same results were seen in their analysis of a subgroup of 
untreated patients 
       Far more than its intrinsic effects on prognosis, the importance of oestrogen 
receptor lies in its ability to predict response to adjuvant endocrine therapy in the 
form of tamoxifen or aromatase inhibitors. Tamoxifen is an antioestrogen that has 
oestrogenic properties. It inhibits expression of oestrogen-regulated genes. It is 
mainly cytostatic, slowing cell proliferation, although it has also been shown to be 
pro-apoptotic (Osborne 1998). A recent meta-analysis of all tamoxifen trials 
(EBCTCG 2005) confirms shows that women with ER positive tumours derive 
significant benefit from 5 years of tamoxifen as regards recurrence reduction and 
longterm survival whereas ER negative women do not. In the group of 30,000 
women who were ER positive or ER unknown, 5 years of tamoxifen treatment 
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provided a recurrence reduction of 47%, and a mortality reduction of 26% at 10 
years of follow-up.  In a further 8000 women who were ER negative, tamoxifen had 
no significant effects on mortality and recurrence.   Therefore, ER positive cancers 
are of ‘better prognosis’ than ER negative cancers due to the effects of hormonal 
therapy.  
      This does not mean that all oestrogen receptor positive patients will respond to 
endocrine therapies; between 30 and 40% of ER positive tumours are estimated to be 
refractory to tamoxifen from the start. Indeed, most ER positive tumours do become 
tamoxifen resistant over time. There has been much recent interest in translational 
research into the roles of various signal transduction pathways in de novo and 
acquired tamoxifen resistance.  The development of aromatase inhibitors has 
therefore given new hope in the endocrine treatment of oestrogen receptor positive 
cancers. Aromatase inhibitors reduce circulating oestrogen levels and their use as 
adjuvant therapy (in postmenopausal women only) reduces recurrence rates (Winer 
et al. 2002). The results of the ATAC trial suggested improved disease free survival 
with anastrozole over tamoxifen, although it remains unclear whether 
postmenopausal women should receive aromatase inhibitors as first line therapy 
(Howell et al. 2005; Winer et al. 2002). There are indications that aromatase 
inhibitors should be used as first line therapy when certain characteristics of the 
tumour which suggest intrinsic tamoxifen resistance, such as HER-2 positivity and 
PR negativity, are present (Winer et al. 2002). 
 
Progesterone receptor (PR) 
The progesterone receptor gene is under the control of oestrogen receptor. It was 
initially hypothesised by Horwitz and McGuire in 1975 that its presence suggested 
that its oestrogen receptor was functional, and that the tumour was likely to respond 
to endocrine therapies. It has indeed been shown that adjuvant tamoxifen is less 
effective in ER +ve , PR –ve tumours than in ER +ve PR+ve tumours, with up to  
double the recurrence rate in the PR-ve tumours (Bardou et al. 2003; Howell et al. 
2005; Winer et al. 2002). However in the ATAC trial the patients with ER+ve, PR –
ve tumours responded almost as well to anastrozole as ER+ve PR+ve tumours 
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(Howell et al. 2005), suggesting that many  PR negative tumours may in fact still 
have a functioning oestrogen receptor. Similarly ER has been shown to be 
transcriptionally active in some ER+ve PR-ve tumours (Cui et al. 2005). 
      Various mechanisms for loss of PR have been studied such as hypermethylation 
of the PR promoter or genetic loss at the PR gene (Cui et al. 2005). However, these 
mechanisms do not explain the aforementioned resistance to selective oestrogen 
receptor modulators (SERMs) such as tamoxifen. A recent study of over 40,000 
breast cancers (Arpino et al. 2005) showed that ER +ve PR -ve patients express 
higher levels of HER-1 and HER-2 than ER +ve PR+ve patients and display more 
aggressive characteristics. The authors hypothesise that reduced PR expression may 
be a marker of aberrant growth signalling, and it is this altered signalling that 
suppresses PR and also causes tamoxifen resistance to develop. In a later paper the 
hypothesis is detailed  that hyperactive growth factor signalling not only represses 
PR expression directly by inhibiting PR promoter activity, but promotes tamoxifen 
resistance by causing ligand-independent activation of ER-responsive genes or 
causing a shift to membrane initiated signalling which is associated with increased 
tamoxifen agonist activity (Cui et al. 2005). Other postulated mechanisms of 
tamoxifen resistance in ER+ve PR-ve tumours include altered ER coregulator levels, 
or the ER may be unable to bind DNA (Cui et al. 2005)  
    The findings of reduced efficacy of SERMs in women with the ER+ve PR-ve 
phenotype have important implications for endocrine adjuvant therapies. Some 
members of the 2005 American Society of Clinical Oncology Technology 
Assessment panel (Winer et al. 2002) felt that such  patients should be given an 
aromatase inhibitor as first-line adjuvant therapy instead of tamoxifen whilst others 
disagreed. For premenopausal women, options may include degradation of ER by 
oestrogen receptor degraders such as fulvestrant. Preclinical trials have suggested 
that combined use of a SERM and a growth factor inhibitor may in the future be the 
treatment of choice for ER+ve PR-ve tumours (Winer et al. 2002). 
     As to whether progesterone positivity has an effect on prognosis independently of 
the use of endocrine therapies, the analysis of Coradini et al. (2000) of outcome 
patients receiving no adjuvant therapy revealed that high progesterone receptor 
levels correlated with reduced risk of relapse which persisted over time. 
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HER-2 
The presence of HER-2 , while not a hormone receptor, has prognostic significance. 
The HER-2/neu gene, also known as the Erb-B2 gene,  allows the expression of the 
HER-2/neu protein,  which is a transmembrane tyrosine kinase growth factor 
receptor. It is closely related to three other growth factor receptors, HER-1,-3 and -4. 
Studies have shown that the amplification of the HER-2 gene and overexpression of 
the HER-2 protein  correlates with poor outcome in terms of overall and disease-free 
survival, with HER-2 positive breast cancer being universally recognised as an 
aggressive form of the disease (Chang et al. 1999; Gusterson et al. 1992; Rilke et al. 
1991; Ross & Fletcher 1999; Slamon et al. 1987; Witton et al. 2003). The differences 
between HER-2 +ve and negative patients appear to be most marked in node positive 
patients (Rilke et al. 1991), and survival differences appear to level out after 4-5 
years (Rilke et al. 1991). HER-2 overexpression is associated with high grade, 
lymphocytic infiltration, high mitotic index and p53 mutation (Menard et al. 2001; 
Menard et al. 2003).  
            HER-2 positive tumours are more likely to be ER negative than ER 
positive(Konecny et al. 2003). However, in those tumours that are ER positive, 
overexpression of HER-2 has been linked with de novo tamoxifen resistance 
(Carlomagno et al. 1996; De Laurentiis et al. 2005; Dowsett et al. 2001; Elledge et 
al. 1998; Horiguchi et al. 2005; Menard et al. 2001; Menard et al. 2003; Tovey et al. 
2005; Winer et al. 2002; Wright et al. 1992). Overexpression of growth factors like 
HER-2 can directly modulate ER activity independently of oestrogen or cause a 
switch towards membrane-based signalling which allows tamoxifen to act as an 
agonist and inhibits its apoptotic ability (Arpino et al. 2005; Cui et al. 2005).  Some 
have therefore suggested that ER positive, HER-2 positive patients should be 
considered for aromatase inhibitor therapy as a first line; the ASCO 2005 guidance 
(Winer et al. 2002) was that there was inadequate clinical data to support this. The 
advent of a monoclonal antibody to HER-2 in the form of trastuzumab (Herceptin) 
has allowed some modification of this poor outcome, with a disease free survival 
improvement of up to 50% at 3 years when used adjuvantly (Piccart-Gebhart et al. 
2005; Romond et al. 2005). HER-2 protein is detected by immunohistochemistry and 
conventionally scored as 0, 1+, 2+ or 3+, with 2+ being indeterminate and requiring 
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determination as positive or negative with fluorescent in-situ hybridization which 
tests for actual gene amplification (Bartlett, Mallon, & Cooke 2003; Bartlett et al. 
2001; Dowsett et al. 2003; Garcia-Caballero et al. 2006) 
 
Grade  
The relationship between the morphology and degree of differentiation of breast 
cancers and the outcome of the patients was first noted by Greenhough in 1925 
(Going et al. 2001). In the 1950s Bloom and Richardson developed a grading system 
assessing presence of tubule formation, nuclear pleomorphism and numbers of 
mitoses, classified into grades 1-3, and found that grade correlated with prognosis. 
The Nottingham modification of the Scarff-Bloom-Richardson grading, which 
retains the three main histological features described by Bloom, was introduced in 
1987 and is widely used in the UK; however, a variety of different grading systems 
are used worldwide. The use of grade as an independent prognostic factor has 
remained controversial despite the fact that many studies have confirmed the 
correlation of grade and prognosis.   
       When constructing their (now widely used) Nottingham Prognostic Index, The 
Nottingham Breast Group performed multivariate analysis to establish those factors 
that were independently related to prognosis, and found grade to be an independent 
significant factor (Galea et al. 1992; Haybittle et al. 1982). In a 1997 review of the 
literature, Roberti et al. (1997) found that low grade predicted either higher 
recurrence-free or overall survival in almost all the studies. Included in this was a 
study of 22,616 cases of breast cancer (Henson et al. 1991) which showed 93%  5-
year survival in the grade 1 group and 65% 5-year survival in the grade 3 group. 
Another study of 1537 node-positive women in an adjuvant therapy trial 
demonstrated that grade retained its significance in a multivariate analysis (Davis et 
al. 1986). Reasons for the reluctance outside the UK to accept grade as a prognostic 
factor may include the lack of standardisation and reproducibility and concern that, 
despite the results of multivariate analyses, it may not be a truly independent risk 
factor and thus not give any additional prognostic information over tumour size or 
stage (Burke & Henson 1997; Going et al. 2001). 
 46 
 
1.6 Why might breast cancer biology be changing?   
It is possible that a change toward hormone receptor positive cancers reflects 
increasing exposure of women to certain factors which not only increase the risk of 
breast cancer but preferentially increase the risk of ER positive or negative cancers.  
There is no evidence thus far that this is due to changes in hormonal exposures.  An 
exhaustive systematic review by Althuis et al. (2004) evaluated the results of 40 
cohort and case-control studies of risk factors for hormone receptor positive and 
negative breast cancer.  For late age at first pregnancy, the strongest associations 
were with increased risk of ER positive and ER+/PR+ cancers.  For total parity, the 
reduction in breast cancer risk with increasing parity was most closely linked with 
ER positivity; there was no link with joint receptor positivity and only one study 
showing a reduced risk of PR positive disease. Older age at menarche was not linked 
with ER or PR status in those studies that assessed receptors separately, although 
studies of joint positivity suggested a link with reduced risk of ER+PR+ disease.   
          A consistent association of postmenopausal obesity and ER+PR+ status was 
demonstrated. Among the large prospective cohort studies, the Iowa Women’s 
Health Study (Potter et al. 1995) showed an association with ER+, PR+ and 
ER+PR+ disease and the Nurses’ Health Study (Colditz et al. 2004) showed that 
only PR positivity was independently correlated with raised BMI. There was weak 
evidence that ever-use of combined oral contraceptives was associated with 
increased risk of ER negative phenotype; the inclusion of older women in many 
studies may have affected the validity of this result.  Most of the studies did not find 
any evidence of increased breast cancer risk with use of hormone replacement 
therapy; the Nurses’ Health Study (Potter et al. 1995), however, did show an 
increased risk of ER positive tumours in past users of HRT. Breast-feeding, 
smoking, alcohol, family history and premenopausal obesity were not associated 
with receptor status differences. 
      As noted earlier, changes in all these factors are occurring; not only will this 
increase risk of breast cancer but it could potentially selectively increase the risk of 
ER positive and potentially PR positive disease.  
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1.7 Deprivation and its relation to incidence, mortality, screening 
trends 
 
 It has long been recognised that breast cancer rates are higher in areas of higher 
socio-economic status (Faggiano et al. 1997; Ketcham & Sindelar 1975; van Loon et 
al. 1995). The reasons behind this have not been conclusively proven, but differences 
in risk factors such as reproductive factors and body mass index have been 
suggested.   There have been suggestions that the incidence gap between affluent and 
deprived in terms of breast cancer incidence is in fact narrowing, with more and 
more deprived women developing breast cancer (Population Trends 1997; Dano et 
al. 2003) although these observations were made in cohort study data rather than 
population data. There are also inequalities in survival, with women of lower socio-
economic status having significantly lower survival rates (Thomson et al. 2001). 
Torgerson et al (1994) postulated that socio-economic differences in body mass 
index could explain survival differences. 
          The survival differences do not appear to be due to deprived women 
presenting with tumours of higher stage or grade. For example Carnon et al. (1994) 
showed that 32% of women in the most affluent group presented with tumours under 
2cm compared with 31% of the least affluent group and  Brewster et al. (2001) 
examined cancer registry data and found no difference in tumour stage at 
presentation.  
       The only prognostic factor that possibly differs between affluent and deprived 
women is a tendency towards more oestrogen receptor negative tumours. Thomson 
et al. (2001) showed that in deprived women under 65 there were significantly 
higher rates of ER negative tumours and lower rates of ER positive tumours than in 
affluent women. However, they did note that although the distribution of unknown 
status tumours was no different between the groups, one third of the women in their 
study had a tumour status that was unknown. Furthermore, they did not feel that ER 
status difference explained survival differences; they estimated that only 4% of the 
22% difference in survival between groups was explicable by ER status.  
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          There has been much recent interest in the epidemiology of Marin County in 
the Bay area of San Francisco. This county has significantly higher breast cancer 
rates per 100,000 than the rest of San Francisco and in many parts of the United 
States (Benz, Clarke, & Moore 2003; Hwang et al. 2005; Prehn et al. 2002; Prehn & 
West 1998; Robbins, Brescianini, & Kelsey 1997; Wrensch et al. 2003). Its 
population is demographically homogeneous and it has a high proportion of women 
of high socio-economic status.  In fact it has been shown that rates in Marin County 
are similar to rates in other areas of California with a similarly high socio-economic 
status (Prehn & West 1998).  
           The affluence of the women in Marin County may be a marker for exposure 
to certain risk factors over time which promote the development of breast cancer. 
Several studies have attempted to elucidate such risk factors. Robbins et al  (1997) 
analysed incidence rates in the San Francisco Bay Area and elsewhere in the SEER 
registry, correcting them for the presence of identifiable risk factors, such as age at 
first pregnancy, age at menarche, alcohol use, parity and breastfeeding duration. 
They concluded that the high incidence in the San Francisco Bay area could be 
completely explained by regional risk factor differences. Wrensch et al. performed a 
case-control study of women in Marin County and found the only difference in risk 
factors between cases and controls to be that of a difference in alcohol consumption 
(Wrensch et al. 2003).      
            Deprived women in the UK (Gatrell et al. 1998) and the US (CDC 2005) take 
up invitations for screening in lower numbers than affluent women; reasons may 
include differences in awareness and attitudes to health, availability of services and 
access to public transport. There is also some suggestion from cross-sectional studies 
that women of lower socioeconomic status are less likely to use hormone 
replacement therapy (Lawlor, Smith, & Ebrahim 2004). 
       The excess breast cancer incidence in the population of Marin County includes a 
higher than expected number of ER + PR+ cases (Benz, Clarke, & Moore 2003). As 
discussed above, particular risk factor profiles may contribute to development of 
oestrogen receptor positive breast cancers, and it is notable that these risk factors 
(low parity, late age at first pregnancy) are typical of the women in Marin County. 
Therefore the theory of a difference between the receptor status of tumours in 
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women of different socio-economic categories is plausible and may be explained by 
risk factor profiles.  
1.8 Aims of This Thesis 
 
This thesis presents research carried out on two separate but closely related projects; 
an epidemiological study of influences on breast cancer incidence in Scotland, and a 
laboratory project studying the grade and receptor status of breast cancers in 
Scotland over time. The aim of the thesis as a whole was an exploration of 
influences on breast cancer incidence and molecular epidemiology in Scotland. Each 
of the chapters 2 (Materials and Methods) and 3 (Results) is divided into Part 1 
(Epidemiology project) and Part 2 (Laboratory project). 
 
Aims: Part 1 - Breast Cancer Incidence in Scotland and Its Influences 
 
On the background of the changing breast cancer incidence patterns in the UK, the 
following research aimed to establish: 
- trends in breast cancer incidence in Scotland, by age group and birth cohort 
up to 2003, particularly concentrating on women aged 50-64 
- the potential influence of screening on incidence trends aged 50-64 in 
Scottish women over this period: both temporally and by birth cohort 
- incidence rates within women of different socioeconomic standing over this 
period 
- the potential contribution of breast cancer risk factors to these incidence 
trends 
 
Aims: Part 2 - Is The Biology Of Breast Cancer Changing? A Study Of 
Hormone Receptor Status And Grade 1984-86 And 1996-97 
 
The project was designed in order to identify any changes that have occurred in the 
biology of breast cancers over time. 
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The primary aim of the study was: 
To compare the percentage of breast cancer patients from two Glasgow hospitals in 
two separate time periods (1984-1986 and 1996-1997 ) who had tumours which were 
1) oestrogen receptor positive 
2) of  high and low pathological grade 
3) progesterone receptor positive 
4) HER-2 positive 
 
Previous studies of changes in receptor status over time have retrospectively studied 
database records of receptor positivity, with the inherent problem of heterogeneity of 
receptor testing over time; this is the first such study to apply immunohistochemistry 
to use archival tissue to establish the prevalence receptor positivity. Studies have 
show stability of antigenicity over time in archived tissue blocks (Camp et al. 2000, 
Shibata et al. 1988).  
 
Secondary aims included: 
! To study the distribution of hormone receptor positivity and pathological 
grade between different socio-economic groups and how this may have 
changed over time 
! To study and compare the distribution of hormone receptor positivity and 
pathological grade in screen-detected and symptomatic tumours.  
! To assess the contribution of these changes to the survival of the patients 
 51 
Chapter 2: Materials and Methods 
 
Materials and Methods Part 1: Breast Cancer Incidence in Scotland 
and Its Influences 
 
This section explores trends in breast cancer incidence in Scotland, by age group and 
birth cohort up to 2003, particularly concentrating on women aged 50-64, i.e. those 
women routinely invited for screening by the NHS Breast Screening Programme in 
Scotland during this period. A specific study of breast cancer incidence by year of 
birth in these women was performed (section 2.2); as discussed above, birth cohort 
cancer incidence rates can provide information on the likely contribution of risk 
factors to incidence, and this particular analysis  was the first such analysis to try to 
incorporate the effects of a screening programme into the calculations. Further 
exploration of changes in the screening programme was also performed (section 2.3, 
section 2.6). The difference in incidence trends in different socioeconomic categories 
was performed (section 2.5), and the potential contribution of known breast cancer 
risk factors (hormone replacement therapy, BMI, alcohol, fertility patterns) to these 
incidence trends was also undertaken (section 2.4, section 2.7). 
General Notes on the Epidemiological Data and Statistical Methods 
Used 
 
Data on breast cancer incidence in Scottish women were obtained from the Scottish 
Executive’s Information and Statistics Division (ISD), as discussed in more detail in 
the sections below. The ISD manages the Scottish Cancer Registry, which is 
responsible for collecting information on all new cases of malignant tumours in 
Scotland. Since 1997 a computer system with linkage to hospital discharge codings 
and pathology records has been used to obtain data on cancer cases along with the 
relevant prognostic criteria and demographic data of the patients, and frequent 
validation checks are carried out to ensure data completeness. The Cancer Registry 
was independent between 1958 and 1997, and during this time a system of 
compulsory notification by clinicians of cancer cases was in place while the lack of 
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computer linkage is likely to have reduced the completeness of the data, regular 
validation audits were carried out and the Registry has long had a reputation for the 
accuracy of its data. Other data obtained from ISD Scotland as described below 
includes data on prescriptions and breast screening. The Scottish Breast Screening 
Programme has always rigorously maintained and analysed data about the activity of 
its service, including screening invitations, numbers of mammograms performed and 
details of findings on these, and this data is all passed to ISD.  
         Data on births in Scotland is kept by the General Register Office for Scotland; 
with the compulsory registration of a birth at a local register office birth, the parents’ 
occupations and ages are recorded and all data passed directly to the General 
Register Office where it is immediately checked and now digitised ensuring data 
completeness. The Register Office staff add further information to those data, for 
example comparing with previous certificates to determine whether a birth is the 
mother’s first or not.  
       Some data on lifestyle-based risk factors is taken from the Scottish Health 
Surveys of 1995, 1998 and 2003 (Bromley et al. 2005; Dong & Erens 1997; Shaw et 
al. 2008). These ground-breaking cross-sectional surveys studied around 6000 male 
and female subjects in Scotland, recording detailed information on lifestyle factors 
based on anthropometric recordings and self-reporting; extensive statistical analyses 
were performed and the authors of each study compared their results to the studies 
before to give an estimate of trends. In 1995 the subjects were aged 16-64, 16-74 in 
1998 and 16 and over in 2003. These data have been extrapolated extensively by the 
Scottish Executive and other researchers to represent the health and lifestyle of 
Scotland as a whole. The benefit of such projects is to gain information that would 
be impossible to collect from the population of Scotland as a whole; while greater 
computer recording by GP surgeries is now providing more data about the health and 
lifestyle of patients, a large proportion of the population will rarely attend a GP.  
Using the data requires extrapolating to represent the Scottish population, and this 
assumption may be invalid if there has been a selection bias in the subjects assessed 
by the Survey. In order to minimise the risk of this selection bias, extensive 
statistical advice was used to ensure representativeness, with stratified cluster 
sampling being carried out. Additionally, while the data has been divided into age 
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categories there is no data on the menopausal status of the women in the study, 
information which may have been of relevance for this thesis. 
             A note on the regression analyses used in this thesis: as incidence rates are a 
form of count data, they should follow a Poisson distribution. The Poisson 
distribution assumes that the events are integers that are not less than 0, they occur 
singly and independently of time since the last event, and the probability of an event 
occurring in a given time interval is constant over time. Poisson regression is the 
corresponding model used to describe the association between explanatory variables 
and count or rate data. A limitation of Poisson regression, however, is that regression 
on rate data requires the absolute population denominators and these may not be 
readily available from routine data that are expressed as rates per 100 000 
population. A useful technique is the Normal approximation to the Poisson for large 
values (> 30) of the Poisson parameter, which allows one to use the log-transformed 
rates in a linear regression and does not require absolute denominator data - that is, 
routinely available rates per n population can be used. The Normal approximation 
produces very similar regression coefficients to Poisson regression particularly 
where counts are large, as is the case for nationally published breast cancer incidence 
rates. Therefore, linear regression on log-transformed rates was used to produce all 
regression analyses of incidence data in this thesis. Simple regression analyses were 
used when appropriate, e.g. percentage uptake of screening invitations.  
 
2.1. Temporal Breast Cancer Incidence Trends in Scotland 
 
Incidence rates of breast cancer in women younger than and older than screening age 
in the UK have shown little variation over time and it is the age groups offered 
screening who have seen the biggest changes in incidence. Therefore, a detailed 
study of breast cancer incidence trends in Scotland in the age ranges 50-54, 55-59 
and 60-64, that is, women who are offered screening mammography, and women of 
65-69, that is, women just above screening age, was felt to be of most value in 
elucidating influences on incidence.  
        The breast cancer incidence rates per 100,000 women for each year from 1975 
to 2003, divided into 5 year age ranges, were obtained from the website of the 
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Scottish Executive’s Information and Statistics Division. To assess the magnitude of 
the changes in incidence in women aged 50 to 69 in this study, a plot was 
constructed and then an ‘observed versus expected’ analysis (as described by Smith 
et al. 2008) was performed to estimate what breast cancer trends in Scotland were 
likely to have been in the absence of the screening programme and compare them to 
current trends.  
 
“Observed versus Expected” Analysis 
 
Observed trends: 
 The mean incidence rate for 1999-2003 was calculated, to represent the ‘observed’ 
incidence rate in 2001, with a time range being more reliable than a single year 
Expected number of cases: 
The annual percentage increase in cases per 100,000 per year between 1975 and 
1987 (when the screening programme began) for each of the four age groups (50-54, 
55-59, 60-64 and 65-69) was calculated by performing linear regression analysis of 
log-transformed incidence rates using SPSS statistics package version 14.0; annual 
percentage increase was determined by 100 x (e 
B
 – 1) where B is the B coefficient 
of the regression equation.  The expected number of cases for 2001 – the midpoint of 
the 1999-2003 range - was then determined by sequentially increasing the 1987 rate 
by the annual percentage increase determined above for each of the intervening 14 
years. 
The percentage increase in incidence rate was calculated by dividing expected (E) by 
observed (O), minus 1 and multiplied by 100%.  
 
2.2. Birth Cohort Incidence of Breast Cancer in Scotland and the 
Influence of the Screening Programme 
Age and year specific breast cancer incidence rates per 100,000 were supplied for 
women aged 45 to 69 years from 1977 to 2003 inclusive by the Information and 
Statistics Division. The data were placed into a Lexis diagram (appendix 1), a format 
which allows easy identification of the birth year represented by each age within 
 55 
each calendar year. The mean incidence rate for women aged 50 to 64 was calculated 
for each birth year cohort from 1920 to 1949. Mean incidence rates were then 
calculated for each birth year for  the age ranges 45-49, 50-54, 55-59, 60-64 and 65-
69. The time points at which the women in each cohort and age range became 
eligible for screening in the prevalent round (1987-1994) and the time points 
between which ALL women in the cohort and age range would have been eligible 
for screening in the prevalent round were identified. For example, women born in 
1933 were aged 50-54 between 1983 and 1987.  Some of the 50-54 year old age 
group who were born in 1933 were thus eligible for screening when the round began 
in 1987, albeit only those aged 54.  In the 1934 birth cohort, only 53- and 54-year 
olds were eligible for screening.  The 1937 birth cohort was thus the first in which all 
50-54 year olds were eligible for screening in the prevalent round.  Similarly, as 
women in the oldest ages of any age-group reach the end of the prevalent round in 
1994 they will then go on to be screened during the established (“incident”) round of 
screening.  Thus the 1940 cohort was the last in which all 50-54 year olds would 
have been part of the prevalent screening round.   
      Breast cancer incidence rates per 100,000 were plotted against birth year. Mean 
incidence rates were then plotted against birth year separately for each age range, 
with the region of the graph representing all women in the cohort being offered 
screening being highlighted. 95% confidence intervals (CI) for the differences in 
breast cancer incidence rates were calculated using a method based on that described 
by Altman and others for differences in proportions for paired samples (Altman  et 
al. 2000):  
 
p = incidence rate / 100,000 (1 = rate at end of period, 2 = rate at start) 
n= population (100,000)  
1.96 = constant used based on 95% confidence interval, as listed in Altman  
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Difference in rates  =  
 
! 
p1" p2 ±1.96 #
p1(1" p1)
n
+
p2(1" p2)
n
#100,000
 
The differences in rates (with confidence intervals) was calculated for each age 
range for: 
1) the rate in the cohort representing the start of the study period to the rate  in the 
cohort where  women began to be offered screening 
2) the rate in the cohort where women began to be offered screening as part of the 
prevalent round  and the cohort where women began to be offered screening as part 
of the ‘incident round’ of screening (this therefore includes cohorts where some or 
all women would have been offered screening in the prevalent round) 
3) the rate in the cohort where women began to be offered screening as part of the 
‘incident round’  to the cohort representing the end of the study period.   
A Lexis diagram  (Appendix 1) was used to identify the points at which women were 
entering or leaving screening periods.  
 
2.3 Breast Screening Data 
The Scottish Breast Screening Programme was introduced in 1987. All eligible 
women had been invited for a first screen – that is, the ‘prevalent round’ had been 
completed, by 1994. In 2003/04 a phased extension of age range or routine invitation 
to 50-70 years began. Figures studied here, however, are from before this age 
extension began.  
      As detailed above, improvements in the breast screening programme may 
artificially raise incidence rates by improving the ability of the screening programme 
to detect cancers, and increasing uptake rates may also increase incidence rates as 
more women have a ‘prevalent’ screen. Self-referrals and GP referrals for screening 
are not covered by figures on uptake rates, and changes in these figures may 
similarly affect incidence rates. In particular, if numbers of older women self-
referring for screening increase, this could have an effect on incidence rates in older 
women. Information on the history of the screening programme in Scotland was 
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obtained from ISD Scotland’s website. Information on percentage uptake of 
screening invitations, self-referrals for screening and standardised detection ratio 
over time was obtained by contacting the Scottish Executive’s Information and 
Statistics Division (ISD). The author went on to further analyse these trends using 
log-linear regression on SPSS v14.  
 
2.4. Risk factor trends 
 
Information of fertility trends was obtained from the General Register Office for 
Scotland and ISD Scotland. This comprised completed family size data (as a marker 
for parity) and data on births at different maternal ages, both temporal trends and 
trends by maternal age. Further analysis by constructing graphs and performing 
linear regression (SPSS v14.0) was carried out by the author.  
        Specific attention was paid to trends in numbers of women having their first 
birth at ages 35-39. Having a first birth over the age of 35 increases breast cancer 
risk; the data were available divided into 4-year age groups and as it was felt that 
grouping the data from different age groups together was not epidemiologically 
sound, the 35-39 age group was analysed. The author also calculated first births to 
women aged 35-39 as a percentage of all first births.  
       Data on trends in body mass index and prevalence of obesity over time were 
obtained using the published Scottish Health Surveys of 1995, 1998 and 2003 
(Bromley et al. 2005; Dong & Erens 1997; Shaw et al. 2008).  Without having the 
full dataset it was not possible to further statistically analyse BMI trends over time 
and so here a simple reporting of changes in mean BMI was made by the author. In 
1995 the subjects were aged 16-64, 16-74 in 1998 and 16 and over in 2003, so a 
comparison was made between women who were aged 16-64 only. 
      Data on trends in oral contraceptive use were not felt to be relevant in this 
analysis; as risk is thought to disappear 10 years after last use, and these women are 
unlikely to have used oral contraceptives less than 10 years previously.  The only 
data available from ISD Scotland on hormone replacement in Scotland was total 
numbers of prescriptions from 1993 to 2003. Therefore estimation of prevalence was 
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made by the author in a similar fashion to the calculations of Townsend when 
estimating prevalence in England and Wales (Townsend 1998). Trends in alcohol 
use in Scottish women over time had been assessed by the authors of the Scottish 
Health Surveys (Bromley et al 2005; Dong & Erens 1997; Shaw et al 2008) and 
these trends are detailed here.  
 
 
2.5 Incidence trends in different socioeconomic categories 
Statistics of breast cancer incidence by socioeconomic status have been collected by 
the Information and Statistics Division. Each patient is assigned a deprivation 
quintile. Quintiles of deprivation were calculated by ISD Scotland using the 
Carstairs and Morris index. This index is calculated on the basis of the results of the 
most recent census (in the case of these data, the 1991 census) and is based on four 
main indicators: lack of car ownership, Registrar General Social Class, overcrowded 
households and male unemployment. Index scores are then divided into quintiles in a 
weighted manner so that 20% of the population fall into each quintile. ‘Deprivation 
categories’ were the original categories proposed by Carstairs and Morris and were 
used until the recent adoption of the quintile method. Categories 1 to 7 were based 
on index scores and were designed to retain the discriminatory value of each 
category rather than divide the population into equal groups. Since 2001, deprivation 
quintiles have been calculated on the basis of the more complex Scottish Index of 
Multiple Deprivation. This is based on 37 separate indicators within 7 headings  
(current income, employment, health, education, geographic access, crime and 
housing) for each postcode, which are used in a weighted manner to give a ‘score’ to 
an area. 
    In order to analyse breast cancer incidence trends in different socio-economic 
groups it is important to calculate trends on the basis of similarly categorised data 
and so rates from 1991 to 2000, which were categorised into deprivation quintiles on 
the basis of Carstairs and Morris index, were used. At any rate, such data are more 
‘stable’ when analysed several years down the line. 
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      Breast cancer incidence rates from 1991 to 2000 for the five quintiles of 
deprivation were obtained from ISD. Unfortunately age-specific data are not kept by 
ISD.  Linear regression of log-transformed rates was performed on the rates of breast 
cancer in each deprivation quintile; p-values for each regression equation were 
assessed to look for the presence of a significant trend. Then in order to see whether 
the slopes differed significantly from one another, analysis of interaction was 
performed using the univariate ANOVA in SPSS v14.  
 
2.6 Breast screening and socioeconomic status 
 
Data were obtained from the Scottish Breast Screening Programme via ISD Scotland 
on percentage uptake of screening invitations by deprivation category (1-7), divided 
into one- year periods from 1990-1991 to 2001-2002. A graphical representation of 
trends was made, which suggested that uptake was increasing over time in all 
deprivation categories. It was important to assess not only whether percentage 
uptake was increasing in each category, but also whether it was increasing to the 
same degree in each category.  Therefore linear regression (using SPSS v14) was 
performed of the rates over time for each deprivation category and an interaction 
term (using univariate ANOVA) was added into the analysis. The p value for the 
interaction term gives an understanding of whether the rates are increasing to the 
same extent in all deprivation categories. 
 
2.7. Risk factor trends and socioeconomic status 
The General Register Office for Scotland  supplied data on numbers of first births at 
various maternal ages by deprivation category (1-7) from 1975 to 2003. In view of 
the particular influence on incidence of first pregnancy over the age of 35, particular 
attention was paid to the maternal age category 35-39. Data on completed family 
size and nulliparity by deprivation category were not calculated by the General 
Register Office for Scotland or ISD Scotland. 
      A graphical representation carried out by the author of numbers of births to 
women of maternal age 35-39 divided into deprivation category suggested that births 
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at late maternal age in all deprivation categories was increasing in a linear fashion, 
but with a widening gap as a result of many more affluent women than deprived 
women having first birth over 35 in recent years. In order to confirm this, linear 
regression of log-transformed numbers of births was performed by the author using 
SPSS v14, with univariate ANOVA to test for interaction. The p-value for the 
interaction term was assessed to identify whether rates of late first birth were 
increasing to the same degree in all categories.  
       Data on BMI and socio-economic status was obtained from the Scottish Health 
Surveys of 1995, 1998 and 2003.  In Health Surveys 1995 and 1998, Registrar 
General Social Class was used to classify socio-economic status but in 2003 the 
Scottish Index of Multiple Deprivation was used. The association of BMI and 
obesity prevalence and social class in each study year was analysed by the author 
(Sylvia Brown) using Spearman’s correlation with SPSS v 14.0. Trends in oral 
contraceptive and hormonal therapy use by deprivation category were not available 
from any agency.  
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Methods Part 2: Laboratory Project - Is the biology of breast cancer 
changing? A study of hormone receptor status and grade 1984-86 
and 1996-97 
 
 
2.8 Study Design Summary 
The project was designed as a laboratory based study comparing archival tumour 
samples from every female patient who had surgical treatment for breast cancer in 
one of the two study periods. The study periods 1984-86 and 1996-1997 were 
chosen, and patients from Glasgow Royal Infirmary and Glasgow Western Infirmary 
included in the study, having been identified from the Scottish Cancer Registry. A 
database was constructed and archival tissue from each patient obtained. New 
sections were taken and prepared by the author for grade analysis (which was 
performed by Dr. Elizabeth Mallon at Glasgow Western Infirmary) and samples 
were taken to put into tissue microarrays (TMAs). Sections were taken from the 
TMAs and immunohistochemistry performed for oestrogen receptor, HER-2 and 
progesterone receptor. Positivity for each of these receptors was assessed by visual 
assessment using the weighted histoscore method. Statistical analysis was then 
carried out to compare pathological grade and positivity between the two time 
cohorts. Analysis of the influence of socioeconomic status and screening status on 
pathological and molecular tumour characteristics was also undertaken.  
 
 
 
2.9 Patient Selection 
The study period was chosen as Scottish Cancer Registry data existed for these 
women, the period was before screening had been introduced, and a suitable length 
of time was present between this and the later study period.  By using patients from 
Glasgow Royal Infirmary whose catchment area mostly consists of patients of 
deprived and intermediate socioeconomic status, and the Western Infirmary which 
includes intermediate and affluent patients, a wide range of socioeconomic 
 62 
categories would be present in the study, allowing analysis of association of receptor 
status, pathology and socioeconomic status to be undertaken. In 1984 tamoxifen was 
offered to ER positive women as adjuvant therapy in Glasgow hospitals.  
A sample size calculation was undertaken to ensure that the study was sufficiently 
powered to detect a difference in receptor positivity. A sample size adequate to 
detect a 10% difference in oestrogen receptor positivity was felt to be the most 
important criterion. Sample size was calculated using the following formula 
(Whitley & Ball, 2002): 
 
n = 2 x [p1 x (1-p1)] + [p2 x (1-p2)]     x Cp,power (a constant based on power and p)  
                                (p1-p2)
2
                                                          
 
where p1 is old cohort predicted percentage and p2 new cohort.  If the older cohort 
oestrogen receptor positivity level is predicted to be 60% (from pilot studies at 
Glasgow Royal Infirmary)  and the newer cohort to be 70%, a total of 712 patients 
are required to show a 10% difference in receptor status with a power of 80% and 
level of significance of 0.05.   As the cohorts were expected to be of unequal size 
(cohort 2: cohort 1 ratio expected to be 1.5:1) as a result of the increase in incidence 
of breast cancer, an adjustment had to be made to estimate the sample number in 
each group. Using a formula detailed by Whitley and Ball (2002), the required 
sample size in cohort 1 was estimated to be 296 and the sample size in cohort  2,  
446.  
 
2.10  Ethical Approval and Consent 
Ethical approval was obtained from the Glasgow East Local Research Ethics 
Committee 1 on December 17
th
 2004. Women from 1998 onwards at Glasgow Royal 
and Western Infirmaries signed a consent form before surgery which specifically 
stated consent for use of tumour samples in research.  Before this, consent for tissue 
use in research was not specifically requested. Ethical approval for this study was 
granted without the need to retrospectively acquire consent from the patients or their 
next of kin, in the light of data from the QUASAR colorectal radiotherapy study 
suggesting that most women would not object to use of tumour samples for research, 
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and in view of the difficult and potentially traumatising nature of a request to the 
next of kin for use of their relative’s tumours sample.  
 
2.11 Construction of Database      
The Scottish Cancer Registry had collected data from every patient with breast 
cancer in the period 1984-1986 who had been seen at Glasgow Royal and Glasgow 
Western Infirmary. Those women who had a clinical diagnosis only or core biopsy 
diagnosis only were excluded from the analysis (this was evident from the Cancer 
Registry data and confirmed by a search of stored pathology records). An additional 
41 patients had Registry data suggesting that they had undergone breast cancer 
surgery but search of stored pathology records revealed either only core biopsy 
pathology or no pathology record at all. These patients may have had an operation at 
a different hospital or the pathology record may have been lost, and therefore these 
patients could not be included in the study. This gave a database of 423 patients who 
were operated on for breast cancer between 1984-1986 in Glasgow’s Royal and 
Western Infirmaries.  
        At this time in Glasgow pathologists often did not report the pathological size 
of the tumour. In addition, the practice of axillary clearance as the only surgical 
technique used in the axilla meant that more women were denied axillary surgery on 
the grounds of age or fitness than would be refused today. This meant that many of 
these patients do not have full pathological data to allow us to retrospectively assess 
their prognosis. 120 of these patients had incomplete pathological data, with tumour 
size and/or nodal status data missing. These patients were nevertheless included in 
the study, as their exclusion would preclude the direct comparison of two full 
cohorts of patients.  
       Patients from 1996 and 1997 were obtained from the Glasgow Breast Cancer 
Audit, maintained by Greater Glasgow Health Board. 653 patients were suitable for 
inclusion in our study database. Only 12 of these had incomplete pathology data.  
This gave a total of 1076 patients. A computer database was formed in SPSS version 
14. Each patient was assigned a database number to allow anonymisation, and data 
for each patient included: age, hospital, deprivation category (based on Carstairs 
index data calculated from the 1981 or 1991 census), tumour size, nodal status, 
 64 
method of tumour detection (screen-detected or symptomatic), cause of death if 
appropriate, survival status at time of last follow-up, survival time from diagnosis 
and  pathology number.  Pathology numbers for 1996-7 patients were included in the 
Glasgow Audit database; pathology numbers for 1984-6 patients were obtained by 
searching paper pathology records. Names and dates of birth were not included. The 
database was securely stored on a password protected server.  
 
2.12 Tumour Retrieval 
Once the pathology number was obtained for each patient, a paraffin-embedded 
tumour block was sourced from storage. For the 1984-1986 cohort of patients, the 
block which appeared most likely to contain tumour was chosen. For the 1996-1997 
cohort, blocks containing tumour were already identified by an orange block casing. 
For some patients, either no block at all could be retrieved or no tumour-containing 
block could be found. 
Of 1076 patients 123  tumour blocks could not be found.    
1984-1986:  100 blocks were missing (24% of 423): 323 in study ‘cohort 1’  
1996-1997:  76 blocks were missing (11% of 653):   577 in study ‘cohort 2’   
 
2.13 Mercuric chloride: Testing possible interference with IHC  
After retrieving specimens from 1984-1986 it became evident that specimens from 
this time period at the Western Infirmary had been fixed with mercuric chloride 
which was previously used to enhance H&E staining. As there was little literature on 
the possible effects of mercuric chloride, immunohistochemistry for oestrogen 
receptor was performed on whole sections from ten tumours and compared with 
negative and positive controls. Receptor immunohistochemistry did not appear to be 
affected by the presence of mercuric chloride in the specimens.  
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2.14 Haematoxylin and eosin staining 
A 4µm-thick section was taken from each block (sectioning carried out by Miss 
Fiona Campbell of the Endocrine Group at Glasgow Royal Infirmary). Haematoxylin 
and eosin (H&E) staining was carried out to allow microscopy to confirm the 
presence of tumour, allow grading of the tumour and allow marking of  tumour areas 
for tissue microarray construction. 
 
H&E protocol 
 
Materials:  
Deparaffinisation and rehydration: 
! Xylene         
! 99% industrial  grade methylated spirits 
! 90% industrial grade methylated spirits  
! 70% industrial grade methylated spirits  
Staining: 
! Mayer’s Haematoxylin 
! Scott’s Tap Water substitute (3.5 g sodium bicarbonate, 20g magnesium 
sulphate, 1 litre distilled water) 
! Eosin (1 spoonful calcium chloride dihydrate added at the start of each 
protocol) 
! Calcium chloride dihydrate 
Dehydration: 
! 70% industrial grade methylated spirits  
! 90% industrial grade methylated spirits  
! 99% industrial grade methylated spirits  
! Xylene  
Mounting:  
! DPX (dibutylphthalate and xylene) 
! 22mm x 40 mm glass coverslips 
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Protocol: 
Tissue sections were dewaxed in xylene by dipping 3 times for 2 minutes each time, 
and then rehydrated by immersing in graded alcohol (two separate periods of 2 
minutes in 99% methylated spirits and 2 minutes in each of 90% and 70% 
methylated spirits). 
      Tissue sections then underwent Haematoxylin and Eosin staining. Initial staining 
was performed by placing slide trays in Mayer’s haematoxylin for 3 minutes, then 
running water for 30 seconds and then Scott’s tap water substitute until the slides 
were stained dark blue. After a further running water step, the slide trays were placed 
in Eosin for 10 minutes and then rinsed. Dehydration was then performed by placing 
tissue sections in graded methylated spirits, initially 30 seconds in 70% methylated 
spirits, then 1 minute in 90% and finally 2 separate periods of 1 minute in 99% 
methylated spirits. Finally, 3 separate 2  minute periods of immersion in xylene were 
carried out. 
 
Mounting: 
Coverslips were then mounted onto each slide using a drop of DPX fixative. Slides 
were left to dry overnight. 
 
 
2.15 Grading 
H&E slides of whole sections from the tumours were sent to Dr. Elizabeth Mallon, 
consultant histopathologist at the Western Infirmary in Glasgow, to establish 
pathological grade. This established that the same pathologist for all the tumours to 
allow valid comparison of all the tumours had calculated in the same way and the 
grade. The Nottingham grading system (Elston-Ellis modification of the Scarff-
Bloom-Richardson system) was used to grade the tumours; this modification has 
increased reproducibility of grading (Dalton et al. 2000; Elston & Ellis 1991; Going 
et al. 2001).  This grading system classifies tumours as Grade 3 (high grade), Grade 
2 (intermediate grade) and Grade 1 (low grade) based on a cumulative score of 
tubule formation, mitotic count and nuclear pleomorphism as below: 
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Tubule formation: 
Majority of tumour (>75%)  1 
Moderate degree (10-75%) 2 
Little or none (<10%) 3 
Mitotic count: 
0-9 mitoses/ 10 high power fields 1 
10-19 mitoses/ 10 hpf  2 
" 20 mitoses/ 10 hpf    3 
 
Nuclear Pleomorphism: 
Small regular uniform cells  1 
Moderate nuclear size and  variation  2 
Marked nuclear variation   3 
 
Combined histologic grade 
Total score 3-5 Grade 1 (low)  
Total score 6-7 Grade 2 (intermediate) 
Total score 8-9 Grade 3 (high) 
 
An initial check was made on microscopy to  confirm the presence of tumour, as 
certain of the older blocks were not automatically identified containing tumour. For 
those that did not contain tumour, further blocks were obtained and the sectioning, 
H&E and microscopy process was repeated.  The presence of lymphovascular 
invasion and the type of cancer (lobular or ductal)  was also noted. 862 tumours were 
graded in this way.  The study population undergoing immunohistochemistry was 
larger than this due to further tumour blocks having been retrieved after the grading 
part of the project had been completed. 
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2.16 Immunohistochemistry 
Construction of Tissue Microarrays 
Tissue microarrays are a convenient and widely used technique, allowing 
immunohistochemistry to be performed on samples from multiple patients 
simultaneously. At least 20 studies have shown that the sample of tumour taken for 
use in a tissue microarray (generally a cylindrical core 0.6mm in diameter) is 
representative of the sample as a whole (Simon, Mirlacher, & Sauter 2003). Camp et 
al. validated the use of tissue microarrays in breast cancer (Camp et al. 2000). They 
noted that expression of oestrogen receptor, progesterone receptor and HER-2 is 
heterogeneous from place to place in breast cancers. They still found, however, that 
using only two needle cores from a tissue block accurately represented antigen 
expression on a whole tissue section with 95% accuracy. Cores were taken by the 
author from areas confirmed as invasive carcinoma by a pathologist. Zhang et al 
(2003) suggested that even a single core could be sufficiently representative of the 
tumour as a whole. Additionally, tissue microarray technology means that all the 
specimens in the microarray are processed at one time under identical laboratory 
conditions, and also results in much less damage to original archival samples, 
allowing them to be used many more times than would previously have been the 
case. 
  An initial decision was made to take three cores from each tumour sample, as 
described by Camp et al. (Camp, Charette & Rimm 2000). A pathologist (Dr. 
Elizabeth Mallon, consultant histopathologist at the Western Infirmary in Glasgow) 
marked 2mm areas of invasive tumour on whole sections to ensure the cores were 
taken from the correct areas. Two separate areas of invasive tumour were marked in 
each whole section. Two 0.6mm cores were taken from one area and one from the 
other area giving a total of three cores. Cores were inserted into paraffin blocks; each 
of the three cores from the same tumour was inserted into a separate block resulting 
in the tissue microarrays being reproduced in triplicate. Cores were inserted into 
each block in an asymmetric pattern, which facilitated the correct orientation of 
sections at the time of microscopy. A grid format was used to record the study 
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number of each sample inserted into the TMA. 18 tissue microarrays in total were 
constructed.  
Despite careful sampling in triplicate a small number of tumour blocks were not 
represented by a tumour-containing core (as this was discovered on microscopy of 
the TMAs at the end of immunohistochemistry, the tumour could not be re-sampled). 
  
Sections 4"m in thickness were cut from each TMA to be used in the study.  
 
 
Standardisation 
 
In order to eliminate the effect of alteration in laboratory conditions, sections from 
every TMA underwent each individual immunohistochemistry protocol at the same 
time. Fresh sections were taken from each TMA on the day of the study in order to 
avoid the risk of loss of antigenicity (Fergenbaum, 2004). 
 
 
 
 
Oestrogen Receptor Immunohistochemistry 
 
Materials 
Slide rehydration and dehydration: 
Xylene 
99% industrial grade methylated spirits 
90% industrial grade methylated spirits  
70% industrial grade methylated spirits 
Antigen retrieval:  
Optimisation steps: 
Tris-EDTA solution ph8.0  (Sigma EDTA 0.37g, Sigma Tris Base 0.55g , 1 litre 
distilled water) 
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Tris-EDTA solution pH 9.0 (Sigma EDTA 0.37g, Sigma Tris Base 1.21g, 1 litre 
distilled water 
Citrate buffer pH 6.0 (3.84g anhydrous citric acid in 1.8 litres distilled water) 
Final protocol: Tris-EDTA solution ph8.0   
Endogenous peroxidase blocking agent:  
Hydrogen Peroxide 3% (40mls 30% hydrogen peroxide in 400mls distilled water) 
Primary antibody: 
Novocastra Oestrogen Receptor Clone 6F11 (mouse anti-human) 
Final protocol dilution 1:50 
Dako antibody diluent  
Secondary antibody:  
Dako Envision Chem-Mate  
(Dextran –labelled Goat anti-mouse/rabbit antibody with horseradish peroxidase) 
Visualisation reagent:  
Dako DAB (3,3-diaminobenzidine) 
Dako DAB substrate buffer (Tris-Hcl) 
Wash buffer:  
Optimisation steps: Tris-buffered saline  
Counterstain: 
Mayer’s haematoxylin 
Distilled water 
Mounting: 
DPX (dibutylphthalate and xylene) 
22mm x 40 mm glass coverslips 
 
 
Antigen retrieval steps and antibody optimisation steps were performed using TMAs 
containing ER positive tumour samples; the final protocol was carried out using the 
study TMA sections. 
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Slide preparation: 
Tissue sections were dewaxed in xylene by dipping slide trays 3 times for 2 minutes 
each time, and then rehydrated by immersing in graded alcohol (two separate periods 
of 2 minutes in 99% methylated spirits and 2 minutes in each of 90% and 70% 
methylated spirits). 
 
ER Antigen retrieval optimisation 
 
A test battery was performed in order to find the antigen retrieval process and 
antibody concentration which gave optimum tissue staining: that is, strong staining 
with minimal non-specific ‘background’ staining.  No difference in staining was 
seen between those samples that had been fixed in formaldehyde and those that had 
been fixed in mercuric chloride throughout the optimisation steps. 
 
Optimisation of antigen retrieval was performed using each of Tris-EDTA pH 8.0, 
Tris-EDTA pH 9.0 and Citrate buffer (pH 6.0) as buffers in combination with each 
of the following heat induction methods: water bath at 100 degrees centigrade, 
microwave pressure cooker for 1 minute, microwave pressure cooker for 2.5 minutes 
and the microwave pressure cooker for 5 minutes.  
In the pressure cooker steps, the solution was heated in a microwave until boiling 
and placed in a pressure cooker along with the prepared slides. The pressure cooker 
was placed in the microwave until pressure was reached and then heated at pressure 
for the desired length of time.  The pressure cooker was removed from the 
microwave, the lid was removed and the slides allowed to cool down in the antigen 
retrieval solution for 20 minutes.  
In the water bath steps, the slides and  retrieval solution were placed in a Coplin jar 
in water bath at to 100  degrees centigrade and heated for 20 minutes; the jar was 
removed from the water bath and left to cool for 20 minutes. 
The optimum staining was found to be with EDTA pH 8.0 using the microwave 
pressure cooker technique for 5 minutes. 
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ER Immunohistochemistry Optimisation 
 
Immunohistochemistry optimisation steps were then carried out using different 
concentrations of primary antibody. While oestrogen receptor staining is a well-
established technique, optimisation before the protocol is always preferable due to 
inter-laboratory variation in conditions. After antigen retrieval using EDTA pH 8.0 
with the microwave pressure cooker technique for 5 minutes as above, tissue 
sections were placed in TBS and stirred continuously for 5 minutes. The blocking of 
any endogenous peroxidase in the tissue was ensured by placing the sections in 
400mls hydrogen peroxide 3% for 10 minutes. The slides were placed in TBS, which 
was stirred continuously for 5 minutes. Primary antibody (clone 6F11) was diluted in 
antibody diluent to strengths of 1 in 50, 1 in 100, 1 in 200 and 1 in 400.  For each 
dilution, 200 "l of solution was placed onto an ER positive slide (a water-
impermeable barrier (Dako pen) having been placed around the tissue). 200"l of 
antibody diluent was then added to a breast tumour section to act as a negative 
control. The slides were then left for 1 hour at room temperature.  
 
Slides were placed in TBS, which was stirred continuously for 5 minutes, and were 
then placed in fresh TBS for a further 5 minutes. 200"l of HRP-labelled anti-mouse 
secondary antibody were placed on each of the optimisation slides and left for 30 
minutes at room temperature. Slides were placed in TBS which was stirred for 5 
minutes, and were then placed in fresh TBS for a further 5 minutes. For 
visualisation, DAB and substrate buffer were mixed in a ratio of 20"l DAB to every 
1ml of substrate buffer. 100"l of the resulting chromogen solution was pipetted onto 
each slide and left for 6 minutes before washing the slides in distilled water.  Slides 
were placed in haematoxylin as a counterstain for 30 seconds before washing in 
distilled water. Dehydration was then performed by placing tissue sections in graded 
methylated spirits, initially 30 seconds in 70% methylated spirits, then 1 minute in 
90% and finally 2 separate periods of 1 minute in 99% methylated spirits. Finally 3 
separate 2-minute periods of immersion in xylene were carried out. Coverslips were 
placed on the slides using DPX. 
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The optimum primary antibody concentration was found to be 1:50. 
 
Final Oestrogen Receptor Protocol 
 
 After antigen retrieval using EDTA pH 8.0 with the microwave pressure cooker 
technique for 5 minutes as above, tissue sections were placed in TBS and stirred 
continuously for 5 minutes. The blocking of any endogenous peroxidase in the tissue 
was ensured by placing the sections in 400mls hydrogen peroxide 3% for 10 
minutes. The slides were placed in TBS, which was stirred continuously for 5 
minutes 
200 "l of 1:50 primary antibody solution were pipetted onto each of the study TMA 
slides and one positive control (an ER-positive full tumour section). 200 "l of 
antibody diluent alone were pipetted onto a breast tumour section to act as a negative 
control. The slides were then refrigerated overnight to allow maximum antibody 
binding (as recommended by colleagues at another laboratory who used this 
technique with clone 6F11). 
Slides were placed in TBS, which was stirred continuously for 5 minutes, and were 
then placed in fresh TBS for a further 5 minutes. 
200"l of HRP-labelled anti-mouse secondary antibody were placed on each of the 
study TMA slides and control slides and they were left for 30 minutes at room 
temperature. 
Slides were then placed in TBS, which was stirred for 5 minutes, and were then 
placed in fresh TBS for a further 5 minutes. For visualisation, DAB and substrate 
buffer were mixed in a ratio of 20"l DAB to every 1ml of substrate buffer. 100"l of 
the resulting chromogen solution was pipetted onto each slide and left for 6 minutes 
before washing the slides in distilled water.  Slides were placed in haematoxylin as a 
counterstain for 30 seconds before washing in distilled water. Dehydration was then 
performed by placing tissue sections in graded methylated spirits, initially 30 
seconds in 70% methylated spirits, then 1 minute in 90% and finally 2 separate 
periods of 1 minute in 99% methylated spirits. Finally 3 separate 2 minute periods of 
immersion in xylene were carried out. Coverslips were then placed on the slides 
using DPX. 
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Progesterone Receptor Immunohistochemistry 
 
Materials: 
 
Slide rehydration and dehydration: 
Xylene 
99% industrial grade methylated spirits 
90% industrial grade methylated spirits  
70% industrial grade methylated spirits 
Antigen retrieval:  
Optimisation:  
Tris-EDTA solution ph8.0  (Sigma EDTA 0.37g, Sigma Tris Base 0.55g , 1 litre 
distilled water) 
Tris-EDTA solution pH 9.0 (Sigma EDTA 0.37g, Sigma Tris Base 1.21g, 1 litre 
distilled water 
Citrate buffer pH 6.0 (3.84g anhydrous citric acid in 1.8 litres distilled water) 
Final protocol:  
Citrate buffer pH 6.0 
Endogenous peroxidase blocking agent:  
Hydrogen Peroxide 3% (40mls 30% hydrogen peroxide in 400mls distilled water) 
Primary antibody : 
Dako Progesterone Receptor Clone 636 (mouse anti-human)  
Final protocol dilution: 1:50 
Dako antibody diluent  
Secondary antibody:  
Dako Envision Chem-Mate  
(Dextran –labelled Goat anti-mouse/rabbit antibody with horseradish peroxidase) 
Visualisation reagent:  
Dako DAB (3,3-diaminobenzidine) 
Dako DAB substrate buffer (Tris-Hcl) 
Wash buffer:  
Optimisation steps: Tris-buffered saline  
Final protocol: Tween – tris buffered saline for Autostainer  
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Counterstain: 
Mayer’s haematoxylin 
Distilled water 
Mounting 
DPX (dibutylphthalate and xylene) 
22mm x 40 mm glass coverslips 
 
A test battery was performed in order to find the antigen retrieval process and 
antibody concentration which gave optimum tissue staining.  Optimisation was 
performed on stock tissue microarrays containing strongly progesterone receptor–
positive cores with the immunohistochemistry protocol performed manually. No 
difference in staining was seen between those that had been fixed in mercuric 
chloride throughout the optimisation steps. 
  
In the final protocol the immunohistochemistry was performed using the study tissue 
microarrays and the Dako AutoStainer. 
 
Slide preparation: 
Tissue sections were dewaxed in xylene by dipping slide trays 3 times for 2 minutes 
each time, and then rehydrated by immersing in graded alcohol (two separate periods 
of 2 minutes in 99% methylated spirits and 2 minutes in each of 90% and 70% 
methylated spirits). 
 
 
 
Progesterone Antigen Retrieval Optimisation 
 
Optimisation of antigen retrieval was performed using each of Tris-EDTA pH 8.0, 
Tris-EDTA pH 9.0 and Citrate buffer pH 6.0 as buffers in combination with each of 
the following heat induction methods: water bath at 100 degrees centigrade, 
microwave pressure cooker for 1 minute, microwave pressure cooker for 2.5 minutes 
and the microwave pressure cooker for 5 minutes.  
 76 
In the pressure cooker steps, the solution was heated in a microwave until boiling 
and placed in a pressure cooker along with the prepared slides. The pressure cooker 
was placed in the microwave until pressure was reached and then heated at pressure 
for the desired length of time.  The pressure cooker was removed from the 
microwave, the lid was removed and the slides allowed to cool down in the antigen 
retrieval solution for 20 minutes.  
In the water bath steps, the slides and retrieval solution were placed in a Coplin jar in 
water bath at to 100 degrees centigrade and heated for 20 minutes; the jar was 
removed from the water bath and left to cool for 20 minutes. 
 
Optimal antigen retrieval was found to be citrate pH 6.0 heated for 5 minutes with 
the microwave- pressure cooker technique.  
 
Progesterone Immunohistochemistry Optimisation 
 
While progesterone receptor immunohistochemistry is a well-validated technique, 
antibody optimisation was required due to the potential for variation in laboratory 
conditions. After antigen retrieval using citrate pH 6.0 with the microwave pressure-
cooker technique for 5 minutes as above, tissue sections were placed in TBS and 
stirred continuously for 5 minutes. The blocking of any endogenous peroxidase in 
the tissue was ensured by placing the sections in 400mls hydrogen peroxide 3% for 
10 minutes. Primary antibody (PR clone 636) was diluted in antibody diluent to 
strengths of 1 in 50, 1 in 100, 1 in 200 and 1 in 400.  For each dilution, 200 "l of 
solution was placed onto an ER positive slide (a water-impermeable barrier (Dako 
pen) having been placed around the tissue). 200"l of antibody diluent was then 
added to a breast tumour section to act as a negative control slide. The slides were 
then left for 1 hour at room temperature. Slides were placed in TBS, which was 
stirred continuously for 5 minutes, and were then placed in fresh TBS for a further 5 
minutes. 200"l of HRP-labelled anti-mouse secondary antibody were placed on each 
of the optimisation slides and left for 30 minutes at room temperature. Slides were 
placed in TBS which was stirred for 5 minutes, and were then placed in fresh TBS 
for a further 5 minutes. For visualisation, DAB and substrate buffer were mixed in a 
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ratio of 20"l DAB to every 1ml of substrate buffer. 100"l of the resulting 
chromogen solution was pipetted onto each slide and left for 6 minutes before 
washing the slides in distilled water.  Slides were placed in haematoxylin as a 
counterstain for 30 seconds before washing in distilled water. Dehydration was then 
performed by placing tissue sections in graded methylated spirits, initially 30 
seconds in 70% methylated spirits, then 1 minute in 90% and finally 2 separate 
periods of 1 minute in 99% methylated spirits. Finally 3 separate 2 minute periods of 
immersion in xylene were carried out. Coverslips were placed on the slides using 
DPX. 
 
The optimal staining was found to be a 1:50 dilution. 
 
Final Progesterone Receptor Immunohistochemistry Protocol 
 
After antigen retrieval using citrate pH 6.0 with the microwave pressure-cooker 
technique for 5 minutes as above, tissue sections were placed in TBS and stirred 
continuously for 5 minutes.  
The Dako AutoStainer was then used to perform the steps of immunohistochemistry 
from peroxidase blocking onwards. In addition to the study TMA sections, a section 
was added to act as a negative control slide and a PR positive tumour section was 
used as a positive control. On each slide a waterproof barrier was drawn around the 
tissue. 
Set-up: 
The autostainer was set up to ensure the primary antibody step lasted for 1 hour and 
secondary antibody step 30 minutes. Reagents were added to the wells of the 
autostainer in appropriate amounts for each slide: hydrogen peroxide 3% (200"l per 
slide) to block endogenous peroxidase, primary antibody (PR clone 636) at 1:50 
dilution (200"l per slide), secondary antibody (HRP-labelled anti-mouse, 200"l per 
slide) and chromogen solution for visualisation (20"l DAB per 1ml substrate buffer, 
100"L per slide). Antibody diluent (200"l) was added to the negative control slide 
instead of primary antibody.  Tween-tris-buffered saline was used as wash buffer.  
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Once the immunohistochemistry had been carried out, slides were placed in 
haematoxylin for 30 seconds as a counterstain before washing in distilled water. 
 
Dehydration was then performed by placing tissue sections in graded methylated 
spirits, initially 30 seconds in 70% methylated spirits, then 1 minute in 90% and 
finally 2 separate periods of 1 minute in 99% methylated spirits. Finally 3 separate 2 
minute periods of immersion in xylene were carried out. Coverslips were then placed 
on the slides using DPX. 
 
HER-2 Immunohistochemistry 
 
The protocol used for HER-2 immunohistochemistry was the well-validated Dako 
Herceptest. 
 
Materials: 
 
Slide rehydration and dehydration: 
Xylene 
99% industrial grade methylated spirits 
90% industrial grade methylated spirits  
70% industrial grade methylated spirits 
 
Antigen retrieval:  
Citrate buffer pH 6.0 (3.84g anhydrous citric acid in 1.8 litres distilled water) 
Endogenous peroxidase blocking agent:  
Hydrogen Peroxide 3% 
Primary antibody : 
Dako Anti-HER-2 antibody (rabbit anti-human)  
Dako antibody diluent for negative control 
Secondary antibody:  
Envision Chem-Mate 
(Dextran –labelled Goat anti-rabbit/mouse antibody with horseradish peroxidase) 
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Visualisation reagent:  
Dako DAB (3,3-diaminobenzidine) 
Dako DAB substrate buffer (Tris-Hcl) 
Wash buffer:  
Optimisation steps: Tris-buffered saline  
Final protocol: Tween – tris buffered saline for Autostainer 
Counterstain: 
Mayer’s haematoxylin  
Distilled water 
Mounting: 
 
DPX (dibutylphthalate and xylene) 
22mm x 40 mm glass coverslips 
 
Slide preparation: 
Tissue sections were dewaxed in xylene by dipping slide trays 3 times for 2 minutes 
each time, and then rehydrated by immersing in graded alcohol (two separate periods 
of 2 minutes in 99% methylated spirits and 2 minutes in each of 90% and 70% 
methylated spirits). 
 
 
HER-2 Antigen Retrieval 
 
Slides were heated in a glass jar in citrate pH 6.0 in a water bath at 100 degrees 
centigrade for 20 minutes; they were then removed and left to cool in the citrate for 
20 minutes. 
 
HER-2 Immunohistochemistry 
 
After antigen retrieval using citrate pH 6.0 with the water bath technique as above,  
tissue sections were placed in TBS and stirred continuously for 5 minutes. The Dako 
Autostainer was used to perform the steps of immunohistochemistry from peroxidase 
blocking onwards. In addition to the study TMA sections a breast tumour section 
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was added to act as a negative control and a HER-2 positive control slide (supplied 
by Dako) was used. On each slide a waterproof barrier was drawn around the tissue. 
Set-up: 
The autostainer was set up to ensure the primary antibody step lasted for 1 hour and 
secondary antibody step 30 minutes. Reagents were added to the wells of the 
autostainer in appropriate amounts for each slide: Hydrogen peroxide 3% to block 
endogenous peroxidase (200"l per slide), primary antibody (Dako Anti-HER-2), 
200"l per slide, secondary antibody (HRP-labelled anti-mouse, 200"l per slide), 
chromogen solution for visualisation (20"l DAB per 1ml substrate buffer, 100"L per 
slide). Antibody diluent (200"l) was added to the negative control slide instead of 
primary antibody. Tween-tris-buffered saline was used as wash buffer. Slides were 
placed in haematoxylin for 30 seconds as a counterstain before washing in distilled 
water. 
 
Dehydration was then performed by placing tissue sections in graded methylated 
spirits, initially 30 seconds in 70% methylated spirits, then 1 minute in 90% and 
finally 2 separate periods of 1 minute in 99% methylated spirits. Finally 3 separate 2 
minute periods of immersion in xylene were carried out. Coverslips were then placed 
on the slides using DPX. 
 
 
 
2.17 Scoring 
ER/PR scoring  
Each sample was studied under a microscope at 40x power. After confirming the  
presence of tumour a weighted  histoscore was calculated to assess the level of 
nuclear staining. The weighted histoscore is a semiquantative method of assessing 
strength of staining, calculating a score based on percentage staining of cells and a 
graded intensity scale (0=no staining , 1= weak staining, 2 =moderate to strong  
staining,  3= very strong staining). It was originally developed in the late 1980s 
(Katz et al. 1990) and its validity in assessing receptor status and prognosis 
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confirmed by its use in various other studies, particularly in those carried out at 
Glasgow Royal Infirmary (Cannings et al. 2007; Fraser et al. 2003; Kirkegaard et al. 
2005; Kirkegaard et al. 2007; Tovey et al. 2004; Witton et al. 2003). 
Histoscore was calculated as follows: 
Histoscore = ((% cells staining at 0) x 0)+ ((%  cells staining at 1) x 1) + ((%cells 
staining at 2) x 2) + ((% cells staining at 3) x 3) 
Histoscores were averaged for the three cores. In the case of ER staining, 140 of the 
tumours had only two scoreable cores as there was little tissue left in one of the 
tissue microarrays by the time of the final study. ‘Negative’ staining was qualified as 
histoscore below 10.  Interobserver variability was assessed by 10% of samples 
being independently scored by a second experienced scorer (this task was performed 
variously by Drs. Joanne Edwards, Beatrix Elsberger and Liane McGlynn of 
Glasgow Royal Infirmary). Discordance (conventionally accepted as a difference 
between histoscores of > 50) was resolved by observers simultaneously re-scoring 
the disputed samples.  
The intraclass coefficient for interobserver variability was calculated using SPSS 
version 14. 
 
 
HER-2 scoring: 
A weighted histoscore was calculated for HER-2 staining. The intensity of 
membrane staining was graded as 0=no membrane staining, 1=incomplete 
membrane staining, 2=weak or moderate complete staining, 3=strong complete 
staining. Histoscore  was calculated as follows: ((% cells staining at 0) x 0)+ ((%  
cells staining at 1) x 1) + ((%cells staining at 2) x 2) + ((% cells staining at 3) x 3). 
HER-2 positivity was taken as a score of 90 or over (Witton et al. 2003). 
Interobserver variability was assessed by 10% of samples being independently by a 
second experienced scorer (Kirkegaard et al. 2006). Discordance (conventionally 
accepted as a difference between histoscores of > 50) was resolved by observers 
simultaneously re-scoring disputed samples.  
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2.18 Statistical Analysis 
 
Comparison of the demographics of the two groups was carried out using chi-
squared analysis  performed on SPSS v. 14 (Fisher’s exact test was used in one case 
where numbers were small). The grade of each case was inserted into the previously 
constructed SPSS v.14 database (containing all the other prognostic and 
demographic data). For each case and for each  stain, a mean histoscore for each 
tumour was calculated from the three scores. This score was then inserted into the 
SPSS database. Statistical analysis was then performed using this software.  
          Comparison of the molecular profiles in the groups was carried out using chi-
squared analysis for hormone receptor or grade status, t-test to compare mean 
receptor levels and Mann-Whitney test to compare median receptor levels. A 
multivariate analysis was performed using binary logistic regression to assess 
whether age, screening and deprivation affected the percentage of ER positive 
tumours in the groups. Initial tests suggested there was not a direct linear 
relationship between ER and age, but ER positivity rates rose from age 60 onwards 
and so ‘age over or under 60’ as a categorical variable was included in the 
regression.  
 
2.19  Survival Analysis 
 
A comparison of survival between the older and newer cohorts was performed to 
establish if our cohorts reflected the changing population-based survival from breast 
cancer seen in Scotland (as in the introduction to this thesis). Data supplied by the 
Scottish Cancer Registry and the Glasgow Breast Cancer Audit included status at 
last review (Breast Cancer Audit patients) or status at 31
st
 December 2003 (Cancer 
Registry patients), survival time in days from diagnosis to last follow-up or death if 
applicable, and  cause of death if applicable. Data on recurrences was unfortunately 
not available. This allowed survival analysis to be performed using the Kaplan-
Meier method using SPSS v.14. Survival analysis was performed for all patients in 
the original database regardless of whether or not they were entered into a TMA; for 
the ER status comparisons data on those patients who had been entered into the 
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TMA and had ER status determined were analysed.  A 5-year survival analysis was 
thought to be the most appropriate way to compare the two groups and so those 
patients whose survival was longer than 5 years (1825 days) were considered as 
being alive at the 1825-day stage. The log-rank test was used to assess the 
significance of the differences in survival.   
 
Survival comparisons performed were: 
! Overall survival in cohort 1 vs cohort 2 
! Disease-specific survival in cohort 1 vs cohort 2  
! Disease-specific survival in ER positive vs ER negative patients in the whole 
study 
! Disease-specific survival in ER positive vs ER negative patients in cohort 2 
! Overall survival in cohort 1 vs cohort 2, symptomatic patients only 
! Disease-specific survival   in cohort 1 vs cohort 2, symptomatic patients only 
! Disease-specific survival in screen-detected vs symptomatic patients in whole 
study  
! Disease-specific survival in lymph node positive vs negative patients overall and 
in each cohort 
 
Cox’s proportional hazard regression was performed in a stepwise fashion. Cohort, 
ER status, HER-2 status, grade, nodal status, tumour size, age, screen-detected 
status, and deprivation category were inserted into the model. The final model 
excluded those variables in which a difference of in survival could be explained by 
one or more other variables, and generated hazard ratios for death from breast cancer 
for each variable after adjusting for the others. 
Kaplan-Meier survival curves estimate the probability of survival beyond a certain 
time. The y-axis shows the proportion of the total group remaining with the x-axis 
showing time in days, and each downward step in the curve represents an event, i.e. 
a death. However, each event does not cause a downward step of equal magnitude, 
because the curves take into account censoring which in effect represents ‘loss to 
follow-up’. With each censoring, i.e. loss of a patient to follow-up, a death 
represents a greater proportion of the total group and hence the downward step gets 
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larger.  Kaplan-Meier curves assume that censored events are not related to cancer 
prognosis and that the probability of survival is the same early and late in a study. 
The log-rank test is a statistical test used to test the hypothesis that there is no 
difference in survival between the groups, and shares the same assumptions as the 
Kaplan-Meier curve. Cox’s proportional hazard regression calculates the effect of 
changes in predictor variables on survival curves and hence whether a variable is a 
significant independent predictor of survival or not. The main assumption of this 
form of regression is that curves based on two predictor variables will each have a 
hazard function (i.e risk of death) that is relative and proportional to the other   curve 
throughout. This is usually the case in terms of variables influencing cancer survival.  
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Chapter 3:  Results and Analysis 
 
Results Part 1: Epidemiology Project 
 
 
3.1 Breast cancer incidence rates in Scotland 
 
In 1975, 2213 cases of breast cancer in females were registered in all age groups in 
Scotland. In 2003, 3823 cases of female breast cancer were registered. The incidence 
rate of breast cancer in Scotland in 1975 adjusted to European standard population 
was 79.6 cases per 100,000 women and in 2001 it was 111.2 cases per 100,000 
women.  
In women under the age of 49 the incidence of breast cancer remained fairly constant 
over the time period of interest, and as expected rates were higher with successive 
age groups. In women aged 70-74, 75-79 and 80-84 incidence rates were higher with 
successive age group and had been rising since 1975, with a downturn in incidence 
since around 1998. Incidence rates on women of 85 and over were the highest of all; 
in this group the incidence of breast cancer rose between 1982 and 1985 before 
staying fairly constant with some year on year variation, with another rise incidence 
between 1991 and 1996 and a decrease in incidence after this. Incidence rates in 
women aged 50-64 showed the greatest changes of all, with rates rising to the extent 
that they were higher than in women in the 70-74 age group. A thorough analysis of 
incidence trends in the age groups affected by screening, along with the age group 
just above this, is shown below in figure 3.1. 
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Figure 3.1:  Breast cancer incidence rates in Scottish women in age groups 50-
54, 55-59, 60-64 and 65-69, between 1975 and 2003 (per 100,000 women) Dotted 
lines mark 1987 and 1994 – the years when screening began in Scotland and when 
the prevalent round was completed.  
 
In women of screening age and just above, incidence rates appeared to have been 
rising even before the introduction of screening; this is confirmed by linear 
regression below. From 1987 there was a sharp rise in incidence rates in women of 
screening age, as would be expected as a screening programme undergoes its 
‘prevalent round’. Women aged 65-69 have no such rise. The incidence rates reach a 
peak and begin to fall just before the end of the prevalent round; again this peak and 
fall replicates the expected pattern for a screening programme (Schouten, de Rijke, 
Huveneers, & Verbeek 2002). However, the prediction for after the completion of 
the prevalent round is that rates should remain just higher than and parallel to the 
underlying background incidence rate. However we see that rates in women of 
screening age are much higher and are continuing to increase at a steeper rate than 
would have been expected if trends up to 1987 had continued. A thorough analysis 
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of rates in the age groups affected by screening is undertaken below and in the 
discussion. 
 
 
 
 
Observed vs Expected Analysis 
 
 
 
Table 3.1: Comparison of observed mean rate in 1999-2003 and 2001 predicted 
rate  
 
 
 
3.2 Breast screening data 
 
Screening uptake 
 
 
Age Group 1975  actual 
incidence  rate per 
100,000  per year 
1999-2003 mean 
rate  (O)       
2001 predicted 
rate (E) 
% 
difference 
50-54 151.1 293.0 185.7 +58 
55-59 165.8 302.1 212.5 +42 
60-64 193.4 329.6 234.7 +40 
65-69 200.8 266.9 238.6 +18 
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Figure 3.2: Percentage uptake of screening invitations for all invitations and 
first invitations by financial year 
 
There was a small but significant trend towards increasing breast screening uptake 
between 1991-92 and 2001-02, from 70.9 to 74.5% of invited women (p=0.02). In 
women being invited for a first screen the uptake increased from 70.9 to 73.8% 
(p=0.017). 
Self-referrals 
 
As a percentage of all screening appointments, the level of self-referrals gradually 
increased throughout the prevalent round as the screening programme became more 
established, rising from 2.5% in 1991-2 to 3.9% in 1994-5. However in the 
intervening years, percentage self-referrals have continued to increase gradually to 
the extent that 10.5% of all screening appointments in 2001-2 were self-referrals. 
Unfortunately it is not known what percentage of these self or GP referrals are from 
women older than screening age, as other common reasons for self-referral for 
screening include GP concern, patient concern and family history. 
Trends in standardised detection ratio 
 
The standardised detection ratio of the screening programme in Scotland (rate of 
invasive cancers detected divided by number expected for the background incidence 
rate) for first screens has been above the target SDR of 1.0 since 1993/4-1995/6. The 
 89 
SDR has increased from 1.1 to 1.5 since the prevalence ‘round’ of screening was 
completed, again suggesting that continued improvements in the screening service in 
Scotland could be continuing to improve incidence rates. For second (‘incident’) 
screens the SDR has been above the target of 1.0 since 1992/3-1994/5. The SDR has 
increased, but by less than for first screens, to 1.2 since the prevalent completed. 
Improvements in ‘incidence’ screening should reduce the number of cancers 
developed between screening periods (interval cancers), on the basis that some 
interval cancers are true interval cancers but some may have been missed on 
screening mammograms.  
 
 
 
 
3.3 Birth cohort analysis 
 
 
Table 3.2 demonstrates breast cancer incidence rates in women aged 50-64 by birth 
year cohort, with incidence rates grouped by 5-year age group, as derived from the 
Lexis diagram described in the materials and methods section. Dark shaded areas 
represent cohorts where some or all women would have been offered screening as 
part of the prevalent round; lighter shading either indicates where some or all women 
were either offered no screening at all (earlier cohorts) or were offered screening as 
part of the incident round of screening (later cohorts).  Cohorts where all women 
would have been offered screening have a bold border.  
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Table 3.2 Breast cancer incidence rates in women aged 50-64 by birth year 
cohort, with incidence rates grouped by 5-year age group, as derived from the 
Lexis diagram 
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The data are plotted in figure 3.3 below; the dotted lines represented the central 
portion of the dark shaded boxes in table 1 where all women in the cohorts should 
have been offered screening.  
 
 
 
 
 
 
 
 
 The incidence of breast cancer was higher with increasing age group between 50 
and 64 years.  In 50-54 year olds and 55-59 year olds there were small increases in 
incidence with birth cohort year before the screening programme began. In all age 
groups there were significant rises in incidence throughout the duration of the 
prevalent round.  The fall in incidence that was expected after the majority of 
Scottish women had been screened at least once!was not observed.  Large rises in 
breast cancer incidence with increasing birth cohort continued after the screening 
Figure 3.3: Breast cancer incidence in women aged 50-64 years in 1977-2003  by  
year of birth 
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programme had been fully established (although as described below, the confidence 
intervals were wide).  Rising incidence with increasing birth cohort occurred in 
parallel across all three age categories.  
        In 50-54 year olds, cohort incidence changed from 141.7 to 183.0 per 10
5
 in the 
years before 1987 (a rise of 41.3 per 10
5
 , 95%CI 6.1 to 76.5) ; from 155.7 to 263.8 
per 10
5
 (a rise of 108.1 per 10
5
, 95%CI 68 to 148.2) in cohorts where some or all 
women were eligible for screening in the prevalent round; and from 287.5 to 323.5 
per 10
5
 (a rise of 35.9 per 10
5
, 95%CI -12.45 to 82.9) in cohorts where women were 
offered screening in the established screening programme.  In 55-59 year olds, 
cohort incidence changed from 168.0 to 204.2 per 10
5
 in the years before screening 
(a rise of 36.2 per 10
5
, 95%CI  -1.5 to 73.9) ; from 190.6 to 271.17 per 10
5
  (a rise of 
80.5 per 10
5
, 95%CI 38.5 to 122.7) in cohorts where some or all women were 
eligible for the prevalent round; and from 287 to 322.2 per 10
5
 (a rise of 35.2 per 
10
5
, 95%CI -13.1 to 83.5) in cohorts who were entering screening during the  
‘incident round’. In 60-64 year olds, cohort incidence changed from 213.1 to 194.6 
per 10
5
 in the years before screening (a decrease of 18.5 per 10
5
, 95%CI –17.4 to 
54.4); from 209.53 to 304.8 per 10
5
 (a rise of 95.2, 95%CI 50.8 to 146) in cohorts 
where some or all women were eligible for screening in the prevalent round; and 
from 298.7 to 314.7 per 10
5
 in the cohorts beginning screening after the prevalent 
round was complete  (an increase of 16 per 10
5
, 95%CI –32.4 to 64.4). 
 
 
 
Figure 3.4, below, shows breast cancer incidence in the same birth cohorts presented 
in Figure 2.4, but for women in the 5-year age groups below and above the screening 
ages.  There was no appreciable change in incidence in 65-69 year olds from the 
1922 to the 1948 birth cohort.  Among 45-49 year olds, there was little change in 
incidence until 1942 and a small but non-significant rise thereafter from 160.6 to 
175.3 (a rise of 14.7 cases per 10
5 
female population, 95% CI -21.1 to 50.5) in the 
1948 cohort. 
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 3.4. Risk factor trends 
 
Figure 3.4: Breast cancer incidences in women aged 45-49 and 65-69 years in 
1977-2003, by year of birth and age 
 
Late age at first pregnancy 
 
Figure 3.5 below demonstrates the changing pattern of age at first pregnancy within 
Scotland over the past 25 years. From just under 12,000 first pregnancies to women 
20-24 in 1976, the number has fallen gradually to under 6000 in 2001; however the 
numbers of pregnancies to women aged 30-34 have tripled, and women aged 35-59 
has risen from 431 in 1976 to almost 2000 in 2001. 
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Figure 3.5: Numbers of first births at different maternal ages in Scotland over 
time  
Figure 3.6, below, demonstrates how this compares overall to the numbers of first 
births in Scotland over time; in 1976 1.4% of all first births were in women aged 35-
39 but by 2001 this had increased to 9%, with the rates increasing slowly up until the 
late 1980s and more rapidly after this. 
Figure 3.6: First births to mothers aged 35-39 as a percentage of all first births 
in Scotland 
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Completed family size 
 
Figure 3.7: Completed family size by age 44 by maternal birth cohort year (as 
at 2004) 
 
 
Completed family size (cumulative fertility by age 44) by birth cohort is shown in 
figure 3.7 above. A downward trend of family size begins around the 1935 birth 
cohort, with completed family size gradually falling from 2.63 to 1.9 in the 1960 
cohort.  
  
BMI trends 
 
In the women aged 16-64 in the Scottish Health Surveys) age-standardised mean 
BMI increased from 25.7 kg/m
2
 in 1995 to 26.9 kg/ m
2
 in 2003 (Bromley et al. 2005; 
Dong et al. 1995; Shaw et al. 2008. In women aged 55-64, mean BMI increased from 
27.6 kg/ m
2
 in 1995 to 28.6 kg/ m
2
 in 2003. The percentage of women with BMI 
over 25 was 47.2% in 1995 and 57.3% in 2003; for women aged 55-64, percentage 
rose from 68.2% to 73%.  
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Alcohol trends 
 
The average weekly alcohol consumption of women aged 16-64 in the Scottish 
Health Surveys of 1995, 1998 and 2003 showed an increase between 1995 and 2003, 
from 6.4 to 7.4 units.  In women aged 55 to 64, weekly consumption increased from 
4.6 to 5.4. Similarly, there was a small increase in the proportion of women aged 16-
64 whose drinking exceeded 14 units per week, increasing from 13% in 1995 to 15% 
in 1998, and again to 17% in 2003. In women aged 55-64 the increase was from 8 to 
11%. 
Hormone Replacement Therapy 
 
Data were available on total numbers of prescriptions of hormone therapy in 
Scotland. The reduction in numbers of prescriptions has been demonstrated in other 
countries and almost certainly reflects a response to the published findings of the 
Million Women study about increased risk of breast cancer (Usher 2006). 
 
Figure 3.8: Numbers of prescriptions of hormone replacement therapy in 
Scotland, 1993 to 2003 
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Table 3.3: Calculated HRT prevalence 
 
Year Women using HRT 
(prescriptions / 4) 
Number of 40-64  
year olds 
Prevalence (%) 
1993 105500 764246 13.8 
1994 113377 769040 14.7 
1995 122777 773511 15.9 
1996 133668 778828 17.2 
1997 137894 785338 17.6 
1998 139692 795053 17.6 
1999 136823 805416 17.0 
2000 138851 815507 17.0 
2001 135496 827346 17.0 
2002 127712 838568 15.0 
2003 103088 852358 12.0 
 
 
Each HRT prescription is for a 3-month supply. Previous studies of HRT prevalence 
have suggested that up to 90% of all women using HRT will use it for at least a year 
(Bromley, de Vries, & Farmer 2004).  If it is assumed that most women using HRT 
will require 4 prescriptions in a year, then the overall annual prescription rate can be 
divided by 4 to obtain an estimate of the number of women using HRT in any given 
year. The above number for women using HRT was divided by the number of 
women aged 40-64 in each year  (as in Townsend, 1998), based on annual population 
estimates published by the General Register Office for Scotland to obtain an 
estimated prevalence level.  This allowed prevalence in 40-64 year olds to be 
calculated, as in table 2.3. It can be seen that the calculated prevalence rates 
increased up to 1996 but changed little between then and 2001 and thereafter 
prevalence has fallen. 
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A comparison of HRT prescriptions and breast cancer incidence for women aged 50-
64 is shown in figure 3.9 below. 
 
Figure 3.9 Comparison of HRT  prescriptions over time and breast cancer 
incidence in Scotland 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Breast cancer incidence 
HRT prescriptions 50-54 
60-64 
55-59 
  2003 
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3.5. Breast Cancer Incidence and Deprivation 
 
 
Figure 3.10: Breast cancer incidence 1991-2000 by quintile of deprivation (1= 
least deprived, 5 = most deprived) 
 
 
It can be seen from the figure that between 1991 and 2000, breast cancer incidence 
rates in Scotland continue to be lower with increasing deprivation.  Linear regression 
of log-transformed data reveals a significant rise in incidence over this period in all 
quintiles except for quintile 3 and 4.  
 
Quintile 1: p = 0.44 
Quintile 2:, p = 0.06 
Quintile 3:, p = 0.250 
Quintile 4:  p = 0.102 
Quintile 5: p = 0.016 
However, including an interaction term  into the analysis  revealed regression slopes 
to be parallel (p=0.835),  confirming that incidence rates are rising to the same 
degree in all deprivation categories. 
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3.6 Breast screening uptake and deprivation 
 
 
 
Figure 3.11 : Percentage uptake of screening invitations by deprivation category  
 
 
 
 
 
 
 
 
 
 
 
 
It is well recognised that uptake of organised screening programmes is lower in areas 
of socio-economic deprivation, and this is true in the Scottish Breast Screening 
Programme.  While higher levels of screening uptake do not explain the breast 
cancer excess in affluent populations – these trends were well recognised before 
screening began, it was felt possible that increased uptake of screening in affluent 
women with levels in deprived women staying static could explain the rising     
incidence in the affluent seen in the Scottish figures above.  
     Screening uptake data for each one-year period from 1990-91 to 2001-02 for each 
deprivation category was analysed by linear regression. This revealed that all 
deprivation categories have seen a rise in screening uptake over this ten year period. 
(p for category 1 = 0.01 , category 2 = 0.1 , category 3 = 0.099, category 4 = 0.029, 
category 5 = 0.02, category 6 = 0.11, category 7 = 0.16). However p value for the 
interaction analysis was 0.551, indicating that uptake has increased to the same 
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extent in all categories, with no diverging trend to explain a widening gap in 
incidence. 
 
 
3.7  Risk factors and socioeconomic status 
Late age at first pregnancy 
 
Figure 3.12: Numbers of first births in Scotland at maternal ages 35-39 since 
1975  (Quintile 1 = least deprived, quintile 5 = most deprived) 
 
 
 
This graph of numbers of first births at age 35-39 divided by deprivation category 
shows that the number of first birth to women aged 35-39 has increased in all 
deprivation categories but the magnitude of this rise increases with increasing 
affluence – that is, there is a widening gap between the deprived and affluent in 
terms of first pregnancy over 35. 
       The p value for the interaction analysis was <0.001 indicating a larger increase 
in numbers of first births between quintile 1 and 2 than between 2 and 3, a larger 
increase between 2 and 3 than between 3 and 4 and so on: i.e. confirming numbers of 
first births at over 35 are increasing by greater magnitude in the affluent than in the 
deprived. 
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BMI trends 
!
As seen in table 3.4, in both 1995 and 1998,  mean BMI appeared to increase slightly 
from social class I to V although the correlation was not statistically significant  
(1995 p=0.397 and 1998 p=0.084).  The mean BMI in each social class had changed 
little between 1995 and 1998.   Although a different classification of socioeconomic 
status was used in 2003, precluding direct statistical comparison, mean BMI in all 
categories had increased markedly since 1998.  The correlation of higher BMI with 
increasing deprivation was significant (p<0.01)  (table 3.5). 
      In 1995 a statistically significant inverse association of social class and obesity 
prevalence was seen (p=0.019).  In 1998 the significant association was still present 
(p<0.01) (table 3.6). Prevalence of obesity in all classes appeared to have increased 
between 1995 and 1998 but grouping of social classes together in 1998 meant that 
direct statistical comparison was not possible.  In 2003 a statistically significant 
inverse association between quintile of Scottish Index of Multiple Deprivation and 
obesity prevalence was still noted (p<0.01) (table 3.7).  Again, in 2003 the 
prevalence of obesity in all quintiles appeared to have increased from the prevalence 
in individual categories in  1998 but a statistical comparison could not be made. 
 
Table 3.4: Mean BMI (kg/m
2
, age-standardised), women aged 16-64 by Registrar 
General Social Class , from  Scottish Health Survey 1998 (Shaw, McMunn, & Field 
2008) 
 I II IIINM IIIM IV V 
1995 22.8 22.3 23.5 23.6 23.3 23.0 
1998 22.8 22.9 22.9 24.0 23.8 23.6 
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Table 3.5: Mean BMI (ages-standardised), women aged 16 and over by quintile of 
Scottish Index of Multiple Deprivation: from Scottish Health Survey 2003 (Bromley, 
Sproston, & Shelton 2005) 
 1st 2nd 3rd 4th 5th 
2003 26.4 26.9 27.1 27.4 28.1 
 
 
Table 3.6: Percentage prevalence of obesity (BMI >30) in women aged 16-64 (1995) 
and 16-74 (1998) by Registrar General Social Class, from Scottish Health Surveys 
1995 (Dong & Erens 1997) and 1998 (Shaw, McMunn, & Field 2008) 
 I II IIINM IIIM IV V 
1995 13.9 9.9 17.8 18.1 22.1 20.2 
1998 18.2 19.7 25.5 26.0 
 
 
Table 3.7: Percentage prevalence of obesity (BMI>30) in women aged over 16 by 
quintile of Scottish Index of Multiple Deprivation, from Scottish Health Survey 2003 
(Bromley, Sproston, & Shelton 2005) 
 1st 2nd 3rd 4th 5th 
2003 21.0 22.8 27.7 27.9 32.1 
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Results Part 2: Laboratory Project 
 
 
 
3.8 Patient and tumour characteristics 
The original sample size had been 1076 patients (423 in 1984-86 [‘cohort 1’] and 
653 in 1996-97 [‘cohort 2’]). 900 tumour blocks were available (323 in cohort 1, 577 
in cohort 2).  Mean age of diagnosis was 56.9 in the first cohort and 58.4 in the 
second cohort. All tumours in the first cohort had been detected symptomatically 
rather than by screening, the screening programme having yet to be introduced in 
Scotland. 71% of tumours in the second cohort were detected symptomatically and 
29% had been detected at the screening programme. There was no significant 
difference in the cohorts as regards socioeconomic status. In cohort 1, 12.1% of 
patients were affluent (deprivation category 1-2), 40.9% intermediate (category 3-5) 
and 47% deprived (category 6-7); in cohort 2, 16.5% of patients were affluent, 
47.2% intermediate and 36.3% deprived. 59.3% of tumours in the 1984-86 cohort 
had been node-positive compared with 42.4% of the tumours in the 1996-97 cohort. 
Comparisons were performed using chi-squared analysis (Fisher’s exact test in the 
case of screening as the numbers were small).  
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Table 3.8 Patient demographics 
 
 
 1984-1986 1996-1997 p for difference  
Mean age at 
diagnosis 
56.9 58.4  
0.049 
Median age at 
diagnosis 
59 58  
0.179 
Age range 23-74 24-93  
%detected at 
screening 
0 29 <0.001 
% of patients in 
each deprivation 
category: 
   
Affluent   12 17  
Intermediate  41 47  0.05 
Deprived  47 36  
Node positive % 59.3 42.4 0.001 
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3.9 Grade 
 
Overall grade distribution: 
862 tumours (less than the full study complement of 900) underwent standardised 
grading using modified Scarff-Bloom-Richardson classification. The percentage of 
tumours in each cohort that were of grade 1, grade 2 and grade 3 was calculated and 
the difference in grade distribution between cohorts was assessed using Pearson’s 
chi-squared (#
2
) analysis, using SPSS v.14.  
Cohort 1  (1984-86):  
8% of tumours were grade 1 , 49.2% grade 2, and 42.9% grade 3 
Cohort 2  (1996-97): 
14.9% of tumours were grade 1, 48.3% grade 2 and 36.8% grade 3 
Pearson’s #
2 
analysis revealed there to be a significant difference in grade 
distribution between the two cohorts (p=0.009); this effect appears to be a result of 
there being fewer grade 3 tumours and more grade 1 tumours in the later cohort.  
 
Grade distribution and relation to screening 
In cohort 1 none of the tumours were screen-detected as the National Breast 
Screening Programme had not yet been introduced; in cohort 2 a proportion of 
tumours would be screening-detected at a time when the screening programme had 
been long established. A layered #
2 
analysis was performed to assess differences in 
grade distribution in symptomatically detected tumours in different cohorts, and the 
grade distribution of screen detected as compared to symptomatic tumours in cohort 
2.  
 
For symptomatic patients only:  
Cohort 1  (1984-86) 
8% of tumours were grade 1, 49.2% were grade 2 and 42.9% were grade 3 
Cohort 2  (1996-97): 
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12.2% of tumours were grade 1, 46.8% were grade 2 and 41% were grade 3 
Pearson’s #
2
 showed there to be no significant distribution in grade (p=0.2) strongly 
suggesting that the difference in grade distribution between the older and more 
recent cohort is being exerted by the screen detected tumours, with the grade of 
symptomatically detected tumours not differing between the cohorts.  
 
Symptomatic vs. screen-detected in Cohort 2: 
Screen-detected tumours: 22.3% were grade 1, 53% were grade 2 and 24.7% were 
grade 3. 
Symptomatic tumours: 12.2% of tumours were grade 1, 46.8% were grade 2 and 
41%  were grade 3. 
 
The difference in grade distribution was significant (p<0.001). 
 
The data supports the hypothesis that the difference in grade distribution between the 
two cohorts is being exerted by the screen-detected tumours in cohorts 2 having 
fewer grade 3 and more grade 1 tumours.  
 
A further analysis was performed in order to show the tumour grade in women 
having a subsequent (‘incident’) screen; as discussed later, the difference in grade 
between tumours detected at incident screens and symptomatic tumours has been 
used to support the hypothesis of ‘phenotypic drift’ of breast cancer. Data on 
whether tumours were detected in a woman having her first screen or a subsequent 
screen had not been recorded; however any women aged 50 to 53 with a screen 
detected tumour is likely to have been having a first screen as these are the ages at 
which women are invited for a first screen. Therefore analysis was performed of the 
grade distribution within screen-detected tumours in women aged over 53 as 
compared with women aged 50 to 53 and with non screen-detected tumours. A 
potential confounding factor in the use of the age cut-off as a surrogate for screening 
type is that some women aged over 53 may be having a first screen having not 
attended screening previously. Also, some 53-year old women may have previously 
had a screen aged 50 and be having a repeat screen.  
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Symptomatic tumours in cohort 2: 12.2% of tumours were grade 1, 46.8% were 
grade 2 and 41% were grade 3. 
Tumours presumed detected at subsequent screen in cohort 2: 21.9% of tumours 
were grade 1, 52.3% were grade 2 and 25.8% were grade 3. 
The p value as calculated by Pearson’s #
2
 was <0.001 showing that there was a 
significant difference in grade distribution between women likely to have been 
having a ‘subsequent’ screen and those with symptomatic tumours. The obvious 
possibility of misclassification of screening episodes  decreases the validity of this 
conclusion.  
 
Grade and socioeconomic status 
 
In both cohort 1 and cohort 2  there was no significant difference in grade 
distribution of tumours between socioeconomic categories (p=0.95, p=0.822).   
 
 
3.10 Oestrogen Receptor  
Overall difference in percentage of tumours ER positive: 
20% of the 323 tumours in the original 1984-1986 cohort  and 19% of the 577 in the 
1996-1997 cohort did not undergo ER staining as none of the three cores put in 
tissue microarrays contained a tumour sample, mainly as cores had become  
fragmented but also occasionally because normal tissue had been sampled. The 
percentage of tumours that were ER positive (weighted histoscore of 10 or over) in 
each cohort was calculated and the difference between the cohorts calculated using 
Pearson’s #
2
, using SPSS v.14.   
 
Cohort 1: 
64.2% of the tumours were ER positive and 35.8% ER negative 
Cohort 2: 
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71.5% of tumours were ER positive and 28.5% ER negative 
 
7.3 % more of the tumours in the newer cohort were ER positive than in the older 
cohort. Pearson’s #
2
 analysis revealed this to be a significant difference (p=0.042).  
 
Comparison of mean ER score in each cohort: 
Further analysis was performed to assess whether there was not only a change in ER 
positivity but a change in mean ER score for the two cohorts; as the data were 
normally distributed a two-tailed unpaired t-test was performed. 
Cohort 1: mean ER score 97.1 
Cohort 2: mean ER score 102 
T-test showed that there was no difference in mean ER score between the two 
cohorts (significance = 0.454) 
 In cohort 1 the median ER score was 104.2; the interquartile range was 0-190; in 
cohort 2 the median ER score was 120 and the interquartile range 0-180. (p by 
Mann-Whitney  0.744). 
ER status and pathological factors  
 
Tumour size: 
A layered Pearson’s chi-squared analysis was performed to assess whether ER status 
was related to tumour size in either cohort. Tumour size classification was based on 
the TNM classification: <2cm, 2-5cm and over 5cm. 
Cohort 1: within each tumour size group, there was no difference in the percentage 
that were ER positive and negative (p=0.234) 
Cohort 2: within each tumour size group, there was no difference in the percentage 
that were ER positive and negative (p=0.431) 
 
Nodal status:  
59.3% of the tumours in the 1
st
 cohort and only 42.4% of those in the second cohort 
were node positive (p<0.001). A layered Pearson’s #
2
 analysis was performed to 
assess whether ER status was related to nodal status in either cohort.  
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Cohort 1: 68.8% of node positive patients were ER positive and of 56% of node 
negative patients were ER positive  
Cohort 2: 70% of node positive patients were ER positive and 71%  of node negative 
patients were ER positive  
In neither cohort was there found to be a significant difference in ER status between 
node-positive and node-negative groups (p=0.058 and p=0.819 for cohorts 1 and 2 
respectively).  
 
ER status and screening 
 
Having noted that there was an overall difference in ER status between groups, 
further #
2
 analyses was performed to establish whether, as in the case of tumour 
grade, this was related to the impact of screening, as cohort 1 patients were 
diagnosed before screening and cohort 2 when screening had been long established.  
Within the tumours that successfully underwent ER analysis, 66.8% of symptomatic 
patients were ER positive and 78.4% of the screen-detected tumours were ER 
positive; this difference was statistically significant (p = 0.009).  
Within symptomatic patients only, in cohort 1, 64.2% of patients were ER positive 
and in cohort 2 68.8% were ER positive (p=0.32). 
In cohort 2, 68.8% of  symptomatic patients were ER positive and 78.4% of screen-
detected tumours were ER positive – again this was significant (p=0.04). These 
analyses could perhaps suggest  that the rise in ER positivity appears to be exerted 
by the presence of screen-detected tumours.  
 
 
ER status and deprivation 
 
As detailed in the introduction, studies have suggested that deprived populations 
may have higher rates of ER negative tumours. A comparison was made of the 
distribution of deprivation status (affluent [‘depcat’ 1 or 2], intermediate [‘depcat’ 
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3,4 or 5] and deprived [‘depcat’ 6 or 7]) between the different cohorts to assess 
whether this could have influenced the results.  
Cohort 1: 12.1% of patients were affluent, 40.9% intermediate and 47% deprived. 
Cohort 2: 16.5% of patients were affluent, 47.2% intermediate and 36.3% deprived. 
There was a borderline significant difference in deprivation status of the patients in 
each cohort (p=0.05). 
 
An assessment was therefore made of the relationship between deprivation status and 
ER status in the patients. Overall in the study there was no significant difference in 
ER status by deprivation status (p=0.979). 68.6%, 69.6% and 69% of the affluent, 
intermediate and deprived groups respectively were ER positive. When cohorts were 
separated there was still no significant relation of ER status and deprivation (p=0.926 
and p=0.842 for cohorts 1 and 2 respectively).  
ER Status and Age 
 
It is notable that the upper limit of age in the second cohort is higher than in the first, 
although as seen in table 3.1 the influence this has had on mean and median age at 
diagnosis is small. A breakdown of percentage ER positivity within the different age 
ranges in the two cohorts is shown below. The number of cases over the age of 75 in 
the later cohort represents 44 cases.  
 
 
 
 
 
 
 
 
 
 
 
 112 
 
Table 3.9  ER positivity by age  
 1984-86 % ER positive 1996-97 % ER positive 
Age: under 29 100 33 
 
30-34 43 60 
35-39 38 44 
40-44 54 50 
45-49 59 73 
50-54 55 69 
55-59 59 65 
60-64 72 77 
65-69 74 77 
70-74 80 80 
75-79  77 
80 -84  100 
85 and over  100 
 
The percentage positivity for each age range is on the whole higher in the second 
cohort than in the first except for those under 29, although the small numbers reduce 
the validity of this observation. Interestingly an initial peak in ER status at the 45-49 
age group is seen, with rates then rising again from around the 65-59 age group. The 
ER status of breast tumours becomes more likely to be positive with increasing age 
at diagnosis, as seen here (Elwood, 1980). The peak at age 45-49 was noted by 
Elwood and authors in their 1980 study.  
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3.11 Multivariate Analysis of Factors Influencing ER positivity 
 
Multivariate analysis using binary logistic regression was performed to ascertain the 
influence of the following factors on ER positivity: cohort, age, screening, 
deprivation, in order to ascertain whether observed differences in demographics of 
the two cohorts could have resulted in the difference in ER positivity detected in the 
study.  The distribution of age and ER status above suggested a non-linear 
relationship of age and ER positivity; plotting the B coefficients of the logistic 
regression equation for age category and ER status confirmed the non-linearity and 
hence age category was not felt appropriate to include in logistic regression. Instead 
‘age over or under 60’ was included as a categorical variable. In the final model, 
cohort and deprivation were no longer  significant predictors of ER status, with. 
screening status and age over 60 remaining significant predictors of ER status. It is 
notable that when only age and cohort were included in the model, correcting for age 
over/under 60 made the link between cohort and ER status just below the level of 
significance (p=0.068).   
 
 
3.12 PR  status 
Overall difference in percentage of tumours PR positive: 
14% of the 323 tumours in the original 1984-1986 cohort  and 10% of the 577 in the 
1996-1997 cohort did not undergo PR staining as none of the three cores put in tissue 
microarrays contained a tumour sample, mainly as cores had become  fragmented 
but also occasionally because normal tissue had been sampled. The percentage of 
tumours that were PR positive (weighted histoscore of 10 or over) in each cohort 
was calculated and the difference between the cohorts calculated using Pearson’s #
2
, 
using SPSS v.14.   
 
Cohort 1: 
44.9% of the tumours were PR positive and 55.1% PR negative 
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Cohort 2: 
49.9% of tumours were PR positive and 50.1% PR negative 
 
5% more of the tumours in the second cohort were PR positive than in the first 
cohort; this was not a significant difference (p=0.181). 
 
Comparison of mean PR score in each cohort: 
Further analysis was performed to assess whether there was not only a change in PR 
positivity but a change in mean PR score for the two cohorts; as the data were 
normally distributed a two-tailed unpaired t-test was performed. 
Cohort 1: mean PR score 41.2 
Cohort 2: mean PR score 37.9 
The mean PR scores of the two cohorts are not significantly different (p=0.418)  
The median PR score in cohort 1 was 0 and the interquartile range 0-79.6; the 
median PR score in cohort 2 was 8.3 and the interquartile range 0-61.3 (p by Mann-
Whitney 0.181). 
 
3.12 Combined ER/PR status 
#
2
 analysis was performed to assess whether the rise in ER status is limited to ER 
positive tumours that are also PR positive or whether it is independent of ER status. 
Analysis was performed on those tumours that had successfully undergone ER and 
PR immunohistochemistry. 
Cohort 1:  
42.4% were ER+ve/PR+ve  
21.8% were ER+ve/PR-ve 
33.3% were ER-ve/PR-ve 
2.5%  were ER-ve/PR +ve 
 
Cohort 2: 
46.7% were ER+ve/PR+ve 
24.8% were ER+ve/PR-ve 
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23.5% were ER-ve/PR-ve 
5% were ER-ve/PR+ve 
 
#
2
 analysis showed there to be a significant difference in the distributions (p=0.023). 
The most marked difference is a 10% decrease between the first and second cohorts 
of percentage of ER-ve/PR-ve tumours; there is a corresponding increase between 
the two groups of the prevalence of the other tumour types.  
 
 
3.13 HER-2 
15% of the 323 tumours in the original 1984-1986 cohort and 18% of the 577 in the 
1996-1997 cohort did not undergo HER-2 staining as none of the three cores put in 
tissue microarrays contained a tumour sample, mainly as cores had become 
fragmented but also occasionally because normal tissue had been sampled. The 
percentage of tumours that were HER-2 positive (weighted histoscore of 90 or over) 
in each cohort was calculated and the difference between the cohorts calculated 
using Pearson’s #
2
, using SPSS v.14.   
Cohort 1: 21.5% of tumours that could be scored were HER-2 positive and 78.5% 
negative 
Cohort 2: 20.6% of tumours were HER-2 positive and 79.4% negative 
There was no significant difference between the cohorts in terms of percentage that 
were HER-2 positive (p=0.772) 
 
Further analysis was performed to assess whether there was an increase in mean 
HER-2 score for the two cohorts; as the data were normally distributed a two-tailed 
unpaired t-test was performed. 
Cohort 1: mean HER-2 score 52.2 
Cohort 2: mean HER-2  score 43.1 
Although mean HER-2 score appears to be lower in the second cohort there is no 
significant difference between the groups (p=0.170). 
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The median Her 2 score in cohort 1 was 0 and the interquartile range 0-50; the 
median HER-2 score in cohort 2 was 0 and the interquartile range 0-66.7 (p by 
Mann-Whitney =0.773). 
 
 
 
 
 
3.14 Survival Data 
Overall and Cancer-specific Survival 
 
Figure 3.13 below shows the overall 5-year survival within the study group of 
patients by cohort. Log-rank test confirmed that 5-year survival in cohort 1 (1984-
1986) is significantly lower than in cohort 2 (1996-1997) (p<0.001). The cumulative 
5-year survival in cohort 1 was 0.58 and in cohort 2, 0.834.  
 
Figure 3.13: Overall survival by cohort (cohort 1 = 1984-86, cohort 2 = 1996-97) 
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Figure 3.14: Breast cancer-specific survival by cohort 
 
 
 
 
In relation to figure 3.14 above, the log-rank test again confirmed that breast cancer-
specific 5-year survival in cohort 1 (1984-1986) is significantly lower than in cohort 
2 (1996-1997) (p<0.001). 5 year survival in cohort 1 was 0.62 ; survival in cohort 2 
was 0.887. 
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ER Status and Breast Cancer Survival 
 
Figure 3.15 Breast cancer-specific survival by ER status  
 
 
 
 
Log rank test confirms the significantly higher disease-specific survival in the ER 
positive patients (ER status 1) (p<0.001). 5 year cumulative survival in ER negative 
patients was 0.647 and ER positive patients 0.856. 
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In both 1984-1986 (cohort 1) and 1996-1997 (cohort 2) there is a significantly higher 
disease-specific 5-year survival in the ER positive patients  (p<0.001 for both). In 
cohort 1, cumulative 5-year survival in the ER negative patients was 0.453 and in the 
 Figure 3.16: Breast cancer survival by ER status in cohort 1, 1984-86  
Figure 3.17:  Breast cancer survival by ER status in cohort 2, 1996-97 
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ER positive patients 0.709. In cohort 2, 5-year survival in the ER negative patients 
was 0.786 and in ER positive patients 0.930. Although survival has increased over 
time for both ER positive and ER negative patients, the survival of ER negative 
patients has improved to a greater extent; possible reasons for this will be discussed 
in the Discussion. 
 
Survival in patients with screen-detected and symptomatic tumours 
 
 
 
Figure 3.18  Breast cancer survival by cohort (cohort 1=1984-86, cohort 2 = 
1996-97) in patients whose tumours were symptomatic and not screen-detected 
 
 
 
 
For breast cancer-specific survival there is a significant improvement in survival in 
symptomatic women in the second cohort compared to the first cohort (cumulative 
survival in cohort 1 =0.620, cohort 2= 0.874, p<0.001).  This suggests that screening 
is not the only explanation for the higher survival in the later cohort of patients. 
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Figure 3.19 : Breast cancer survival and screening status in entire study 
 
Figure 4.10: 
 
 
When all the study patients are assessed, survival in those women whose tumours 
were screen-detected was significantly higher than those who had tumours detected 
symptomatically (cumulative survival for screened= 0.916; for symptomatic= 0.753, 
p<0.001).  However, when the second cohort was analysed there was no significant  
disease-specific survival difference in between women whose tumours were screen-
i   3.2  Breast cancer survival by screening status in cohort 2, 1996-97 
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detected and those detected symptomatically (cumulative survival for screened = 
0.916; for symptomatic = 0.874, p=0.148). Possible explanations for this will follow 
in the Discussion.  
 
Survival and Nodal Status 
 
In both cohort 1 and cohort 2, nodal status was related to survival, with node positive 
patients having a lower 5-year survival than node-negative patients (0.523 vs 0.799 
and 0.801 vs 0.946, with p<0.0001 for each). As with ER status, in the second cohort 
again the survival difference appeared to be narrower than in the first. 
 
 
 
 
 
 
3.15 Cox’s proportional hazards analysis 
 
When the effect of cohort (1 or 2) on survival was adjusted for differences in ER 
status alone using Cox’s proportional hazard regression, the cohort type was a 
significant independent factor in survival, confirming that the changes in ER status 
over time seen in this study were not solely responsible for differences in survival. 
After correcting for all the factors in the model, the effect of cohort on survival 
persisted; patients in cohort 1 still had a higher relative risk of death than cohort 2,  
with hazard ratio of breast cancer death of  3.43. Grade, screen-detected status, HER-
2 status and intermediate deprivation status were not included in the final Cox model 
which means they were not independent predictors of  survival in the study as a 
whole and could be explained by differences in other factors. Increasing age, 
increasing tumour size, node-positive status, ER negative status and  deprived status 
correlated with increased hazard of breast cancer death after adjustment for other 
factors.  
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Table 3.10:  Cox proportional hazard regression analysis of factors influencing 
survival in the study group 
 
 
 
 
 
3.16 Immunohistochemistry: inter-observer correlation 
 
For each of the three antibodies, 10% of samples were also scored by an experienced 
scorer; for weighted histoscores that differed by over 50 scoring was carried out 
again with scorers discussing and agreeing on a final score. The intra-class 
correlation coefficient between the two scorers was then calculated using SPSS 
(using the two-way mixed model method). This coefficient should be as close to 1 as 
possible to ensure reliability of the two observers.  
Variable 
 
p value 
 
Hazard ratio  
of death 
95% CI 
1984-86 cohort <0.001 3.43  2.2-5.2 
 
ER negative status  <0.001 4.29  2.8-6.4 
 
Increasing age (per year) 0.09 1.02  1-1.04 
 
Tumour size (per 1mm 
rise) 
0.01 1.02  1-1.02 
Affluent socioeconomic   
vs deprived 
0.08 0.29  0.11 – 0.72 
Intermediate 
socioeconomic vs 
deprived 
0.345 0.82  0.54 – 1.23 
Node positive status        <0.001 2.65  1.66 – 4.2 
  
HER-2 status Not  included       
in model 
Not included  
in model 
 
 124 
ER: intra-class  correlation coefficient = 0.928:  p<0.001 
PR:  intra-class  correlation coefficient = 0.954 : p<0.001 
HER-2 :intra-class correlation coefficient = 0.986: p<0.001 
 
Therefore the correlation of the two observers is confirmed and the validity of the 
scores of the remaining 90% of samples that were assessed by a single observer 
scores assured.  
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Chapter 4: Discussion 
 
The first part of this thesis aimed to establish trends in breast cancer incidence in 
Scotland up to the year 2003 and how these have been could have been influenced 
by the NHS breast screening programme and trends in known risk factors for breast 
cancer.  The age-adjusted rate of breast cancer in women in Scotland in 1975 
adjusted to European standard population was 79.6 cases per 100,000 women and in 
2001 it was 111.2 cases per 100,000 women. Incidence rates differed significantly in 
different age groups. Breast cancer incidence in those age groups under 49 remained 
relatively stable over time, and within these age groups as expected incidence was 
higher with successive age group. In women aged 75 and above rates of breast 
cancer have been increasing over time, again with incidence being higher with each 
successive age group, although women aged 85 and over the incidence has begun to 
decrease since the late 1990s. In women aged 55-69, however, there have been more 
complex changes in incidence over time.  In women aged 50-64, those women 
invited for screening as part of the NHS breast screening programme, breast cancer 
incidence was seen to be increasing even before the screening programme was 
introduced in 1987, with a mean rise in incidence of 2.31 cases per 100,000 per year.  
After the introduction of the screening programme there was a sharp rise in 
incidence similar to that seen in the initial stages of mammographic screening 
programmes elsewhere in the world (Moller et al. 2005; Olsen et al 2003;  Schouten 
et al. 2002;  Zahl et al. 2004). 
                   In 1987 women in a few areas in Scotland aged 50-64 were invited for 
their first screening mammogram; with every year after that women aged 50-64 in a 
larger geographical area of Scotland were invited for their first screen until by 1994 
every woman in the 50-64 age group had been invited for a first screen. From 1994 
onwards, women were invited for a first screen at some point between the ages of 50 
and 53, with the age of invitation differing between different GP catchment areas.  
Screening is offered up until age 64 although certain areas in Scotland have been 
inviting women for screening to age 70 since 2003. In the first year of the 
programme a certain number of asymptomatic tumours would have been detected in 
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the women aged 50-64 in the areas offered screening, which would have been 
detected in addition to tumours detected symptomatically in unscreened women and 
hence added to the incidence. In the next year, the women aged 50-64 in a larger 
geographical area of the country will undergo their first screen, leading to an even 
higher incidence of asymptomatic and hence total breast cancer than in the year 
before. Rates of breast cancer would have increased year-on-year thereafter; 
however in the last few years of the prevalent round there were few geographical 
areas remaining in which all eligible women had not been invited for screening and 
hence fewer women were having a first screen, so the rates began to fall from the 
peak.  
        Once the prevalent round of a mammographic screening programme such is this 
is complete, the incidence rate in the screened age group is expected to remain 
stable. The incidence consists of symptomatic tumours in unscreened women, 
screen-detected tumours at first screen in women aged 50 to 53, screen-detected 
tumours at a subsequent screen, and a small number of ‘interval’ cancers detected in 
between screening episodes. Only the detection of hitherto asymptomatic tumours in 
the women aged 50 to 53 should contribute to there being a higher incidence in the 
50-64 age group than before screening began, as the incidence rate of the other 
tumour types combined should be similar to the incidence rate of symptomatic 
tumours in this age group before 1987. An observed-expected analysis of 1995-1999 
rate compared with the trends that had been developing before 1987 was performed 
to find out if this had been the case.  
            One notable factor of this analysis is the fact that incidence rates in women 
aged 50-64 had been increasing before the screening programme began, with a mean 
increase of 2.3 cases per 100,000 per year since 1975. In women aged 50-54, 
observed incidence rates of breast cancer in Scotland since the prevalent round of 
screening was completed were 58% higher than would have been expected, had the 
underlying trend before screening continued. As women are invited for a first screen 
in Scotland between 50 and 53 years of age, the majority of the 50-54 year-old age 
group were undergoing ‘prevalence’ screening and this could explain the increased 
breast cancer incidence compared with before screening began. However, the 
increased incidence rate in these women compared to the previous background 
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incidence should be a stable phenomenon but instead the incidence rate has clearly 
been increasing with every year since the end of the prevalent round. In women aged 
55-59 and 60-64, there were 42% and 40% increases, respectively, in incidence over 
the underlying trend that had been developing before 1987.  In women aged 65-69 
incidence rates would have been expected to fall from 1995 onwards. These women 
should have been through the screening programme at least once and after a normal 
screening mammogram, it should take some time for a woman to develop a 
symptomatic tumour. Therefore incidence rates in these women should fall, with the 
incidence rate rising again in the subsequent age group; however in these women no 
such fall was seen. It appears then that breast cancer incidence in middle-aged 
woman has been rising due to factors other than the breast screening programme.     
        The analyses performed cover the incidence of breast cancer in Scotland up to 
the year 2003. Criticism could be levelled that trends developing between then and 
now could have given additional support or indeed contradicted the conclusions 
drawn here about the relationship between breast cancer, screening and risk factors. 
However, the process by which cancer cases are registered and the data compiled 
creates a lag time in which the true number of cases in a year only becomes fully 
known several years afterward. Hence the data here, which were correct as of 2008, 
can be said to be as stable as possible.  The ‘observed versus expected’ analysis is 
based on estimation of what the background incidence rate would be if trends had 
continued from 1987; it is possible that the background incidence rate did not simply 
follow this trend.  The use of a mean for a 5-year period helps increase the validity 
of the ‘observed’ rates, but as with all disease incidence rates the presence of random 
fluctuations with time (random error) can decrease the validity of the calculated 
trends.  
          A further study was made of incidence rates by birth cohort in order to see if 
this shed any additional light on changes in incidence.  Studying cancer incidence in 
women born in the same birth cohort year or range of years regardless of age can be 
useful as these women can be expected to have a similar ‘risk experience’ of factors 
such as fertility patterns and contraceptive pill patterns around the time of their 
childbearing years and HRT prevalence patterns around their time of menopause that 
is independent of the effect of age on their risk of breast cancer. However, factors 
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that may influence the incidence of breast cancer that have an identifiable time 
period in which they extended their influence across all age groups – period effects– 
can easily be superimposed upon and confound cohort effects.  The NHS breast 
screening programme is one of these potential period effects. The incidence rate in 
birth year cohorts in which women are aged 50 to 64 during the ‘prevalent’ round of 
screening is likely to be different from the rate in cohorts in which women were aged 
50 to 64 before screening began to be offered or after the prevalent round had been 
completed regardless of a true difference between the cohorts. The analysis 
performed here attempted to analyse how birth cohort effects relate to the screening 
programme in Scotland.  
       An overall analysis of birth cohort effect in women aged 45 to 69 was initially 
performed; a defined age range was chosen in order to give more information on 
changes with more recent birth cohorts, where information is obviously not available 
on incidence rates in the oldest women.  In addition, women aged 45 to 69 may be to 
be more sensitive to birth cohort effects than women who are still in their 
childbearing years or older women in whom the effects of ageing on breast cancer 
incidence rate may be stronger than birth cohort effect. An increase in incidence rate 
with increasing birth cohort year was seen from the 1920 birth cohort onwards up 
until the 1938 cohort; thereafter rates appeared to level out. However when the data 
were broken down into individual age groups, incidence rates in each age groups 50-
54,55-59 and 60-64 increased with every year difference in birth cohort and there 
was no levelling off at the 1938 cohort. There is a possibility that this levelling off is 
artefactual, resulting from the fact that some age groups will be ceasing to have a 
contribution to incidence rates as other are beginning to contribute (as demonstrated 
in figure 3.3); this problem is inherent to any study of birth cohort incidence rates.  
Certainly it would appear that in women aged 50-64 the incidence rate has truly been 
increasing with more recent birth cohort.  A further analysis was performed looking 
at the likely effects of screening in these women to see if the effects could have been 
produced by the screening programme,  
        In each of the screening groups, the most marked rises in incidence with rising 
birth cohort year were within cohorts where some or all women were offered 
screening during the prevalent round.  This initial trend might be entirely explained 
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by the increasing national coverage of the Scottish population by screening.   
However the prevalent round does not explain the continued increase in incidence 
seen with successive birth cohorts in the 50-54 and 55-59 age groups after the 
prevalent round had been completed. Although confidence intervals for these rises 
are wide, it still appears that this is a true birth cohort effect.  Potential contributing 
factors to a birth cohort specific change in breast cancer incidence rate are the 
reproductive factors explored below.  In women aged 60-64 the relationship of 
incidence to birth cohort since the prevalent round ended was less clear.  In women 
aged 45 to 49 a non-significant rise in breast cancer incidence was developing from 
the 1942 cohort onward; in women aged 65 to 69 there was little change in breast 
cancer incidence across the different birth cohorts.   It may be that in women aged 
65-69, the general effect of ageing on cancer incidence is of greater importance than 
reproductive risk factors.  
          There are several limitations to the approach taken here, the most important 
being the potential for misclassification of screening experience, particularly because 
the study is not based individual patient data and whether their tumours were screen-
detected. In addition some women being screened during the introduction of the 
prevalent round may in fact have also had a subsequent screen three years after the 
original. The study method attempted to minimise the potential for misclassification 
by calculating incidence rates for individual birth cohort years instead of ranges, and 
dividing women into groups based on a calculation of their likely exposure to 
screening. but are still counted amongst ‘women being screened during the prevalent 
round’.  Another approach would have been to undertake formal age-period-cohort 
analysis, taking into account screening experience, as performed for England and 
Wales data by Waller (2007). However, using this approach Waller et al generated 
informative data on incidence rate ratios within different screening groups but did 
not generate data on incidence by birth cohort and the effects of screening on these. 
For the purposes of this thesis, the analysis performed here was felt to be more 
informative than formal age-period cohort modelling.  
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Reasons for an increased temporal and birth cohort incidence of 
breast cancer 
Screening Trends 
 
The analyses above suggest that the increased incidence of breast cancer is not 
accounted for by the effects of the screening programme alone. However, the 
expected effects of an established screening programme on cancer incidence are 
based on this phase of the programme screening women in a stable way, and changes 
such as an increased power of the programme to detect cancers or an increase in 
uptake of screening invitations could contribute to increased incidence rates. As 
described in chapter 2 the standardised detection ratio of the screening programme in 
Scotland (rate of invasive cancers detected divided by the number expected for the 
background incidence rate) for women having a first screen increased from 1.1 just 
after the prevalence ‘round’ of screening was completed to 1.5 in 2001/02.  Factors   
that may have contributed to this include a change from one- to two-view 
mammography for prevalent screens, film density becoming standardised at 1.4-
1.8D, implementation of quality assurance procedures and the establishment of a 
skill base of radiographers and radiologists (Blanks, Moss, & Patnick 2000). For 
second (‘incident’) screens the SDR increased from 1.0 to 1.2 between 1994/5 and 
2001/2; this is consistent with the fact that changes in the programme’s ability to 
detect tumours would be expected to have a greater impact on women having their 
first screen and with the fact that two-view mammography was introduced for first 
screens only. It is possible that the increasing SDR of the screening programme and 
the resultant increased detection of asymptomatic tumours could have contributed to 
a rise in breast cancer incidence in women being screened during a period when the 
effects of the screening programme would have been expected to have stabilised out, 
particularly seeing as the greatest effect was in women having a first screen. It is 
unclear whether this effect would have been enough to impact on population 
incidence rates.  
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             A similar effect on incidence could be produced by a gradual rise in the 
uptake of screening invitations. This study has shown a small but significant trend 
towards increasing breast screening uptake in Scottish women with every year from 
1991/2 to 2001/2, with the uptake rising from 70.9% of women taking up the 
screening invitations to 74.5%; in women being invited for their  first screen (ie aged 
50-53) there was also a significant increase in uptake from 70.9% to 73.8%. The 
increase in uptake could have contributed to an increasing incidence of breast cancer 
in the 50-53 year old age group. If women did not take up their first screening 
invitation then they were invited again three years later, and increasing uptake of 
these invitations this may have contributed to more asymptomatic cancers being 
detected in the age groups who would usually have been undergoing second and 
subsequent screening.   It is, however, unlikely that this small rise in uptake has 
contributed substantially to an increase in the disease in any of these age groups. Not 
enough information is available on the demographics of women self-presenting for 
screening to assess the increasing numbers of self-referrals for screening that this has 
had on breast cancer incidence. 
Risk Factor Trends 
As detailed extensively in the Introduction, hormonal risk factors are of pivotal 
importance in the individual risk of breast cancer and the high incidence of the 
disease means that population trends in risk factors could significantly influence the 
population incidence of the disease. This thesis has detailed Scottish trends in the 
following factors: age at first pregnancy, parity, body mass index and use of HRT. 
Data were not available on oral contraceptive use in Scottish women; the absence of 
these data are unlikely to be a significant omission in the analysis of contributions to 
breast cancer incidence in women of screening, as the 50-64 age group that this 
thesis concentrates on are likely to have ceased to use the oral contraceptive at least 
10 years previously, and after this point the effect on breast cancer incidence has 
been shown to disappear (Collaborative Group on Hormonal Factors in Breast 
Cancer, 1996). 
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Fertility 
There has been a dramatic change in the ages at which women in Scotland have their 
first child since the mid-1970s; the number of first births to women aged 20-24 has 
halved over the 25 year period while the number of pregnancies to women aged 30-
34 have tripled in this period and the number of pregnancies to women aged 35 to 39 
have increased five-fold.  Of particular interest are the trends in women aged 35-39; 
as detailed in the Introduction a first pregnancy over the age of 35 is a significant 
risk factor for breast cancer; a woman with a first pregnancy at age 35 has around a 
5% higher relative risk of breast cancer than a nulliparous woman and an even 
higher risk compared to a woman who was parous at a younger age. First 
pregnancies in women aged over 39 also increase risk but the rates are small (several 
hundred only) and have changed little over time and it was felt more useful to 
concentrate on the 35-39 age group. In 1976 1.4% of all first pregnancies in Scotland 
were in women aged 35 to 39 but by in 2001 9% of first pregnancies were to women 
in this age group; the percentage was increasing slowly year-on-year up to the late 
1980s with a greater increase thereafter. The magnitude of the increase in first 
pregnancies in women aged to 35 to 39 is such that it could have influenced 
population rates of breast cancer. However, women aged 35 to 39 in 1988 would be 
aged 45 to 49 in 1998, an age group with little in the way of a breast cancer 
incidence increase, and hence had not reached the 50-64 age range in which the 
greatest increases in breast cancer incidence have occurred. Therefore the increase in 
first pregnancies over age 35 does not explain the incidence trends described in this 
thesis. However there is clearly a possibility that these fertility trends will have an 
impact on breast cancer incidence rates in the 50-64 age group in the future.  
      Low parity is also a risk factor in breast cancer; data on cumulative fertility by 
age 44 was available in relation to maternal birth year. There was little change in 
completed family size up to the 1935 birth cohort but thereafter there was a 
continued drop in  family size from 2.63 to 1.9 in the 1960 birth cohort. In terms of 
how the observed fertility patterns are linked to the observed birth cohort breast 
cancer incidence, the birth cohort breast cancer incidence data in chapter 2 describe 
data up to the 1949 birth cohort, at which point completed family size had dropped 
to 2.12. As displayed in figure 2.4, in women aged 50-54 a steeper increase in 
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incidence can be seen to be developing after the 1935 cohort, although the cohorts 
immediately after the 1935 cohort were within the prevalent round of screening and, 
as already discussed, this could have increased incidence rates with rising birth 
cohort. Continued incidence rate rises in cohorts not affected by the prevalent round, 
however, could have been contributed to by the continued fall in completed family 
size. In women aged 55-59 the 1935 cohort comes at around the end of the birth 
cohorts that would have been influenced by screening, and the continued incidence 
rate rises thereafter could have been affected by the completed family size fall. In 
women aged 60-64 the trend in incidence with birth cohort from 1935 onwards is 
shows rises and falls in incidence with no clear developing trend. Interestingly Chia 
showed decreases in overall breast cancer incidence from the 1935 cohort onwards 
in both Singapore and Sweden (Chia et al. 2005). In Singapore the authors found 
evidence of a relationship between cohort trends in late age at first pregnancy and 
parity but in Sweden they could not.  
 
BMI  
In the women in the Scottish Health Survey (Dong & Erens 1997; Bromley et al. 
2003; Shaw, McMunn& Field 2008) mean BMI increased from 25.7 kg/ m
2
 in 1995 
to 26.9 kg/ m
2
 in 2003. In women aged 55-64, mean BMI increased from 27.6 kg/ m
2
 
to 28.6 kg/ m
2
. The percentage of women with BMI over 25 was 47.2% in 1995 and 
57.3% in 2003; for women aged 55-64, percentage rose from 68.2% to 73%. With 
postmenopausal obesity being a risk factor for breast cancer the 5% rise in 
overweight and obesity in women of screening age could be a possible explanation 
for a rising background incidence rate. 
 
Alcohol 
Data from large cohort studies suggests that alcohol is a significant factor in 
postmenopausal breast cancer and surveys show that mean alcohol consumption has 
been increasing in women aged 55-64 , along with the proportion of women drinking 
over 14 units per week. The increases are small, however they could have been 
enough to have significantly contributed to an increase in postmenopausal breast 
cancer rates. 
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Hormone Replacement Therapy 
Hormone replacement therapy increases risk of breast cancer, with a large meta-
analysis of trial results concluding that the risk of breast cancer increase by a factor 
of 1.023 for every year of use and  that this increased risk disappeared 5 years after 
cessation of use. The use of hormone replacement therapy in the UK doubled 
between 1973 and 1976, fell again and began to rise substantially from the late 1980s 
onwards; prevalence in England was estimated to have risen from 2.2% of 45-64 
year olds in 1987 to 21.7% in 1994 (Townsend 1998). Between the mid-1990s and 
2001 prevalence of use stabilised out (Townsend 2005).  Data were available on 
hormone replacement therapy prescriptions from 1993 onwards. The calculated 
estimated prevalence showed that incidence increased from 13.6 in 1993 to 17.2 in 
1996 but thereafter there was little change up to 2001. Clearly there are potential 
sources for error in the calculations used to estimate prevalence; the inclusion of the 
population denominator of ages 46 to 64 may underestimate prevalence as the 
youngest women are likely to have lower prevalence than the oldest, and the amount 
of time the HRT was used for will have varied. However, in the absence of accurate 
prevalence data this methodology comes as near as possible to estimating HRT 
prevalence. 
      It is unfortunate that data are not available on prevalence of HRT before 1993, 
but the small rise in prevalence and eventual stabilising out of HRT rates 
demonstrated here suggest that the rise in breast cancer incidence by birth cohort 
since the prevalent round of screening ended cannot be explained by changing HRT 
use.   
      The analyses of breast cancer by birth cohort above support the fact that these 
hormonal risk factors could be of importance. However, the observations above 
about the relative contribution of each of these to overall incidence of breast cancer 
are estimates based on literature, given that complex modelling of these risks is 
outwith the scope of this thesis. There are many potential sources of bias within 
these estimates. There is the potential that type I or type II errors have occurred: 
where the author has discounted a risk factor’s importance if its trend does not fit 
with the breast cancer trends seen, or suggested an important effect if the trend in the 
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risk factor fits with breast cancer trends. Essentially the basis of these observations is 
the application of individual risk factors to population incidence rates, and while it is 
a common concept in epidemiology there is no foolproof statistical way of linking 
the two factors. The extrapolation of risk factors changes to population cancer 
incidence also assumes that breast cancer patients have been exposed to the changes 
in risk factors seen in the general population; if this is not true for some previously 
undetected reason, there is a real risk of misclassification bias. There is also the 
possibility that a previously undetected period (temporal) factor has been the major 
defining feature in temporal changes in breast cancer incidence rather than the risk 
factors above.  
 
Affluence and deprivation 
Breast cancer is commoner in the affluent than the deprived; the exact reason for this 
is likely to be multifactorial and involve a variety of risk factor differences. The 
question also remains as to whether incidence rates are rising in parallel across all 
social classes. As noted in the introduction. Dano et al. (2003) studied incidence 
rates over time in social classes in Denmark, and found that rates in the affluent were 
rising at a lower rate than before and rates in the deprived rising at a faster rate than 
before. Recent trends in those enrolled in the Longitudinal Cohort Study of 250,000 
UK women supported this same narrowing incidence gap (Population Trends, 1997). 
It is demonstrated in this thesis that breast cancer incidence rates in Scotland 
between 1991 and 2000 were increasing in parallel in affluent and deprived women. 
The biggest factor that could affect the interpretation of these results is whether the 
breast cancer patients contained within these data have been correctly assigned to a 
particular socioeconomic category, that is, whether there has been misclassification 
bias.  The use of quintiles of deprivation, as in the trends shown here, has become 
popular in recent years. However, the use of quintiles which each contain 20% of the 
population as opposed to the use of unequal deprivation categories risks 
misclassification because the top quintile could contain a mixture of very affluent 
households and far less affluent households. Also, the fact remains that all these 
measures of deprivation are based on postcode, and it has been argued that the 
association of a geographical area with a characteristic of the individual people 
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within it such as socioeconomic deprivation is an ‘ecological fallacy’.  However, 
studies have been carried out at the level of the individual that claims to support the 
use of area-based measures as a surrogate marker of deprivation (Sloggett, 1998), 
and the use of area-based assessment of deprivation is still the norm today. 
         The reproductive risk factors discussed at length in this thesis such as 
increasing age at first pregnancy, reductions in parity, use of hormone replacement 
therapy and oral contraceptives and changing patterns in BMI were studied in 
different socio-economic categories in order to assess their possible impact on breast 
cancer incidence rates. Indeed, studies in Marin County in California (Hwang et al. 
2005; Prehn et al. 2002; Robbins et al 1997; Wrensch et al. 2003), a geographical 
area with an affluent population and corresponding excess of breast cancer, had 
suggested that differences in reproductive risk factors may explain the observation of 
higher breast cancer within that population.  Differing uptake of screening 
invitations among women of different socio-economic categories is also well-known 
phenomenon (CDC 2005; Gatrell et al. 1998), with a higher percentage of affluent 
women taking up screening invitations, and an investigation of screening patterns 
was also performed. It is unfortunate that a breakdown on the figures for affluent and 
deprived women by age was not available, as trends could potentially differ between 
premenopauasal and postmenopausal women as a result of the ‘crossover’ effect of 
reproductive risk factors. However we have presumed that with postmenopausal 
breast cancer being the majority of cases, trends in postmenopausal women are likely 
to reflect the overall trend within each socioeconomic group. !
!!!!!!A study of numbers of first births in women aged 35–39 revealed that numbers 
per year have always been highest in the most affluent and lowest in the most 
deprived. This may be a potential explanation for the persisting high rates of breast 
cancer in the affluent; a woman with a single pregnancy over age 35 can have up to 
double the risk of a woman with several births at a young age (Rosner, Colditz & 
Willett 1994). Since the late 1980s, the number of first births at late maternal age has 
been markedly increasing every year in all deprivation categories, albeit to a greater 
extent with each successive quintile. This is a potential explanation for the rise in 
breast cancer rates across the whole socio-economic spectrum and would be 
expected to produce incidence rates in the affluent that are rising higher than in the 
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deprived, a trend which has not developed. However as noted in the discussion of the 
general effect of fertility trends on breast cancer incidence, the steep increase in late 
first pregnancies from the late 1980s may result in an even steeper rise in breast 
cancer rates in the near future when these women become postmenopausal, and this 
rise may be especially marked in affluent women. Data on parity differences 
between the affluent and deprived women may have given additional information on 
reproductive influences on breast cancer incidence, but such data are not maintained 
by any agency.         
                 Extrapolating from cross-sectional survey data, it appears that the 
prevalence of obesity and mean BMI in Scottish women of all socio-economic 
categories increased between 1995 and 2003  (Dong & Erens 1997; Bromley et al. 
2003; Shaw, McMunn & Field 2008). Again, this could potentially contribute to 
rising breast cancer incidence across all socio-economic categories; a pooled 
analysis of several studies has suggested that the relative risk of breast cancer in 
women with a BMI over 28 is 1.26 and the RR is 1.0 for women with a BMI under 
21 (Key et al. 2003). This level of risk suggests that rising levels of obesity could 
significantly influence patterns of breast cancer incidence. However, the surveys 
suggest that BMI and obesity have consistently remained higher in the lowest socio-
economic categories, and thus BMI differences do not explain the observed socio-
economic gap in incidence.  Torgerson (1994) suggested that differences in BMI 
may explain the socioeconomic effects on breast cancer survival but did not study 
effects on incidence.!
            The presence of an organised screening mammography programme can 
strongly affect breast cancer incidence rates. Women undergoing incidence screens 
have incidence rates that should reflect the background incidence, but the youngest 
women in the programme are always undergoing ‘prevalence screening’, with the 
detection of a relatively large number of asymptomatic tumours which have been 
present for varying lengths of time An increase in the percentage uptake of screening 
invitations is likely to result in increased prevalence screening and therefore may 
cause incidence rates to rise. Figures for the Scottish Breast Screening Programme 
show that screening uptake over 1990–2000 increased by a few percent in all 
deprivation categories - this is unlikely to be enough to explain the overall breast 
 138 
cancer incidence rises in all categories. The socio-economic gap in uptake has 
persisted over time, although it is small, with an absolute difference in uptake of 
17% between highest and lowest quintile in 2001. 
         These data suggest that breast cancer incidence in Scotland is rising in all 
deprivation categories but that rates remain higher in the affluent. Reproductive 
trends shown here may explain the persistent socioeconomic gap, but do not appear 
to be an adequate explanation for rising breast cancer rates. A rising prevalence of 
obesity could be contributing to rises in breast cancer rates, but would not explain 
the deprivation - affluence incidence gap. Screening differences are of insufficient 
magnitude to explain either phenomenon. There was no data available to analyse in 
order to assess differences in hormone replacement therapy use in different 
socioeconomic categories in Scottish women. 
 
Discussion of Laboratory Project 
This study has demonstrated a rise over time in the percentage of breast cancers that 
were ER positive. The rise from 64.2% to 71.5% is statistically significant and 
clinically significant - in that a rise in the number of breast tumours potentially 
responsive to hormonal manipulation could contribute to increasing survival rates as 
a result of the clear prognostic advantage of hormone-treated ER positive disease 
over ER negative disease (Clarke 2005).   There was also a significant change in 
combined ER/PR receptor status, most notably a marked decrease in the percentage 
of tumours that had the poor prognostic ER negative/PR negative status.  The 
percentage of tumours that were PR positive and HER-2 positive did not change over 
time; notably there was no change in mean score over time for any of the three 
receptors.   
         A significant change in grade distribution was seen, particularly a reduction in 
the frequency of grade 3 tumours and an increase in the frequency of grade 1 
tumours. This distribution change appeared to be exerted by the presence of screen-
detected tumours in the second cohort, as there was no significant difference in the 
grade distribution of the symptomatically-detected tumours in both cohorts.  The 
pathological grade of screen-detected tumours and its significance has received 
much attention in the literature; while it is accepted that tumours detected at a first 
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screening mammogram are of lower grade than symptomatically detected tumours it 
is uncertain as to whether this represents an interruption of phenotypic drift or 
whether the lower-grade tumours are preferentially detected at screening because of 
their longer asymptomatic preclinical phase (length bias) (Alexander 1997; Crisp 
1993; Duffy 1991; Tabar 1999).  An attempt was made in this thesis to estimate 
whether women were receiving an incident screen or not, as length bias is an 
unavoidable problem with tumours detected at prevalence screening; the results 
suggested a significant difference in grade between symptomatic patients and 
patients having a tumour detected at an incident screen. This would appear to 
support the theory of phenotypic drift but clearly misclassification of screening 
episode is a clear possible confounding factor. 
        The study has also demonstrated significant differences in the percentage of 
tumours that are ER positive within patients with screen-detected and symptomatic 
tumours, with 78.4% of screen-detected and 68.8% of symptomatic patients in the 
newest cohort being ER positive. Certainly on multivariate analysis screening status 
consistently remained a significant factor in the change in ER status over time (there 
was an increase in the number of ER positive tumours between the symptomatic 
patients in both cohorts but this did not reach statistical significance). There is 
evidence to suggest that screen-detected tumours are more likely to be ER positive 
than negative (Klemi, 1992; Ernst, 2002), probably because the ER positive tumours 
are more likely to be slower-growing with a significant asymptomatic phase.  
         ER status did not appear to relate to levels of deprivation in the patients in the 
study on univariate or multivariate analysis; this is in contradiction to studies such as 
that of Carnon et al .(1994) which would seem to suggest that ER positive disease is 
commoner in the affluent than the deprived. Fertility-related factors such as late age 
at first pregnancy noted in Part 1 of the thesis which are undoubtedly affecting breast 
cancer incidence would be expected to produce more ER positive disease, and are 
commoner in the affluent – as discussed in the Introduction this is a possible 
mechanism of higher levels of ER positive disease in the affluent. It may be that the 
small numbers of affluent patients in our study could be impairing the ability to 
detect a difference in the different deprivation groups.  
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         Multivariate analysis suggested that the observed changes in ER status did not 
persist when adjusting for screen-detected status and age within these groups.  As 
noted above, the increased ER positive prevalence in screened patients likely reflects 
the fact that tumours detected at screening are slower-growing and more likely to be 
ER positive than the symptomatic tumours. it may be argued that even although 
these tumours are preferentially detected at screening, the screening itself is not 
actually causing a change in the hormone receptor status. One would expect a 
corresponding decrease in rates of ER positivity of symptomatically detected 
tumours over the time period, and the fact that this had not occurred could suggest 
that a true change in biology has occurred. However, it  is also possible that these ER 
positive cancers are those that are in fact being ‘overdiagnosed’ as discussed in the 
introduction – that these ER positive tumours are the tumours that would  not have 
ordinarily been diagnosed at the time of a patient’s death from other causes, and 
hence this apparent shift in tumour biology has been artefactual and could not have 
contributed to any changes in survival over time.  
       As for age, it is notable that the age distribution of the two patient groups did 
differ significantly, with the upper limit of the second cohort being 93, reflecting a 
total of 44 patients being  operated on over the age of 75,  whereas the upper limit in 
the first cohort was 74.  This is potentially significant in view of the well-
documented observation of increased ER positivity after the menopause  (Elwood 
1980; McCarty 1983). It was not appropriate to include age by decade in the 
multivariate analysis as there is not a linear relationship between age and ER status. 
Interestingly, a slight increase in ER positivity towards the 45-49 age group was 
seen, and this was also demonstrated by Elwood et al. (1980). Thereafter, rates of ER 
positivity did appear to increase after the age of 60, so ‘age before 60’ and ‘age after 
60’ were included as a categorical dichotomous variable. When age was included as 
a factor in the analysis, this appeared to explain the differences in ER status between 
the groups. However, the use of 60 as a cut-off is an arbitrary measure. Direct 
comparison of percentage ER positivity within the two cohorts when divided into 5 
year age groups shows that the percentage of ER positive tumours has increased in 
each of these age groups over time , and while the individual numbers in each group 
are too small to prove the individual significance of these results, it suggests that the 
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changes in ER status seen in the project are not artefactual, produced by the age 
distribution of the study population. 
      The results of this study are in accordance with the increase in ER positivity seen 
in other studies  (Bradburn 1998; Glass 2007; Henley 2005; Li 2003).  These studies 
are a heterogeneous group with carrying approaches and study populations. In most, 
assays and criteria used to determine ER positivity changed several times during the 
study periods as a result of development of new methods of ER determination. 
Studies of the concordance of ligand-binding assay and immunohistochemistry for 
oestrogen receptor have showed that the concordance can be as low as 82% (Allred 
1990). The importance of the study presented here is that it used 
immunohistochemistry on all samples, thereby eliminating the possibility that an 
increase in ER positivity has been artefactual.  Furthermore for each antibody, all the 
samples underwent immunohistochemistry together to eliminate the potential effect 
of changing laboratory conditions on staining.  
          One criticism that could be levelled at this study is that the most recent 
patients in this study are from 1996-97 and hence the project describes changes in 
ER status that had developed between twenty and ten years ago. The reason for this 
is that a secondary aim of the project was to explore how changes in ER status could 
have contributed to survival; when the laboratory project began in 2004, the cohorts 
were designed to end in 1997 to allow long enough follow-up. Therefore, whereas 
papers such as that of Glass (2007) demonstrate more recent changes in ER status of 
tumours they do not directly apply these to survival data. The demonstration of 
changes in ER status in this ten year period could be the basis for continued research 
into how ER status has changed in more recent years, applying a similar technique of 
re-analysing stored tissue. Image-detection technology could allow computer scoring 
of samples to reduce the time taken to carry out such a project and gain a more up-
to-date view of changes in molecular epidemiology. 
     One explanation for a preferential increase in ER positive breast cancers could be 
a population-wide change in the prevalence of certain factors that have been shown 
to increase the frequency of ER positive breast cancer in large cohort studies. As 
detailed extensively in the introduction, such factors include late age at first 
pregnancy and postmenopausal obesity (Althuis 2004; Colditz 2004; Potter 1995); 
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and use of hormone replacement therapy in one study (Potter 1995).  Within Part 1 
of this study it has been demonstrated that profound changes in certain reproductive 
and endocrine factors have been occurring in Scotland, although hormone 
replacement therapy prevalence changed little over the study time period.  Certainly, 
the percentage of women in the study that had used hormone replacement therapy 
and the relationship to hormone receptor status would have provided important 
epidemiological information but this was not readily available and the fact that many 
of the casenotes of the patients in the earlier had been destroyed would have 
precluded any useful comparisons.  
           Rates of PR positivity increased, but not significantly, between the two time 
periods. In cohort studies PR status has been shown to be influenced by similar risk 
factors to ER status; it may be that the numbers in the study have not been enough to 
let the increase in PR positivity become statistically significant, as the study is 
underpowered to detect such a difference. Interestingly, the distribution of combined 
ER and PR status changed significantly. Particularly noticeable was a 10% decrease 
in the percentage of the poor prognosis ER-/PR- tumours from 33% to 23%; this 
could have influenced the survival differences between the two cohorts. The fact that 
HER-2 distribution has remained unchanged is not unexpected; changes in 
epidemiological risk factors are unlikely to have influenced HER-2 status. However, 
again there may be a true difference that the study has been underpowered to detect. 
In addition the use of Herceptest alone to assess HER-2 distribution rather than FISH 
may have affected the validity of these findings.  
          This study was powered to detect a 10% difference in ER positive prevalence, 
and is hence slightly underpowered to detect the observed 7% difference. The 
inability to retrieve tumour blocks for all patients means that the calculated figures 
are not from the full original study population; the cohort is further reduced by the 
tumours which were not suitable for immunohistochemistry because of sampling 
error or damage to the core while being inserted into the tissue microarray, a factor 
commonly seen in studies using archived tissue for microarray technology (Hager et 
al. 2007). Those tumours that underwent analysis should be representative of the 
study tumours as a whole, as it is unlikely that the lost tissue or non-retrieved tissue 
is anything other than a random sample of the study population.  
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          Breast cancer-specific and overall 5-year survival in cohort 1 were 
significantly lower than in cohort 2. 5-year breast cancer-specific survival was 
significantly higher in ER positive patients than ER negative patients in the study 
overall and in each cohort independently. In the second cohort, improved survival in 
ER positive patients may reflect the fact that in 1984-1986, whilst beginning to be 
used, hormonal therapies may have been relatively under-prescribed by today’s 
standards due to different ER techniques and cutoffs for ‘positivity’ and different 
advice on suitability for hormonal therapy; the more marked survival improvement 
in ER negative patients over this time period is most likely due to improvements in 
chemotherapy.  Unfortunately treatment data are not available for the women in this 
study, as in 1984-86 the Cancer Registry did not routinely record treatment received 
and casenotes were not available.   
      In the second cohort there was no disease-specific survival difference between 
women whose tumours were screen-detected and those whose tumours were detected 
symptomatically; within the symptomatic patients there was a significant survival 
difference between cohorts. However, this cannot be directly extrapolated to the 
conclusion that screening prolongs survival; the effects of screening on survival as 
opposed to mortality are complex because of the potential for lead-time bias and 
further  analysis of these data are outwith the scope of the current study. 
                  Changes in ER status may have contributed to the survival improvements 
observed in the study; breast cancer-specific survival in the 1984-86 cohort was 
significantly lower than in 1996-97. In the Cox proportional hazard analysis, the 
effect of cohort on survival was adjusted for ER status alone, the cohort remained a 
significant independent factor in survival - the difference in survival between cohorts 
is not fully explained by differences in ER status. This is not surprising - treatment 
and global management changes have undoubtedly contributed to changes in 
survival over time (Bradburn 1998; Thomson 2004).  However a true change in ER 
status could also have implications for the application of data from clinical trials 
carried out in previous decades to the women of today, as discussed further in 
‘Conclusions, Implications and Future Research’ section below. 
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Chapter 5: Conclusions, Implications and Future Research 
  
The purpose of this thesis was to explore changes in the incidence and molecular 
epidemiology of breast cancer in Scottish women up to 2003 and the possible factors 
contributing to these changes. The study concentrated particularly on incidence in 
women aged 50 to 64 an age range in which a wide variety of factors could have 
been contributing to breast cancer incidence. The incidence of breast cancer in 
Scottish women aged 50-64 was shown to have increased within expected limits 
during the initial rounds of the NHS breast screening but then to have failed to level 
off as would be expected. Formal assessment of this shows levels in the late 1990s 
that were up to 42% higher than would have been predicted from trends that were 
developing before 1987. Analysis suggests the contribution of birth cohort factors to 
this pattern, supporting the fact that reproductive factors are likely to have been 
contributing. Changes in fertility patterns, BMI and use of alcohol could have 
contributed, although patterns of HRT use would appear not to have made as great a 
contribution.  Completed family size is shown here to be continuing to decrease, and 
prevalence of first pregnancy over age 35 to increase, with the rates of the latter 
increasing particularly steeply. Given that these factors contribute to incidence of 
breast cancer later in life (that is, in the postmenopausal period), there is the potential 
for ongoing increases in individual risk of postmenopausal breast cancer, and hence 
continued increases in postmenopausal breast cancer incidence. The patterns shown 
here does not support a great contribution of HRT use to the population breast cancer 
incidence in Scotland but if in fact it has been contributing, then continuing 
decreases in HRT use and hence risk could mitigate any chances produced by 
reproductive factors. Continuing research into the impact of HRT prevalence on 
population breast cancer incidence would be informative. 
        The possibility of modifying hormonal risk factors in an attempt to reduce 
breast cancer incidence is controversial, as decisions about family size and age at 
first pregnancy are highly emotive decisions made by individuals based on many 
factors. Perhaps information on the contribution of hormonal factors to breast cancer 
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could be included in general information aimed at promoting breast health, e.g. in 
GP surgeries, but any stronger attempts to influence decisions on family planning are 
unlikely to be welcomed. Obesity is a more modifiable risk factor (although again, 
modification relies on decisions being made by individuals about their health). The 
Scottish government has begun a campaign to reduce obesity, and perhaps 
information about the excess cancer risk posed by obesity could be included within 
such advertising campaigns. When it comes to HRT prescribing, women should 
always be able to make an informed decision, and should be given information about 
the risks and benefits, including the increased risk of breast cancer. 
               Predicting cancer incidence trends is important for the future distribution of 
health service resources. While inadequate to allow accurate prediction of future 
trends, analyses here are an important initial step in suggesting future areas of 
research. These could include complex modelling of trends in hormonal factors 
based on their known contributions to individual risk, in an attempt to refine 
predictions of breast cancer incidence.  Such models could also assess the potential 
effect of risk factors on the biology of breast cancer in terms of more ER positive 
disease. In addition, the author acknowledges that despite the obvious importance of 
hormonal factors in breast cancer risk, there remains the possibility that an as yet 
undetermined temporal factor is the major driving force in population breast cancer 
trends. Further research into the contribution of birth cohort effects (as a surrogate 
for reproductive risk factors) and period (temporal) effects to breast cancer 
incidence, and hence determining which of these will have continued relevance to 
ongoing breast cancer incidence, would also be useful. While formal ‘age-period-
cohort’ modelling is one way of doing this, there is growing interest in the ‘median 
polish’ statistical method which is even better at untangling the complex interaction 
of birth cohort and temporal effects in cancer research and this could be applied to 
the data used in this thesis. Indeed this is a research area that the author intends to 
continue to pursue. 
        Changes in screening and their possible effects should continue to be studied. 
The introduction of two-view mammography at ‘subsequent’ screens, and age 
extension in either direction, could cause apparent increases in incidence which 
actually reflect lead-time bias.      
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        This work has also shown that breast cancer incidence appears to be rising in 
parallel across all socioeconomic categories, although the most affluent continue to 
have significantly higher rates than the most deprived. Certain risk factor trends 
could explain this pattern – patterns in late age at first pregnancy mirror this change, 
with rates increasing over time across all socioeconomic categories but with a 
persistently higher rate with higher socioeconomic status. Again, the rate of change 
is increasing with every year. Hence it is important that the increasing rates of breast 
cancer in deprived women continue to be investigated and monitored, as there is the 
danger of deprived women missing out on information and advice if breast cancer is 
thought of as a ‘disease of the affluent’ and resources distributed accordingly.  
    The conclusions of the laboratory work were that the biology of breast cancer is 
changing towards more ER positive disease. As discussed above, the fact that this 
change was ‘cancelled out’ by the presence of screen-detected tumours on the Cox 
regression analysis does not rule out the possibility of a change in biology, as screen-
detected tumours are more likely to be slower-growing, as in ER positive disease.  
There are several limitations to the methodology used here. Certainly the 
information reflects changes that would have been ongoing up to ten years ago, 
suggesting that it would be of critical importance to repeat the project in the future in 
order to assess more recent changes in molecular epidemiology. One disadvantage is 
that the project only assesses the proportions of ER positive to ER negative disease; 
an interesting area of future research would be to directly calculate trends in the 
prevalence of ER positive and ER negative disease to assess if the increased 
incidence of breast cancer is exclusively due to more ER positive disease, or if rates 
of ER negative disease have also increased, as this would be of greater predictive 
value.  
         The implications of rising numbers of ER positive disease could have the 
simple effect of increasing demand for tamoxifen and aromatase inhibitors. It could 
also have implications for the application of data from clinical trials carried out in 
previous decades to the women of today. The original clinical trials of many 
chemotherapeutic and hormonal therapy agents used today were carried out in the 
1980s and 1990s. In certain groups, especially postmenopausal women, the survival 
benefit is narrow. If the molecular biology of women has truly altered towards 
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disease with better prognosis it is possible that such margins may be smaller now if 
such trials were repeated today. Rising levels of better-prognosis disease and the 
consequent rise in numbers of survivors of a disease will also have implications in 
terms of research into longterm follow-up and the prevention of late recurrences.  
     Survival analysis of the patients in the study showed that a change toward better-
prognosis disease did not fully explain the observed improvements in survival, as 
expected. Significant changes in grade distribution were seen between 1984-86 and 
1996-97. There was a reduction in the frequency of grade 3 tumours and an increase 
in the frequency of grade 1 tumours, a change that seemed to be exerted by the 
presence of screen-detected tumours in the second cohort, as there was no significant 
difference in the grade distribution of the symptomatically-detected tumours in both 
cohorts.   An attempt was made to assess whether or not this was due to length bias 
(preferential detection of less aggressive tumours by screening) by removing from 
the analysis women who were estimated to be having their first screen, and the 
difference in grade distribution persisted. This would appear to support the concept 
of ‘phenotypic drift’ of breast cancer toward higher grade with time. Research into 
this controversial concept could have profound implications in for the benefit of 
screening programmes and for interpretation of survival data. As observation of the 
phenomenon in vivo is obviously not possible, continued research and audit of 
tumour grade within screening programmes is the best way of investigating the 
concept.   
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1923 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75         80 
  204.2 180.2 201.4 167.2 175.1 196.9 229.5 225.3 193.6 178.8 220.6 260.3 245.6 216.2 304.6 245.6                       
1924 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74         79 
  149.1 96.0 145.2 133.4 195.1 197.2 219.4 151.4 214.6 207.3 227.9 248.9 237.9 253.4 269.5 267.4 226.2                     
1925 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73         78 
  166.7 181.0 149.9 203.9 195.1 146.6 188.2 193.4 219.3 163.0 189.4 248.5 272.5 280.3 236.7 271.7 288.9 212.6                   
1926 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72         77 
  157.2 136.1 162.5 144.6 166.8 203.8 166.5 187.7 163.0 222.0 254.8 206.3 215.7 250.4 254.3 233.1 237.3 250.0 294.3                 
1927 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71         76 
  137.9 125.8 94.1 173.4 177.4 208.4 196.9 181.7 183.3 250.6 194.0 199.5 292.8 285.3 347.3 253.7 183.5 236.7 249.5 278.9               
1928 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70         75 
  195.2 163.5 151.4 165.6 159.8 150.8 202.4 193.9 198.9 204.2 153.5 144.4 180.8 261.7 352.2 371.7 257.7 231.8 228.7 313.3 231.3             
1929 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70       74 
  176.1 170.5 118.7 159.1 199.3 144.7 172.3 170.1 184.8 166.2 194.9 217.4 208.3 262.6 347.0 333.5 338.0 265.2 213.1 262.6 216.9 339.7           
1930 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71   73 
  169.5 180.1 200.5 159.3 180.9 139.8 153.8 138.3 179.0 186.9 269.1 149.4 235.4 237.3 368.0 330.2 277.2 363.4 179.1 252.5 200.2 257.0 312.5         
1931 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 
  148.3 168.5 146.4 153.6 156.5 127.9 184.6 175.6 163.2 184.2 168.4 213.7 191.0 251.0 294.7 308.0 307.9 254.1 347.5 202.0 190.1 299.1 250.5 227.6       
1932 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 
  137.6 161.4 185.1 159.2 156.3 190.0 177.9 179.0 176.8 191.4 152.2 217.6 225.2 299.1 260.0 296.6 246.3 259.2 294.1 246.7 242.6 242.1 268.2 288.2 277.6     
1933   45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 
    176.7 170.5 143.7 129.4 211.9 123.7 165.8 131.9 181.6 175.6 205.2 227.4 311.4 328.2 344.9 256.3 320.4 263.8 352.9 300.0 257.7 222.3 264.9 236.5 249.3   
1934     45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 
      124.1 152.2 181.6 196.0 172.8 159.7 153.4 147.3 162.2 226.8 223.6 224.8 290.6 245.3 279.4 332.4 294.5 263.6 322.8 310.5 237.5 228.5 285.9 222.5 242.7 
1935       45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 
        154.2 178.8 135.5 187.1 153.7 188.6 179.3 155.9 187.9 181.2 217.0 253.3 332.2 216.6 200.1 330.6 278.8 281.0 331.4 271.4 285.6 299.7 331.4 343.9 
1936         45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 
          187.0 181.1 121.4 176.0 169.7 156.9 157.7 172.2 196.9 277.5 226.6 234.8 253.1 261.3 283.9 282.5 281.5 261.5 267.7 303.0 276.3 200.3 325.0 
1937           45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 
            172.8 177.0 130.8 155.0 159.2 193.9 174.4 188.3 178.6 255.5 318.8 268.4 294.3 267.7 230.7 307.3 295.5 359.6 319.3 362.9 250.9 280.4 
1938             45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 
              164.3 178.1 158.3 189.5 118.9 160.4 167.5 308.2 226.9 241.4 238.8 226.1 290.5 267.8 293.9 313.8 319.8 366.3 387.5 317.6 261.0 
1939               45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 
                201.3 124.5 148.5 193.2 170.1 218.0 232.1 260.2 274.6 275.5 241.8 281.1 237.4 274.1 321.4 298.4 332.7 320.6 313.0 308.5 
1940                 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 
                  155.5 145.9 166.8 164.1 181.5 222.9 268.4 245.0 276.8 246.5 261.3 237.9 316.6 321.2 298.0 366.9 333.7 361.5 317.2 
1941                   45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 
                    141.6 160.0 178.4 189.2 178.8 186.7 266.3 284.6 177.1 286.2 272.3 291.9 285.8 330.7 369.5 289.5 306.7 335.2 
1942                     45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 
                      146.2 204.8 119.5 147.1 185.3 281.6 226.9 213.6 262.7 250.4 318.0 270.2 264.2 240.7 362.2 357.8 359.7 
1943                       45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 
                        197.5 142.6 168.7 211.2 179.1 218.3 231.4 202.6 229.5 240.1 300.3 327.8 369.0 247.3 318.8 356.9 
1944                         45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 
                          138.4 164.5 196.9 158.2 190.6 258.6 298.1 334.8 231.5 196.1 298.4 342.2 273.8 334.4 362.2 
1945                           45 46 47 48 49 50 51 52 53 54 55 56 57 58 
                            130.7 184.6 154.5 208.3 211.4 279.1 303.3 297.1 307.5 250.7 295.6 285.7 259.6 301.9 
1946                             45 46 47 48 49 50 51 52 53 54 55 56 57 
                              135.9 207.2 165.4 220.7 194.9 283.2 326.6 278.3 268.8 279.4 299.8 327.5 285.4 
1947                               45 46 47 48 49 50 51 52 53 54 55 56 
                                175.2 152.7 182.8 175.5 221.5 300.4 316.3 304.5 254.3 203.8 268.2 240.6 
1948                                 45 46 47 48 49 50 51 52 53 54 55 
                                  152.5 158.1 224.1 211 189.6 275.7 337.4 351.9 227.6 253.3 278.9 
1949                                   45 46 47 48 49 50 51 52 53 54 
                                    102.4 205.1 148.3 203 217.8 358.9 356.9 349.1 263.2 289.2 
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